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1. New Tariquidar Analogues: 
Synthesis by Cu(I)-catalyzed N/O-Aryl Coupling and Inhibitory 
Activity against the ABCB1 Transporter i 
 
 
Less lipophilic and better water soluble tariquidar analogues were synthesized from one 
central anthranilic acid derived building block via Cu(I)-catalyzed N/O-arylation 
reactions.ii The compounds were tested for their inhibitory activity against the ABCB1 
transporter in a flow cytometric calcein-AM efflux assay.iii A correlation between their 
calculated log P values and their activities was observed, with the more lipophilic 
analogues being as potent as the reference substance tariquidar. 
 
                                                 
i
 M. Egger, X. Li, C. Müller, G. Bernhardt, A. Buschauer, B. König, Eur. J. Org. Chem. 2007, 2643-2649. 
ii
 The synthetic route to bromo tariquidar 3 was developed together with Xuqin Li who prepared N-Boc-
protected bromo anthranilic acid 6 as well as the tariquidar analogue 17. 
iii
 The flow cytometric calcein-AM efflux assay was carried out by Christine Müller at the Institute of 
Pharmacy, University of Regensburg. 
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1.1. Introduction 
 
The mdr1 gene product ABCB1 (p-glycoprotein 170), a member of the ABC transporter 
family of transmembrane proteins, prevents the entry of a vast variety of structurally 
diverse chemicals into the cell.[1] While protection of the organism against potentially 
toxic compounds is an important biological function, ABCB1 may also play a critical 
role in drug treatment. The efflux of cytostatics due to (over)expression of ABC 
transporters such as ABCB1 is a major limitation in cancer chemotherapy (classical 
multidrug resistance, MDR, of tumor cells).[1-6] In addition to their contribution to drug 
resistance, these transporters are highly expressed in the endothelial cells of brain 
capillaries and represent important components of the blood brain barrier (BBB), 
preventing the entry of a broad variety of xenobiotics, including anticancer drugs, such 
as vinca alkaloids, anthracyclines, epipodophyllotoxins and taxanes, into the central 
nervous system. This leads to very low drug concentrations in the brain and plays a 
crucial role in the clinical resistance of malignant brain tumors to chemotherapy.[7] 
 
In order to improve drug uptake into the brain, several studies explored the possibility 
of inhibiting ABCB1 in the capillaries of the BBB.[4-8]. We recently demonstrated that 
coapplication of the 2nd generation ABCB1 inhibitor valspodar with the anticancer drug 
paclitaxel, an ABCB1 substrate, increased brain levels of the cytostatic in mice by a 
factor of 6-8 compared to the treatment with paclitaxel alone.[8] Moreover, in nude mice 
bearing orthotopically growing human glioblastoma the combination therapy led to a 
decrease in tumor volume by 90%, whereas application of paclitaxel alone was 
ineffective. The antitumor effect in vivo could be clearly attributed to increased 
paclitaxel levels in the brain as a result of inhibited ABCB1-mediated transport at the 
BBB.[8] However, paclitaxel levels also increased in liver, kidneys and plasma 
compared to the control, so that systemic paclitaxel toxicity became dose-limiting with 
valspodar, due to modulation of ABCB1 in liver, kidneys and bone marrow. Using the 
more potent ABCB1 inhibitor tariquidar (1, Figure 1), a higher brain/plasma ratio of 
paclitaxel was detected in mice.[9] However, despite of high tariquidar concentrations in 
the brain, paclitaxel brain levels did not increase compared to the valspodar group.[9] 
The latter result might be explained by the high lipophilicity of tariquidar resulting in its 
accumulation in the lipid compartment of the brain. Therefore, tariquidar might reach its 
target, the ABCB1 transporter, at suboptimal concentration. To investigate this 
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hypothesis we started a project to develop better water soluble tariquidar analogues with 
more favourable pharmacokinetic properties.  
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Figure 1. Structure of tariquidar (1). 
 
The reported activity data of known tariquidar derivatives suggested that modifications 
of the methoxy groups of the central anthranilic amide are likely to be tolerated. Our 
retrosynthetic approach uses bromo tariquidar 3 as a precursor that is converted by 
transition metal catalyzed N- or O-aryl coupling into tariquidar derivatives with 
different overall polarity (Figure 2). While the traditional Cu-mediated Ullmann 
coupling reactions required high temperatures and stoichiometric amounts of copper,[10] 
far more efficient methodologies using catalytic amounts of palladium or copper salts 
have been developed for the coupling of amines to aryl halides.[11] In most cases though, 
the reported reaction conditions were optimized for rather simple substrate 
combinations. Especially for the palladium chemistry the proper choice of the catalyst 
system is crucial for the success of the reactions,[12] and the combination of palladium 
source, ligand, their ratio, base and substrate might be very sensitive to variations.[13] 
We have therefore tested in this work a series of typical palladium and copper catalyzed 
N-arylation conditions for their application on tariquidar. 
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Figure 2. Synthesis of tariquidar derivatives 2 by N- or O-aryl coupling; X = O, N; R = 
alkyl 
 
1.2. Results and Discussion 
 
Synthesis. The preparation of the bromo tariquidar analogue 3 followed the parent 
synthesis[14] in coupling the upper aniline part and the lower quinoline part to 
substituted anthranilic acid as the central moiety. 2-Amino-5-bromobenzoic acid (5) 
was obtained by bromination of anthranilic acid (4) with [bmim]Br3 according to the 
procedure described in literature in good yield.[15] Boc-protection highly improved the 
solubility of the intermediate 7 and was crucial for the efficiency of the subsequent 
coupling reaction. After deprotection and acylation with quinoline-2-carbonyl chloride 
the bromo tariquidar analogue 3 was obtained in an overall yield of 38% over five 
reaction steps (Scheme 1). 
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Scheme 1. Synthesis of bromo tariquidar 3. Reagents and conditions: a) [bmim]Br3, 
CH2Cl2, room temp., 40 min, 95%; b) Boc2O, Na2CO3, CH2Cl2, room temp. to 40 °C, 
60%; c) ArNH2, HBTU, HOBt, DIPEA, CH2Cl2, 0 °C to room temp., 24 h, 85%; d) 
HCl/Et2O, CH2Cl2, 0 °C to room temp., 95%; e) quinoline-3-carbonyl chloride, NEt3, 
CH2Cl2/DMF, room temp., 70 h, 82%. 
  
A primary (9), a secondary cyclic (10) and a secondary acyclic (11) amine were selected 
for N-aryl coupling reactions to probe different amine types and obtain tariquidar 
analogues with increased solubility and decreased lipophilicity (Figure 3).  
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Figure 3. Amines for N-aryl coupling reactions with compound 3. 
 
To compare different catalyst systems the bromo tariquidar precursor 6 was allowed to 
react with morpholine (10) and the primary amine 9 (Scheme 2) using copper and 
palladium salts and the ligand systems given in Figure 4. The ligands were adopted 
from procedures described in literature for the coupling of aryl bromides and primary 
and secondary aliphatic amines, respectively.[12,16-18] 
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Scheme 2. Model reactions with aryl bromide 6. Reagents and conditions: a) 
CuBr×Me2S (20 mol-%), L2 (40 mol-%), K3PO4, DMF, 90 °C, 24 h; b) Pd2(dba)3 (2.5 
mol-%), L4 (4.5 mol-%), NaOtBu, toluene, 90 °C, 24 h; c) CuI (20 mol-%), L3 (40 mol-
%), K3PO4, DMSO, 90 °C, 24 h; d) Pd2(dba)3 (1 mol-%), L5 (4 mol-%), K3PO4, 
toluene, 90 °C, 24 h 
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Figure 4. Ligands used for N-aryl coupling reactions. 
 
The para-amino substituent in compound 6 disfavours the N-aryl substitution 
reaction.[19] While the copper-catalyzed reaction for the primary amine still gave 
moderate coupling yields, the isolated product amounts from the palladium-catalyzed 
reactions were disappointing. Another drawback of the palladium-catalyzed reactions is 
the typical use of toluene as solvent, in which compound 3 is only sparingly soluble 
even at higher temperatures. 
 
Compound 3 was coupled with primary amine 9 using CuI and N,N-diethylsalicylamide 
(L2) or 2-isobutyrylcyclohexanone (L1) as ligand,[16,20] yielding tariquidar analogue 14, 
which shows improved solubility, in moderate yields. Morpholine (10) was introduced 
as substituent into the tariquidar skeleton in good yields with L-proline (L3) as ligand 
following the conditions recently described by Ma.[18] The most critical substrates for 
these kinds of coupling reactions are secondary acyclic amines. Several of the above 
discussed conditions were tested, but none of them gave the desired product in 
1. ABCB1 Inhibition  
 7 
satisfactory and isolatable amounts (Scheme 3). The use of 3 in a CuCl-catalyzed O-aryl 
coupling was demonstrated in the reaction with alcohol 19 in an analogous coupling 
reaction. 
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Scheme 3. Ullmann-type coupling reactions of 3 with amines 9-11. Reagents and 
conditions: a) CuBr×Me2S (20 mol-%), L2 (40 mol-%), K3PO4, DMF, 90°C, 32% (66% 
of 3 recovered); b) CuI (40 mol-%), L1 (75 mol-%), K3PO4, DMF, 90°C, 40% (41% of 
3 recovered); c) CuBr×Me2S (20 mol-%), L3 (40 mol-%), K3PO4, DMSO, 90°C, 75%; 
d) CuBr×Me2S (20 mol-%), L3 (40 mol-%), K3PO4, DMSO, 90°C; e) CuI (40 mol-%), 
L1 (80 mol-%), K3PO4, DMF, 90°C; f) Pd2(dba)3 (1.5 mol-%), L4 (1.5 mol-%), 
NaOtBu, toluene, 90°C; g) i) 19, Na; ii) CuCl (20 mol-%), DMF, 90°C, 52% (46% of 3 
recovered). 
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Flow Cytometric Calcein-AM Efflux Assay (ABCB1 Assay). In Kb-V1 cells calcein-
AM is extruded by ABCB1 before non-specific esterases can cleave the ester bonds, and 
calcein is not accumulated.[21] Therefore, ABCB1 inhibitors can easily be recognized by 
flow cytometric determination of intracellular calcein-AM levels. Depending on the 
modulator concentration the change in the calcein-AM efflux or rather in the relative 
fluorescence intensity of the cells is measured. The assay was performed as recently 
described by Müller et al.[21] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. ABCB1 inhibition by tariquidar and the new inhibitors in dependence of their 
concentrations. Open circle 3, filled triangle 17, filled circle tariquidar, open triangle 
15, filled square 14. 
 
 
Table 1. Calculated properties of the new tariquidar analogues and their biological 
activities as determined by the calcein-AM efflux assay.  
 
Compound log P IC50 (nM) Efficacy (%) Hill-Coefficient n 
Tariquidar 6.1 ± 1.1 223 ± 8 102 2.6 5 
3 7.1 ± 1.0 145 ± 12 98 1.9 3 
17 6.0 ± 1.0 181 ± 6 116 2.7 3 
15 5.1 ± 1.0 593 ± 21 109 2.9 3 
14 4.3 ± 1.1 1 575 ± 98 105 2.3 3 
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The resulting data of the new tariquidar analogues and their calculated pharmacokinetic 
parameters (calculations were carried out with ACD Labs software) are shown in Figure 
5 and Table 1. Compared to tariquidar both the central building block 3 and the aryl 
ether analogue 17 show improved activities in the calcein-AM efflux assay, while the 
two aryl amine analogues 15 and 14 are less potent than the reference substance 
tariquidar in inhibiting ABCB1. The desired decrease in lipophilicity was achieved in 
all three derivatives of 3. In the same order as log P decreases the activity against 
ABCB1 drops. It is still discussed in literature whether high lipophilicity might be an 
important criterion (amongst others) for the inhibition of ABC transporters.[22] The 
results obtained from this small series are in accordance with this hypothesis, assuming 
that the newly introduced side chains only affect physicochemical parameters .  
 
1.3. Conclusion 
 
In summary, we have shown that modern variants of the Ullmann reaction can be used 
to prepare tariquidar analogues from bromo tariquidar 3 and suitable amines in one step. 
Coupling of a primary and a secondary cyclic amine as well as an alcohol was achieved 
in one metal-catalyzed reaction each. The Ullmann-type coupling reactions using Cu(I) 
seem to be more generally applicable for these substrate combinations than the 
Buchwald-Hartwig-aminations using Pd(0). For the Pd-chemistry, the system of Pd 
source, ligand, base and solvent is probably more critical towards different substrate 
combinations and might need to be optimized for each reaction. The synthetic route 
described here allows quick access to new potential MDR modulators.  The results from 
the calcein-AM efflux assay demonstrate that structural changes in the chosen position 
are indeed tolerated without considerable loss of activity. The series of new ABCB1 
modulators is well suited to test the aforementioned BBB selectivity hypothesis in vivo, 
since the lipophilicities of the compounds range from log P 7 to 4, thereby including the 
value of tariquidar (log P = 6.1) on one end and that of valspodar (log P = 4.1) on the 
other end. Further investigations on the new tariquidar-like ABCB1 inhibitors are in 
progress. 
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1.4. Experimental Section 
 
General: Commercial reagents and starting materials were purchased from Aldrich, 
Fluka or Acros and used without further purification. CH2Cl2 was distilled from CaH2, 
anhydrous DMF was purchased from Fluka. Flash chromatography was performed on 
silica gel (Merck silica gel Si 60 40-63 µm); products were detected by TLC on alumina 
plates coated with silica gel (Merck silica gel 60 F254, thickness 0.2 mm). The 
compounds were detected by UV-light (λ = 254 nm) and a solution of ninhydrine in 
ethanol. Melting points were determined with a Büchi SMP 20 and are uncorrected. 
NMR spectra were recorded with Bruker Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz, 
T = 300 K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K) and 
Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 K) instruments. 
Chemical shifts are reported in δ/ppm relative to external standards and coupling 
constants J are given in Hz. Abbreviations for the characterisation of the signals: s = 
singlet, d = doublet, t = triplet, m = multiplet, bs = broad singlet, dd = double doublet. 
The relative number of protons is determined by integration. Error of reported values: 
chemical shift 0.01 ppm (1H-NMR), 0.1 ppm (13C-NMR), coupling constant 0.1 Hz. The 
used solvent for each spectrum is reported. Mass spectra were recorded with Finnigan 
MAT TSQ 7000 (ESI) and Finnigan MAT 90 (HRMS), IR spectra with a Bio-Rad FT-
IR-FTS 155 spectrometer and UV/Vis spectra with a Cary BIO 50 UV/Vis/NIR 
spectrometer (Varian). Compounds 9, 11 and 2-isobutyrylcyclohexanone (L1) were 
prepared by the reported methods. The products of the model reactions (12 and 13) were 
synthesized under the conditions described above, the experimental procedures were 
identical with those of the final reactions. 
 
NHBoc
COOHBr
 
 
5-Bromo-2-(tert-butoxycarbonylamino)benzoic acid (6) 
 
5-Bromoanthranilic acid (5) (4.35 g, 20 mmol) was dissolved in anhydrous 
dichloromethane (150 mL), followed by the addition of Na2CO3 (2.36 g, 22 mmol) and 
di-tert-butyl dicarbonate (4.85 g, 22 mmol). The solution was stirred at room 
temperature for 1 h under nitrogen atmosphere and then heated at reflux temperature for 
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24 h. The mixture was washed with water, 1 M citric acid and brine. The organic phase 
was dried over Na2SO4, evaporated under reduced pressure and separated by column 
chromatography on silica gel (elution with hexane/acetone 5:1, Rf = 0.35) to provide 6 
as a white solid (3.8 g, 60%). 
mp = 177-178 °C – 1H-NMR (300 MHz, CDCl3): δ = 1.52 (s, 9H, Boc), 7.62 (dd, 3J = 
9.1 Hz, 4J = 2.5 Hz, 1H, H-Ar), 8.10 (d, 4J = 2.5 Hz, 1H, H-Ar), 8.30 (d, 3J = 9.1 Hz) – 
13C-NMR (75 MHz, CDCl3): δ = 28.6 (+), 81.9 (Cquat), 114.3 (Cquat), 118.0 (Cquat), 121.4 
(+), 134.9 (+), 137.9 (+), 142.7 (Cquat), 154.0 (Cquat), 170.0 (Cquat) – IR (KBr) [cm-1]: 
ν~ = 3330, 2978, 1729, 1682, 1578, 1516 – UV/Vis (MeOH) λmax [nm] (lg ε): 308 
(3.514), 253 (4.280) – MS (−p ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 314 
(100) [(M − H+)-], 316 (98) [(M − H+)-] – Elemental analysis calcd (%) for C12H14BrNO 
(316.15): C 45.59, H 4.46, N 4.43; found C 45.12, H 4.55, N 4.24. 
 
N
H
OO COOH
NHBoc
 
 
2-(tert-Butoxycarbonylamino)-5-[2-(2-methoxyethoxy)ethylamino]benzoic acid (12) 
 
1H-NMR (300 MHz, CDCl3): δ = 1.52 (s, 9H, Boc), 3.29-3.33 (m, 2H, CH2), 3.41 (s, 
3H, OCH3), 3.56-3.60 (m, 2H, CH2), 3.64-3.68 (m, 2H, CH2), 3.70-3.74 (m, 2H, CH2), 
6.93 (dd, 3J = 9.1 Hz, 4J = 3.0 Hz, 1H, H-Ar), 7.35 (d, 4J = 3.3 Hz, 1H, H-Ar), 8.24 (d, 
3J = 9.1 Hz, 1H, H-Ar), 9.65 (bs, 1H, CONH) – 13C-NMR (75 MHz, CDCl3): δ = 28.4 
(+), 44.4 (-), 59.1 (+), 69.3 (-), 70.2 (-), 71.9 (-), 80.3 (Cquat), 114.7 (Cquat), 115.2 
(+),120.6 (+), 121.7 (+), 134.5 (Cquat), 153.1 (Cquat), 172.2 (Cquat), 176.8 (Cquat) – MS 
(CI, NH3): m/z (%) = 355 (100) [MH+]. 
 
N COOH
NHBoc
O
 
 
2-(tert-Butoxycarbonylamino)-5-morpholinobenzoic acid (13) 
 
1H-NMR (300 MHz, CDCl3): δ = 1.53 (s, 9H, Boc), 3.11-3.14 (m, 4H, 2 CH2), 3.86-
3.89 (m, 4H, 2 CH2), 7.19 (dd, 3J = 9.3 Hz, 4J = 3.3 Hz, 1H, H-Ar), 7.58 (d, 4J = 3.0 Hz, 
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1H, H-Ar), 8.36 (d, 3J = 9.3 Hz, 1H, H-Ar), 9.79 (bs, 1H, CONH) – 13C-NMR (75 MHz, 
CDCl3): δ = 28.5 (+), 50.3 (-), 67.1 (-), 80.7 (Cquat), 114.6 (Cquat) , 118.2 (+), 120.5 (+), 
124.2 (+), 136.5 (Cquat), 145.9 (Cquat), 153.2 (Cquat), 171.8 (Cquat) –  MS (CI, NH3): m/z 
(%) = 323 (83) [MH+], 266 (100) [MH+ − (C4H9)]. 
 
NHBoc
Br N
H
O N
OMe
OMe
 
 
tert-Butyl-4-bromo-2-({4-[2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-
yl)ethyl]phenyl}carbamoyl)phenylcarbamate (7) 
 
Compound 6 (886 mg, 2.8 mmol), HOBt (419 mg, 3.1 mmol) and HBTU (1166 mg, 3.1 
mmol) were added to an ice-cooled solution of DIPEA (0.9 mL, 5.2 mmol) in CH2Cl2 
(10 mL). The solution was stirred for 10 min and 4-[2-(6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinolin-2-yl)ethyl]phenylamine (812 mg, 2.6 mmol) was added in small 
portions. The reaction mixture was allowed to warm to room temperature and stirred for 
24 h, diluted with CH2Cl2 and the organic phase was washed with water, saturated 
aqueous solution of NaHCO3 (3 ×) and dried over MgSO4. After evaporation of the 
solvent the crude product was purified by flash chromatography on silica gel (elution 
with EtOAc/1% NEt3, Rf = 0.27) to obtain a pale yellow solid (1.3 g, 85%).  
mp = 196 °C – 1H-NMR (300 MHz, CDCl3): δ = 1.49 (s, 9H, Boc), 2.75-2.95 (m, 8H, 4 
CH2), 3.66 (s, 2H, NCH2), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 6.54 (s, 1H, H-Ar), 
6.61 (s, 1H, H-Ar), 7.26-7.29 (m, 2H, H-Ar, AA’BB’), 7.46-7.49 (m, 2H, H-Ar, 
AA’BB’), 7.56 (dd, 4J = 2.5 Hz, 3J = 9.1 Hz, 1H, H-Ar), 7.68 (d, 4J = 2.2 Hz, 1H, H-Ar), 
7.74 (bs, 1H, CONH), 8.31 (d, 3J = 9.1 Hz, 1H, H-Ar), 9.72 (bs, 1H, CONH) –  13C-
NMR (75 MHz, [D6]DMSO): δ = 27.8 (+), 28.2 (-), 32.4 (-), 50.5 (-), 55.0 (-), 55.3 (+), 
55.3 (+), 59.5 (-), 80.1 (Cquat), 109.8 (+), 111.6 (+), 113.3 (Cquat), 120.9 (+), 121.3 (+), 
123.4 (Cquat), 125.8 (Cquat), 126.5 (Cquat), 128.7 (+), 131.0 (+), 134.5 (+), 136.1 (Cquat), 
136.5 (Cquat), 138.1 (Cquat), 146.7 (Cquat), 147.0 (Cquat), 151.9 (Cquat), 165.5 (Cquat) – IR 
(KBr) [cm-1]: ν~ = 3321, 2974, 2933, 1728, 1512, 1156 – UV/Vis (MeOH) λmax [nm] (lg 
ε): 281 (4.107), 256 (4.300) – MS (ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 
610 (100) [MH+], 612 (97) [MH+]. 
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2-Amino-5-bromo-N-(4-{-[6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl]ethyl}-
phenyl)benzamide (8) 
 
Compound 7 (1.3 g, 2.2 mmol) was dissolved in CH2Cl2 (30 mL) and cooled in an ice-
bath. After addition of HCl/Et2O the mixture was stirred overnight, concentrated in 
vacuo and the precipitate was suspended in CH2Cl2 and washed with saturated aqueous 
solution of NaHCO3. The organic phase was dried over MgSO4 and the solvent was 
removed to obtain the pure product as a white solid (1.0 g, 95%). 
mp = 157 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.74-2.94 (m, 8H, 4 CH2), 3.65 (s, 2H, 
NCH2), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 5.51 (bs, 2H, NH2), 6.54 (s, 1H, H-Ar), 
6.61 (s, 1H, H-Ar), 6.61 (d, 3J = 8.8 Hz, 1H, H-Ar), 7.23-7.26 (m, 2H, H-Ar, AA’BB’), 
7.32 (dd, 4J = 2.2 Hz, 3J = 8.8 Hz, 1H, H-Ar), 7.46-7.49 (m, 2H, H-Ar, AA’BB’), 7.56 
(d, 4J = 2.2 Hz, 1H, H-Ar), 7.65 (bs, 1H, CONH) – 13C-NMR (75 MHz, CDCl3): δ = 
28.6, 33.4, 51.1, 55.7, 55.9, 55.9, 60.1, 107.8, 109.5, 111.4, 117.8, 119.1, 121.0, 126.1, 
126.3, 129.3, 129.7, 135.3, 135.6, 136.9, 147.2, 147.6, 147.9, 166.3 – IR (KBr) [cm-1]: 
ν~ = 3470, 3373, 3302, 1638, 1596, 1520, 818 – UV/Vis (CH2Cl2) λmax [nm] (lg ε): 346 
(3.366), 264 (3.808), 229 (4.067) – MS (ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z 
(%) = 510 (100) [MH+], 512 (98) [MH+]. 
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N-(4-Bromo-2-{[4-(2-{6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-
yl}ethyl)phenyl]-carbamoyl}phenyl)quinoline-3-carboxamide (3) 
 
Compound 8 (702 mg, 1.4 mmol) and NEt3 (0.4 mL, 3 mmol) were dissolved in a 
mixture of CH2Cl2 and anhydrous DMF (10 mL/1 mL). Quinoline-3-carbonyl chloride 
hydrochloride (477 mg, 2.1 mmol) was added in small portions and the mixture was 
stirred at room temperature for 3 d. After dilution with CH2Cl2 the organic phase was 
washed with saturated aqueous solution of NaHCO3 and dried over MgSO4. 
Evaporation of the solvent and purification by flash chromatography on silica gel 
(elution with acetone/hexanes 1:1, 1% NEt3, Rf = 0.27) yielded the product as a pale 
yellow solid (761 mg, 82%). 
mp = 204-207 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.76-2.97 (m, 8H, 4 CH2), 3.67 (s, 
2H, NCH2), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 6.54 (s, 1H, H-Ar), 6.61 (s, 1H, H-
Ar), 7.31 (d, 3J = 8.5 Hz, 2H, H-Ar, AA’BB’), 7.57 (dd, 4J = 2.2 Hz, 3J = 8.8 Hz, 1H, H-
Ar), 7.61-7.67 (m, 1H, H-Ar), 7.63 (d, 3J = 8.5 Hz, 2H, H-Ar, AA’BB’), 7.78 (d, 4J = 
2.2 Hz, 1H, H-Ar), 7.81-7.87 (m, 1H, H-Ar), 7.99-8.02 (m, 1H, H-Ar), 8.16-8.19 (m, 
1H, H-Ar), 8.47 (bs, 1H, CONH), 8.62 (d, 3J = 8.8 Hz, 1H, H-Ar), 8.78 (d, 4J = 2.2 Hz, 
1H, H-Ar), 9.52 (d, 4J = 2.2 Hz, 1H, H-Ar), 12.07 (bs, 1H, CONH) – 13C-NMR (75 
MHz, CDCl3): δ = 28.7 (-), 33.5 (-), 51.1 (-), 55.7 (-), 55.9 (+), 55.9 (+), 60.1 (-), 109.5 
(+), 111.4 (+), 116.1 (Cquat), 121.0 (+), 123.1 (Cquat), 123.6 (+), 126.1 (Cquat), 126.5 
(Cquat), 126.7 (Cquat), 126.9 (Cquat), 127.6 (+), 129.2 (+), 129.5 (+), 129.5 (+), 130.0 (+), 
131.7 (+), 135.2 (Cquat), 135.4 (+), 136.2 (+), 137.8 (Cquat), 138.3 (Cquat), 147.2 (Cquat), 
147.6 (Cquat), 148.7 (+), 149.5 (Cquat), 164.1 (Cquat), 166.1(Cquat) – IR (KBr) [cm-1]: ν~ = 
2932, 1677, 1597, 1512, 1464, 829 – UV/Vis (CH2Cl2) λmax [nm] (lg ε): 287 (4.333), 
238 (4.637) – HRMS calcd. for C36H33BrN4O4 [M.+]: 664.1685, found: 664.1692 – 
Elemental analysis calcd (%) for C36H33BrN4O4 (665.59): C 64.96, H 5.00, N 8.42; 
found C 64.37, H 4.99, N 8.11. 
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N-(2-{[4-(2-{6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-
yl}ethyl)phenyl]carbamoyl}-4-{2-ethoxyethoxy}phenyl)quinoline-3-carboxamide 
(17) 
 
A 25 mL three-neck flask was evacuated, flushed with nitrogen (3 cycles) and charged 
with 2-ethoxyethanol (2 mL, 21 mmol) and Na (10 mg, 0.4 mmol). After the formation 
of H2 had ceased, DMF (0.5 mL), CuCl (4 mg, 0.04 mmol) and compound 3 (122 mg, 
0.2 mmol) were added under nitrogen. The flask was equipped with a condenser and the 
reaction mixture was stirred at 90 °C for 24 h. After cooling, the mixture was diluted 
with CH2Cl2, washed with water and saturated aqueous solution of NaHCO3 (3×), and 
the organic phase was dried over MgSO4. The solvent was evaporated and the 
remaining solid was purified by flash-chromatography on silica gel (elution with 
acetone/hexanes 1:1, Rf = 0.31) to obtain a white solid (64 mg, 52%). 
mp = 124-126 °C – 1H-NMR (400 MHz, CD2Cl2; HSQC, HMBC, COSY, ROESY): δ = 
1.18 (t, 3J = 7.2 Hz, 3H, CH3, H(36)), 2.76-2.84 (m, 6H, 3 CH2, H(9/4/5)), 2.90-2.93 (m, 
2H, CH2, H(10)), 3.51 (q, 3J = 7.2 Hz, 2H, OCH2, H(35)), 3.62 (s, 2H, NCH2, H(8)), 
3.64 (t, 3J = 4.8 Hz, 2H, OCH2, H(34)), 3.78 (s, 3H, OCH3, H(38)), 3.78 (s, 3H, OCH3, 
H(37)), 4.07 (t, 3J = 4.8 Hz, 2H, OCH2, H(33)), 6.54 (s, 1H, H(1)-Ar), 6.60 (s, 1H, 
H(4)-Ar), 7.10 (dd, 3J = 9.2 Hz, 4J = 2.7 Hz, 1H, H(20)-Ar), 7.28 (d, 4J = 2.7 Hz, 1H, 
H(18)-Ar), 7.31 (d, 3J = 8.3 Hz, 2H, H(12/12’)-Ar), 7.62 (d, 3J = 8.3 Hz, 2H, H(13/13’)-
Ar), 7.62-7.66 (m, 1H, H(30)-Ar), 7.80-7.84 (m, 1H, H(29)-Ar), 7.99-8.02 (m, 1H, 
H(31)-Ar), 8.13-8.15 (m, 1H, H(28)-Ar), 8.38 (bs, 1H, CONH(15)), 8.66 (d, 3J = 9.2 
Hz, 1H, H(21)-Ar), 8.75 (d, 4J = 2.3 Hz, 1H, H(32)-Ar), 9.43 (d, 4J = 2.3 Hz, 1H, 
H(26)-Ar), 11.80 (bs, 1H, CONH(23)) – 13C-NMR (100 MHz, CD2Cl2): δ = 15.3 (+, 
C(36)), 29.0 (-, C(5)), 33.5 (-, C(10)), 51.4 (-, C(6)), 55.9 (-, C(8)), 56.2 (+, C(38)), 56.2 
(+, C(37)), 60.2 (-, C(9)), 67.1 (-, C(35)), 68.5 (-, C(33)), 69.1 (-, C(34)), 110.2 (+, 
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C(1)), 112.1 (+, C(4)), 114.2 (+, C18)), 118.3 (+, C(20)), 121.3 (+, C(13/13’)), 123.1 
(Cquat, C(17)), 123.6 (+, C(21)), 126.7 (Cquat, C(4a)), 127.2 (Cquat, C(25)), 127.4 (Cquat, 
C(8a)), 127.7 (+, C(30)), 127.8 (Cquat, C(31a)), 129.5 (+, C(31)), 129.8 (+, C(12/12’)), 
129.8 (+, C(28)), 131.6 (+, C(29), 133.3 (Cquat, C(22)), 135.8 (Cquat, C(14)), 135.9 (+, 
C(32)), 138.2 (Cquat, C(11)), 147.8 (Cquat, C(2)), 148.1 (Cquat, C(3)), 149.0 (+, C(26)), 
149.8 (Cquat, C(27a)), 154.9 (Cquat, C(19)), 163.8 (Cquat, C(24)), 167.5 (Cquat, C(16)) – IR 
(KBr) [cm-1]: ν~ = 2931, 1633, 1597, 1517, 1408, 1127 – UV/Vis (CH2Cl2) λmax [nm] (lg 
ε): 282 (4.176), 238 (4.550) – HRMS calcd. for C40H42N4O6 [M.+]: 674.3104, found: 
674.3106.  
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N-(2-{[4-(2-{6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-
yl}ethyl)phenyl]carbamoyl}-4-morpholinophenyl)quinoline-3-carboxamide (15) 
 
A 5 mL screw-capped glass vial with stirring bar was charged with CuBr-
dimethylsulfide complex (10 mg, 0.05 mmol) and put in a small Schlenk tube. The 
reaction vessel was heated and evacuated until dimethylsulfide was removed completely 
and the white solid had turned green. After cooling the vial was evacuated and 
backfilled with argon (3 cycles) and L-proline (12 mg, 0.1 mmol), compound 3 (154 
mg, 0.2 mmol), K3PO4 (106 mg, 0.5 mmol), morpholine (40 µL, 0.5 mmol) and 
anhydrous DMSO (2 mL) were added under argon. The vial was closed and the mixture 
was stirred at 90 °C for 44 hours, cooled and diluted with CH2Cl2. The organic phase 
was washed with water and saturated aqueous solution of NaHCO3 and dried over 
MgSO4. After evaporation of the solvent the remaining solid was purified by flash-
chromatography on silica gel (elution with EtOAc/EtOH 4:1, Rf = 0.29) to give a yellow 
solid (116 mg, 75%). 
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mp = 238 °C – 1H-NMR (600 MHz, CD2Cl2; HSQC, HMBC, COSY, ROESY): δ = 
2.87-3.00 (m, 8H, 4 CH2, H(5,6/9,10), 3.15 (m, 4H, 2 CH2, H(33/34), 3.77 (s, 3H, 
OCH3, H(38)), 3.78 (s, 3H, OCH3, H(37)), 3.77-3.79 (m, 6H, NCH2, H(8), 2 CH2, 
H(35/36)), 6.55 (s, 1H, H-Ar, H(1)), 6.62 (s, 1H, H-Ar, H(4)), 7.11 (dd, 3J = 9.0 Hz, 4J 
= 2.6 Hz, 1H, H-Ar, H(20)), 7.26-7.30 (m, 3H, H-Ar, H(12/12’), H(18)), 7.61-7.67 (m, 
3H, H-Ar, H(13/13’), H(30)), 7.81-7.85 (m, 1H, H-Ar, H(29)), 8.00-8.03 (m, 1H, H-Ar, 
H(31)), 8.11-8.14 (m, 1H, H-Ar, H(28)), 8.51 (d, 3J = 9.0 Hz, 1H, H-Ar, H(21)), 8.75-
8.77 (m, 1H, H-Ar, H(32)), 9.30 (bs, 1H, CONH, H(15)), 9.38-9.40 (m, 1H, H-Ar, 
H(26)), 11.70 (bs, 1H, CONH, H(23)) – 13C-NMR (150 MHz, CD2Cl2): δ = 27.5 (C(5)), 
32.5 (C(10)), 49.8 (C(33/34)), 50.9 (C(6)), 54.9 (C(8)), 56.1 (C(38)), 56.2 (C(37)), 60.8 
(C(9)), 67.0 (C(35/36)), 110.1 (C(1)), 111.9 (C(4)), 115.0 (C(18)), 119.9 (C(20)), 121.8 
(C(13/13’)), 123.4 (C(21)), 123.8 (C17)), 124.5 (C(8a)), 125.6 (C4a)), 127.4 (C(31a)), 
127.9 (C(25)), 127.9 (C(30)), 129.2 (C(28)), 129.5 (C(31)), 129.6 (C(12/12’)), 131.6 
(C(22)), 131.7 (C(14)), 131.9 (C(29)), 136.2 (C(32)), 136.5 (C(11)), 147.9 (C(2)), 148.1 
(C(19)), 148.6 (C(3)), 148.9 (C(26)), 149.4 (C(27a)), 163.7 (C(24)), 168.4 (C(16)) – IR 
(KBr)  [cm-1]: ν~ = 2933, 1655, 1598, 1516, 1228, 1123 – UV/Vis (CH2Cl2) λmax [nm] 
(lg ε): 283 (4.245), 236 (4.562) – HRMS calcd. for C40H41N5O5 [M.+]: 671.3108, found: 
671.3122.  
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N-(2-{[4-(2-{6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-
yl}ethyl)phenyl]carbamoyl}-4-{2-[2-methoxyethoxy]ethylamino}phenyl)quinoline-
3-carboxamide (14) 
 
A 5 mL screw-capped glass vial with stirring bar was charged with CuI (20 mg, 0.1 
mmol), compound 3 (176 mg, 0.3 mmol) and K3PO4 (106 mg, 0.5 mmol). The vial was 
put in a small Schlenk tube, evacuated and filled with argon (3 cycles). 2-
Isobutyrylcyclohexanone (34 mg, 0.2 mmol), 2-(2-methoxyethoxy)ethylamine (60 mg, 
1. ABCB1 Inhibition  
 18 
0.5 mmol) and dry DMF were added by syringe under argon, the vial was capped and 
the reaction mixture was stirred at 90 °C for 48 h. After cooling the solution was diluted 
with CH2Cl2, washed with water and a saturated aqueous solution of NaHCO3 and the 
organic phase was dried over MgSO4. Evaporation of the solvent and purification of the 
crude product by flash-chromatography on silica gel (elution with EtOAc/MeOH 4:1, 
1% NEt3, Rf = 0.25) gave 19 as a yellow solid (74 mg, 40%). 
mp = 96 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.82-3.00 (m, 8H, 4 CH2), 3.16 (t, 3J = 
5.1 Hz, 2H, CH2), 3.33 (s, 3H, OCH3), 3.44-3.51 (m, 6H, 3 CH2), 3.73 (s, 2H, NCH2), 
3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 6.54 (s, 1H, H-Ar), 6.61 (s, 1H, H-Ar), 6.72 
(dd, 3J = 9.1 Hz, 4J = 2.7 Hz, 1H, H-Ar), 6.92 (d, 4J = 2.7 Hz, 1H, H-Ar), 7.28 (d, 3J = 
8.5 Hz, 2H, H-Ar, AA’BB’), 7.59-7.65 (m, 1H, H-Ar), 7.67 (d, 3J = 8.5 Hz, 2H, H-Ar, 
AA’BB’), 7.78-7.83 (m, 1H, H-Ar), 7.96-7.99 (m, 1H, H-Ar), 8.14-8.17 (m, 1H, H-Ar), 
8.42 (d, 3J = 9.1 Hz, 1H, H-Ar), 8.69 (bs, 1H, CONH), 8.73 (d, 4J = 2.2 Hz, 1H, H-Ar), 
9.49 (d, 4J = 2.2 Hz, 1H, H-Ar), 11.60 (bs, 1H, CONH) – 13C-NMR (100 MHz, 
CD2Cl2): δ = 24.4, 30.4, 49.8, 52.6, 54.3, 56.2, 56.2, 56.3, 59.0, 68.3, 70.3, 72.2, 109.8, 
111.7, 118.7, 122.1, 122.2, 123.0, 123.4, 123.4, 127.6, 128.0, 128.1, 128.2, 128.4, 
129.5, 129.6, 129.6, 132.6, 133.0, 137.4, 137.5, 147.9, 147.9, 148.2, 149.0, 149.7, 
163.2, 168.0 – IR (KBr) [cm-1]: ν~ = 2930, 1599, 1516, 1252, 1226 – UV/Vis (MeOH) 
λmax [nm] (lg ε): 281 (4.150), 236 (4.519) – HRMS calcd. for C41H45N5O6 [M.+]: 
703.3370, found: 703.3376. 
 
Cell line and culture conditions. Kb-V1 cells, an ABCB1 overexpressing subclone[23] 
of Kb cells (ATCC CCL-17), were maintained in Dulbecco´s modified Eagle´s medium 
(Sigma, Deisenhofen, Germany) supplemented with 10 % FCS (Biochrom, Berlin, 
Germany) and 300 ng/mL vinblastine. Cells were maintained in a water saturated 
atmosphere (95% air/5% carbon dioxide) at 37 °C in 75-cm² culture flasks (NUNC, 
Wiesbaden, Germany) and serially passaged following trypsinization using 0.05 % 
trypsin/0.02 % EDTA (Roche Diagnostics, Mannheim, Germany). Mycoplasma 
contamination was routinely monitored by polymerase chain reaction (Venor® GeM, 
Minerva Biolabs GmbH, Berlin, Germany), and only Mycoplasma-free cultures were 
used. 
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2. Potent and Selective Inhibitors of  
Breast Cancer Resistance Protein (ABCG2) Derived from the  
p-Glycoprotein (ABCB1) Modulator Tariquidar i 
 
 
 
The efflux pumps ABCB1 (p-gp, MDR1) and ABCG2 (BCRP) are expressed to a high 
extent by endothelial cells at the blood-brain barrier (BBB) and other barrier tissues, and 
are involved in drug resistance of tumor (stem) cells. Based on the findings that slight 
structural modifications of the aromatic tariquidar core resulted in potent ABCG2 
inhibition a series of ABCG2 inhibitors was prepared and found to be highly selective 
over ABCB1 and ABCC2. ii  Chemosensitivity assays against MCF-7/Topo cells 
revealed that a non-toxic inhibitor completely reverted ABCG2-mediated topotecan 
resistance at concentrations >100 nM, whereas another analogue showed ABCG2 
independent cytotoxicity.iii ABCG2 inhibitors might be useful for cancer treatment with 
respect to reversal of multidrug resistance, overcoming the BBB and targeting of tumor 
stem-cells. 
  
                                                 
i
 M. Kühnle, M. Egger, C. Müller, A. Mahringer, G. Bernhardt, G. Fricker, B. König, A. Buschauer,  
 J. Med. Chem. 2009, 52, 1190-1197. 
ii
 The calcein-AM efflux assays (ABCB1) and the mitoxantrone efflux assays (ABCG2) were carried out 
by Matthias Kühnle and Christine Müller at the Institute of Pharmacy, University of Regensburg. The 
CMFDA accumulation assays (ABCC2) were done by Anne Mahringer at the Institute of Pharmacy and 
Molecular Biotechnology, University of Heidelberg. 
iii
 The kinetic chemosensitivity assays were performed by Matthias Kühnle and Christine Müller at the 
Institute of Pharmacy, University of Regensburg. 
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2.1. Introduction 
 
ABC transporters use the energy of ATP-hydrolysis to transport a broad variety of 
substrates across the cell membrane. These efflux transport proteins include ABCB1 (p-
glycoprotein 170, P-gp), ABCC2 (multidrug resistance related protein 2)[1,2] and 
ABCG2 (BCRP, ABCP, MXR),[3,4] and appear to play a protective role in normal 
tissues.[5] For example, in the placenta ABCG2 appears to reduce the passage of 
substrates from the mother to the fetus and, as reasoned from mice studies,[6] decreases 
the concentration of certain substrates in the fetal circulation. A high ABCG2 
expression at the luminal surface of the endothelium of microvessel also suggests a 
tutelary function at the blood-brain barrier. In the therapy of CNS diseases the 
aforementioned physiological functions often lead to low drug concentrations in the 
brain.  
 
Numerous anticancer agents are ABCB1 and ABCG2 substrates, which are actively 
pumped out by the transporters located at the blood-brain barrier. This is one of the 
primary causes of the failure of chemotherapy in the treatment of malignant brain 
tumors.[7] Furthermore, ATP-binding cassette (ABC) transporters play a more 
distinctive role in conjunction with multidrug resistance (MDR). It is estimated that 
multidrug resistant tumors account for up to half of all cancer-related deaths.[8, 9] MDR 
is caused by the overexpression of efflux transporters such as ABCB1 and ABCG2, 
located in the plasma membrane of cancer cells and actively extruding a vast number of 
structurally unrelated compounds, including many commonly used anticancer drugs. 
Since its discovery in 1998,[10, 11] ABCG2 has been the subject of many investigations 
concerning its role in MDR, and overexpression of the transporter is associated with 
high-level resistance to a large number of cytostatics.  
 
In addition, ABCG2 transporters have recently attracted interest with respect to a new 
concept of tumor development and progression, the so-called cancer stem cell 
hypothesis. The classical stochastic model of tumor development and progression 
assumes that all cancer cells are tumor initiating and participate in the tumor growth. By 
contrast, the cancer stem cell concept is based on the idea that only a small side-
population of cancer cells proliferate, in analogy to the hematopoietic stem cells in the 
bone marrow. The cells of this side-population divide slowly, are capable of long-term 
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self-renewal and express ABCG2.[12-14] Such cells have been found in numerous 
established tumor cell lines as well as in tumor biopsies[15-17] and might be responsible 
for the long-term failure of many cancer chemotherapies. As a result of their ABCG2-
mediated drug resistance and slow proliferation, they are inefficient targets for classical 
cytostatic drugs. 
 
Thus, in many respects, the potent and selective inhibition of ABCG2 might be a 
promising approach in cancer therapy. The reversal of the multidrug resistance mediated 
by ABCG2 and the specific targeting of the stem-cell like side-population are 
conceivable applications. Specific inhibition of ABCG2 in combination with a 
cytostatic, which is a substrate of ABCG2, might eradicate the tumor stem-cell 
population, provided that ABCG2 expression is actually a characteristic of these cells. 
Another interesting strategy might be the co-administration of potent ABCG2 inhibitors 
with drugs that are substrates of the efflux pump to increase drug levels in the brain.[18] 
The latter has already been proven by the combination of the cytostatic paclitaxel, an 
ABCB1 substrate, and the ABCB1 inhibitors valspodar,[19] elacridar and tariquidar.[20] 
(3 and 4, Figure 1). 
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Figure 1. Structures of the ABCG2 modulators fumitremorgin C (1) and Ko143 (2), the 
dual ABCB1/ABCG2 inhibitor elacridar (3), the ABCB1 inhibitor tariquidar (4) and the 
initial ABCG2 selective lead structure 5 derived from tariquidar. 
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Due to the relatively recent discovery of the ABCG2 transporter only a few ABCG2 
inhibitors have been reported so far.[21-25] Fumitremorgin C (FTC, 1, Figure 1), a 
diketopiperazine isolated from the fermentation broth of Aspergillus fumigatus, was 
reported first.[26] However, its neurotoxicity precluded its use in in vivo experiments. 
The most potent ABCG2 inhibitor known so far is the FTC analogue Ko143 (2).[27] Its 
low cytotoxicity made it promising for in vivo studies, and the bioavailability of orally 
administered topotecan could be increased by a combination with Ko143.[27] 
Novobiocin, a coumermycin derivative and inhibitor of the prokaryotic enzyme gyrase 
was also identified as an ABCG2 inhibitor. In cytotoxicity and flow cytometric assays, 
micromolar concentrations of novobiocin overcame ABCG2-mediated resistance to 
mitoxantrone, topotecan and SN-38, the active metabolite of irinotecan.[28] Several 
ABCB1 inhibitors have also been reported to modulate ABCG2. It was demonstrated 
that elacridar (GF120918, 3)[29] acts as an ABCG2 inhibitor, as does – although with 
lower potency - the ABCB1 inhibitor tariquidar (XR 9576, 4)[30] and the tariquidar and 
elacridar analogue WK-X-34.[31, 32]  
 
A very recent structure-activity relationship study on tariquidar analogues revealed 
preferential inhibition of ABCB1 compared to ABCG2. In these compounds the 
anthranilic acid portion was either acylated with different hetaroyl residues at the o-
amino group or was replaced with (hetero)aromatic carboxylic acids.[33] During our 
work on tariquidar-like compounds as ABCB1 modulators[20,34] we discovered that, 
surprisingly, minimal structural changes at the benzamide core of tariquidar (4, Figure 
1) resulted in a potent and selective ABCG2 inhibitor (5, Figure 1 and Chart 1). Based 
on this finding we prepared a series of new analogues that were characterized with 
respect to their activity and selectivity and are presented in this work. 
 
 
2.2. Results and Discussion 
 
Synthesis. The design of the compounds described in this work was based on the 
serendipitous observation that compound 5 (Figure 1 and Chart 1) was only weakly 
active against ABCB1 but was found to be a potent ABCG2 inhibitor instead. 
Compared to the third generation ABCB1 inhibitor and anthranilic acid derivative 
tariquidar (4) the substitution pattern of carboxylic acid and amine functionalities at the 
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central aromatic core of 5 was changed and the two methoxy groups were replaced by 
an ester group. Since this change apparently had a strong impact on the selectivity for 
ABCG2 versus ABCB1 (Table 1) we decided to prepare two small series of compounds 
in which either the 3-quinolinecarboxylic acid moiety was replaced by various 
heteroaromatic systems or the ester group was exchanged by methoxy and methyl 
substituents at different positions (Chart 1). 
 
Chart 1. Variation of the lead structure 5 (subseries 5-11 and 12-15). 
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The general synthetic route for the title compounds (Scheme 1) comprises the formation 
of an amide bond between 3-nitrobenzoic acid analogues 16a-e and the aromatic amine 
17, which was synthesized as described before.[20] Subsequent hydrogenation of the 
nitro group followed by acylation of the resulting aromatic amines 19a-e with different 
heteroaromatic carbonyl chlorides yielded the compounds 5-15. 
 
 
COOH
NO2
R'
R''
NO2
N
H
O X
R'
R''
NH2
N
OCH3
OCH3
NH2
N
H
O X
R'
R''
N
OCH3
OCH3
R' R''
(iv)
18a-e
19a-e
5-15
+
17
16,
 
18,
 
19
X =
(i) or (ii)
H
H
OMe
OMe
H
(iii)
16a-e
a
b
c
d
e
COOMe
OMe
OMe
H
OMe
 
 
Scheme 1. General synthetic route for compounds 5-15. Reagents and conditions: (i) (1) 
SOCl2; (2) 17, NEt3, CH2Cl2; (ii) HBTU, HOBt, DIPEA, 17, CH2Cl2; (iii) H2, Pd/C, 
EtOAc/MeOH; (iv) HetC(O)Cl . HCl, NEt3, CH2Cl2/DMF.  
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Inhibition of the ABC transporters ABCG2, ABCB1 and ABCC2. The synthesized 
modulators 5-15 and the reference compounds 1-4 were investigated for inhibition of 
ABCG2 and ABCB1 by flow cytometry in a mitoxantrone efflux assay and a calcein-
AM efflux assay. In MCF-7/Topo cells red fluorescent mitoxantrone is not accumulated 
but extruded by the ABCG2 transporter. Therefore, ABCG2 inhibitors can easily be 
recognized by the flow cytometric determination of intracellular mitoxantrone levels. 
Changes in the mitoxantrone efflux caused by different concentrations of the ABCG2 
modulators can be measured by the relative fluorescence intensity of the cells. 
Similarly, in ABCB1 overexpressing KBv1 cells, the accumulation of calcein, a 
fluorescent substrate of ABCB1, can be quantified by flow cytometric analysis. In the 
presence of ABCB1 inhibitors higher intracellular calcein levels lead to increased 
relative fluorescence intensities of the cells. The modulation of ABCC2 was 
investigated on ABCC2-overexpressing MDCK-cells by incubation with chloromethyl-
fluorescein-diacetate (CMFDA) in the absence and presence of increasing 
concentrations of test compounds. After intracellular formation of the ABCC2 substrate 
glutathione methylfluorescein, (GSMF), the extent of intracellular fluorescence was 
monitored with a plate reader in a concentration-dependent manner.  
 
To classify the new compounds with respect to their inhibitory potency against the 
targets ABCG2, ABCB1 and ABCC2 known modulators were investigated as 
references (Table 1). Whereas fumitremorgin C (1) shows only an IC50 value in the 
micromolar range against ABCG2, its analogue Ko143 (2) is a highly potent ABCG2 
modulator with a maximal inhibitory effect of 82% referred to the control. Both 
compounds were inactive against the ABCB1 transporter suggesting that the 
diketopiperazine partial structure confers some selectivity against ABCG2. However, 
the acridone carboxamide derivative elacridar[29] (3) strongly inhibits both transporters 
without a preference to one of the two targets, whereas tariquidar (4) was about 
equipotent with elacridar at ABCB1 but about four times less potent at ABCG2. 
Elacridar and tariquidar have the same N-substituent (dimethoxytetrahydroquinolinyl-
ethylphenyl) at acridone carboxamide and benzamide, respectively. As shown very 
recently, the ABCG2 preference of acridone carboxamides can be improved by 
replacing the amide substituent in elacridar with methoxyphenylethyl residues.[22] Here 
we report that the preference for one of the ABC transporters depends on the core amide 
moiety in tariquidar analogues with kept N-substituent. 
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Table 1. ABCG2, ABCB1 and ABCC2 inhibition of the reference compounds 1-3 and 
the new inhibitors 5-15 determined in the mitoxantrone (ABCG2), the calcein-AM 
efflux (ABCB1) and the CMFDA accumulation (ABCC2) assay. 
 
Compound ABCG2 ABCG2 ABCB1 ABCC2 
 IC50 [nM] a MIE [%] a, b IC50 [nM] c IC50 [nM] 
1 Fumitremorgin C > 11 000 100 inactive d inactive d 
2 Ko143 225 ± 33 82 ± 5 inactive d > 50,000 
3 Elacridar 250 ± 45 46 ± 2 193 ± 18 inactive d 
4 Tariquidar 916 ± 197 39 ± 3 223 ± 8 inactive d 
5 119 ± 22 41 ± 3 9,450 ± 417 inactive d 
6 60 ± 10 56 ± 6 >  29,000 e >20,000 
7 183 ± 50 55 ± 3 >  34,000 n.d. 
8 179 ± 35 25 ± 2 inactive d n.d. 
9 552 ± 125 44 ± 2 >  57,000 e > 20,000 
10 632 ± 222 38 ± 3 >  20,000 e > 50,000 
11 1,015 ± 403 47 ± 4 >  14,000 e > 20,000 
12 317 ± 131 63 ± 7 >  6,000 e inactive d 
13 858 ± 210 36 ± 3 >  17,000 inactive d 
14 977 ± 244 43 ± 6 >  15,000 inactive d 
15 1,990 ± 355 52e >  15,000 e > 50,000 
16 MK571f inactive - inactive > 1000 
17 LTC4 g inactive - Inactive < 150 
a Mean values ± SEM, calculated from two to three independent experiments. b Maximal 
inhibitory effects (MIE) [%] are expressed as inhibition caused by the highest 
concentration of the compound tested (7 or 10 µM, respectively) relative to the 
inhibitory effect caused by 10 µM fumitremorgin C (100% inhibition). c Mean values ± 
SEM, calculated from two to five independent experiments. d No effect up to 50 µM  
Fumitremorgin C: 0.8 % inhibition at 10 µM. e N= 1. IC50 values were calculated using 
SIGMA PLOT 9.0, four parameter logistic curve fitting. f MK571: 3-(((3-(2-(7-
chloroquinoline-2-yl)ethenyl)-phenyl)((3-dimethylamino-3-oxopropyl)thio)methyl)thio) 
propanoic acid. g LTC4: leukotriene C4. 
2. ABCG2 Inhibition  
 29 
Minimal structural changes at the benzamide core of tariquidar resulted in a change 
from ABCB1 to ABCG2 inhibition. The shift of the quinoline-3-carboxamido 
substituent from position 2 (tariquidar, 4) to position 3 of the benzamide moiety (13) 
proved to be key to increase the selectivity for ABCG2 over ABCB1: whereas the 
moderate inhibition of ABCG2 was maintained (13: IC50 858 nM, 4: IC50 916 nM), the 
inhibition of ABCB1 decreased by a factor of >75 (IC50 >17,000 vs. 223 nM for 13 and 
4, respectively). An additional step towards potent and selective ABCG2 inhibitors was 
the introduction of an ester instead of the methoxy groups. Comparing the methyl ester 
5 with tariquidar (4) and 13, the structural modification on the one hand led to a strong 
increase in the modulatory potency against ABCG2 and on the other hand the affinity 
against the original target ABCB1 was dramatically reduced. Similar to the lead 
structure 5, the substances 6-11 were potent inhibitors of ABCG2 with up to 500-fold 
lower activity at ABCB1. None of the novel tariquidar derivatives (up to a concentration 
of 50 µM) exerted any inhibitory effect on ABCC2 (MRP2). 
 
Obviously, the shift of the hetarylcarboxamido substituent from the 2- to the 3-position 
at the benzamide core of tariquidar dramatically changes the selectivity of the 
compounds for ABCG2 over ABCB1. All compounds with bicyclic 
hetarylcarboxamides in position 3 (5-8) were highly potent ABCG2 modulators (IC50 
values within the range of the known ABCG2 inhibitor Ko143) superior to the 
substances with monocyclic heteroaromatic moieties (6-8). The most potent inhibitor 
(IC50: 60 ± 10 nM) was obtained with a quinoline-2-carboxamido substituent (6). 
Although the methoxy-substituted compounds 12-14 showed some selectivity for 
ABCG2 these compounds were less potent than 5. The decrease in activity was most 
pronounced with 5-methoxy substitution (14). Presumably, the carbonyl oxygen of the 
ester group in 5-11 contributes to the interaction with ABCG2. As the esters 5-11 may 
not be considered drug-like due to susceptibility towards enzymatic hydrolysis, 
compound 5 was exemplarily converted to the carboxylic acid. The cleavage product 
turned out to be about 80 times less potent than the parent compound 5 as an inhibitor of 
ABCG2, i. e., higher potency resides in the esters.  
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Figure 2. Concentration-response curves of ABCG2 inhibition by selected tariquidar 
analogues (5, 6, 9 and 11) and the reference compounds Ko143 and tariquidar. 
 
As shown in Figure 2 the quinoline-3-carboxamide 5 and the structural isomer 6 were 
about as potent as Ko143 (2), the most potent ABCG2 modulator described so far. 
However, the maximum inhibition obtained by Ko143 was not reached. Although the 
lower efficacy compared to fumitremorgin C appears to be characteristic of the new 
ABCG2 inhibitors related to 3,[22] 4 and 5, the low water solubility of the tariquidar 
analogues presented in this work might contribute to this phenomenon. Stability 
investigations, as well as the search for more stable bioisosteric replacements of the 
ester group and compounds with higher water solubility are subject of ongoing studies. 
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Figure 3. Effect of compound 6 alone (A) and in combination with 100 nM topotecan 
(B) on proliferating MCF-7/Topo cells (long-term drug exposure). Vehicle (open stars), 
100 nM topotecan (filled circles) and 6 at different concentrations: 10 nM (filled 
triangles), 100 nM (filled diamonds) and 500 nM (filled inverted triangles). Effect of 
compound 5 alone (C) and in combination with topotecan (D) on proliferating MCF-
7/Topo cells (permanent incubation with the test compounds). Vehicle (open stars), 100 
nM topotecan (filled circles) and 5 at different concentrations: 1 nM (filled squares), 10 
nM (filled triangles), 100 nM (filled diamonds) and 500 nM (filled inverted triangles). 
 
 
 
2. ABCG2 Inhibition  
 32 
Cytotoxicity and reversal of drug resistance. Based on the results of the mitoxantrone 
efflux assay the ability of the two most potent modulators (5 and 6) to overcome 
multidrug resistance mediated by ABCG2 was investigated using a kinetic 
chemosensitivity assay. For this purpose ABCG2 positive topotecan-resistant MCF-7 
breast cancer cells (MCF-7/Topo cells) were incubated with the new inhibitors alone 
and in combination with topotecan at a non-toxic concentration. The results are shown 
in Figure 3. 
 
Incubation of MCF-7/Topo breast cancer cells with 6 alone resulted only in a weak 
cytostatic effect up to concentrations of 500 nM (Figure 3A). However, compound 6 at 
a concentration of 100 nM combined with a non-toxic concentration of topotecan (100 
nM) resulted in a strong cytostatic effect. The effective inhibition of ABCG2 led to a 
total reversal of the ABCG2 mediated topotecan resistance (Figure 3B).  Surprisingly, at 
a concentration of 100 nM compound 5 had a cytostatic effect against proliferating 
MCF-7/Topo cells (Figure 3C), which was only slightly enhanced by the combination 
with topotecan (Figure 3D). Chemosensitivity assays with proliferating ABCG2 
negative U-373 MG glioblastoma cells indicate that the toxicity of 5 is independent 
from ABCG2 modulation. In addition, quiescent U-373 MG cells were not affected by 
5, indicating that the antiproliferative effect is cell cycle dependent (data not shown). 
 
Specific modulators are desired as pharmacological tools for the functional analysis and 
characterization of the ABCG2 transporter as the mechanism of action and the selection 
and binding of substrates is far from being understood. Some anticancer drugs, e.g. 
topotecan, are substrates of different ABC transporters. This might be one of the reasons 
why the reversal of MDR by inhibition of one of these proteins often fails in the 
clinics,[35, 36] suggesting a potential therapeutic value of dual inhibitors of ABC 
transporters.[37] Selective inhibition should be superior to dual ABCB1/ABCG2 
inhibition, if the coadministered drug is preferentially transported by one specific efflux 
pump. Additionally, combination therapy could improve the pharmacokinetics of 
transported drugs, thereby increasing oral bioavailability,[38] plasma half-lives and brain 
penetration.[18, 39]   
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2.3. Conclusion 
 
Starting from the ABCB1 preferring dual ABCB1/ABCG2 modulator tariquidar 
structural modifications at the benzamide core were performed. The synthesized 
compounds are among the most potent and selective ABCG2 inhibitors known so far. 
Such compounds could be useful in combination with cytostatics that are ABCG2 
substrates in order to overcome drug resistance of tumor cells or to modulate ABCG2 at 
the blood-brain barrier and thereby improve the outcome of cancer chemotherapy of 
malignant brain tumors. Kinetic chemosensitivity assays revealed two main effects of 
the new compounds. Firstly, weakly toxic modulators such as compound 6 were able to 
reverse the ABCG2 mediated topotecan resistance in MCF-7/Topo breast cancer cells. 
Secondly, compound 5 showed additional cytotoxicity. The latter is an unexpected 
interesting aspect since ABCG2 modulators with intrinsic antiproliferative activity may 
offer a new chemotherapeutic approach addressing the tumor stem cell concept.[40] 
 
2.4. Experimental Section 
 
General. Commercial reagents and starting materials were purchased from Aldrich, 
Fluka or Acros and used without further purification. Flash chromatography was 
performed on silica gel (Merck silica gel Si 60 40-63 µm); products were detected by 
TLC on alumina plates coated with silica gel (Merck silica gel 60 F254, thickness 0.2 
mm) and visualized by UV-light (λ = 254 nm). Melting points were determined with a 
Büchi SMP 20 and are uncorrected. NMR spectra were recorded with Bruker Avance 
300 (1H: 300.1 MHz, 13C: 75.5 MHz, T = 300 K), Bruker Avance 400 (1H: 400.1 MHz, 
13C: 100.6 MHz, T = 300 K) and Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, 
T = 300 K) instruments. Chemical shifts are reported in δ/ppm relative to external 
standards and coupling constants J are given in Hz. Abbreviations for the 
characterization of the signals: s = singlet, d = doublet, t = triplet, m = multiplet, bs = 
broad singlet, dd = double doublet. The relative number of protons is determined by 
integration. Error of reported values: chemical shift 0.01 ppm (1H-NMR), 0.1 ppm (13C-
NMR), coupling constant 0.1 Hz. The used solvent for each spectrum is reported. Mass 
spectra were recorded with Finnigan MAT TSQ 7000 (ESI) and Finnigan MAT 90 
(HRMS), IR spectra with a Bio-Rad FT-IR-FTS 155 spectrometer and UV/Vis spectra 
with a Cary BIO 50 UV/Vis/NIR spectrometer (Varian).  
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General procedure A for the preparation of carbonyl chlorides. The corresponding 
(hetero-) aromatic carboxylic acid was suspended in SOCl2 (10-15 mL) and heated to 
reflux for two hours. Excess SOCl2 was removed under reduced pressure and the 
resulting white solid was dried under vacuum. 
 
General procedures B and C for the preparation of the amide bonds. (B) The 
aromatic amine (17, 19a-d) (1 eq) and NEt3 (3 eq) were dissolved in CH2Cl2 and the 
aromatic carbonyl chloride (1.5 eq) derived from the corresponding acid via general 
procedure A was added in small portions. The solution was stirred at room temperature 
for 24 hours, diluted with CH2Cl2, washed with water and saturated aqueous solution of 
Na2CO3 (3 ×), dried over MgSO4 and concentrated to give the crude product which was 
purified by flash chromatography on silica gel or recrystallisation. (C) The aromatic 
carboxylic acid (1.1 eq), DIPEA (2 eq), HOBt (1.2 eq) and HBTU (1.2 eq) were 
dissolved in CH2Cl2 at 0 °C and stirred for 20 min. The amine (1 eq) was added in small 
portions and the solution was allowed to warm to room temperature and stirred for 24 h. 
The solution was diluted with CH2Cl2, washed with water (2×) and saturated aqueous 
solution of Na2CO3 (3×), dried over MgSO4 and concentrated to give the crude product 
which was purified by flash chromatography on silica gel. 
 
General procedure D for the reduction of the nitro group. The corresponding nitro 
compound was dissolved in a mixture of ethyl acetate and methanol, palladium on 
activated charcoal (10 % m/m) was added and the solution was stirred under 5 bar H2 
atmosphere overnight. The catalyst was filtered off and the solvents were removed to 
obtain the amines in quantitative yields. 
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Methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2-(quinolin-3-ylcarbonylamino)benzoate (5).  
 
The compound was synthesized following general procedure B and recrystallized from 
methanol to obtain compound 5 as a white solid (0.20 g, 58%); mp = 191 °C 
(decomposition) – 1H-NMR (400 MHz, [D6]-DMSO; COSY): δ = 2.66–2.89 (m, 8H, 4 
CH2, H(13/14), H(17/18)), 3.55 (s, 2H, CH2, H(15)), 3.70 (2 s, 6H, CH3, H(23)/H(24)), 
3.91 (s, 3H, COOCH3), 6.64 (s, 1H, H(22)-Ar), 6.65 (s, 1H, H(19)-Ar), 7.26 (d, 3J = 8.5 
Hz, 2H, AA'BB', H(11/11’)), 7.71 (d, 3J = 8.5 Hz, 2H, AA'BB', H(10/10’)), 7.74-7.78 
(m, 1H, H(30/31)-Ar), 7.85 (dd, 3J = 8.2 Hz, 4J = 1.5 Hz, 1H, H(5)-Ar), 7.92-7.96 (m, 
1H, H(31/30)-Ar), 8.09 (d, 3J = 8.2 Hz, 1H, H(6)-Ar), 8.15 (d, 3J = 8.2 Hz, 1H, 
H(29/32)-Ar), 8.21 (d, 3J = 7.8 Hz, 1H, H(32/29)-Ar), 8.81 (d, 4J = 1.5 Hz, 1H, H(3)-
Ar), 8.99 (d, 4J = 2.1 Hz, 1H, H(27/28)-Ar), 9.41 (d, 4J = 2.1 Hz, 1H, H(28/27)-Ar), 
10.45 (s, 1H, CONH), 11.57 (s, 1H, CONH) – 13C-NMR (100 MHz, [D6]-DMSO): δ = 
28.8 (-), 32.9 (-), 48.9 (-), 53.2 (+), 55.5 (-), 55.9 (+), 56.0 (+), 60.0  (-), 109.9 (+), 111.7 
(+), 120.4 (+), 121.7 (Cquat), 122.1 (+), 122.8 (+), 125.8 (Cquat), 126.4 (Cquat), 126.5 
(Cquat), 126.8 (Cquat), 127.7 (+), 128.7 (+), 128.8 (+), 129.3 (+), 130.5 (+), 131.7 (+), 
136.0 (+), 136.1 (Cquat), 136.6 (Cquat), 138.8 (Cquat), 139.6 (Cquat), 146.8 (Cquat), 147.0 
(Cquat), 148.3 (+), 148.7 (Cquat), 163.7 (Cquat), 164.2 (Cquat), 167.1 (Cquat) – IR (KBr) [cm-
1]: ν = 3414, 2921, 1650 – UV/Vis (CHCl3) λmax [nm] (lg ε): 288 (4.508), 240 (4.967) – 
MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 323 (30) [MH22+], 645 (100) 
[MH+] – Elemental analysis calcd (%) for C38H36N4O6 (644.73): C 70.79, H 5.63, N 
8.69; found C 69.98, H 5.68 N 8.27. 
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Methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2-(quinoline-2-carbonylamino)benzoate (6).  
 
The compound was synthesized following general procedure C and purified by flash 
chromatography on silica gel (5% MeOH/CHCl3, Rf = 0.36) to obtain a pale yellow 
solid (70 mg, 10%). mp = 176°C (decomposition) – 1H-NMR (300 MHz, CD2Cl2): δ = 
2.85–3.02 (m, 8H, 4 CH2), 3.78 (s, 2H, NCH2), 3.84 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 
4.07 (s, 3H, COOCH3), 6.54 (s, 1H, H-Ar), 6.60 (s, 1H, H-Ar), 7.24-7.27 (m, 2H, H-Ar, 
AA'BB'), 7.64-7.67 (m, 2H, H-Ar, AA'BB'), 7.62-7.67 (m, 1H, H-Ar), 7.69 (dd, 3J = 8.2 
Hz, 4J = 1.6 Hz, 1H, H-Ar), 7.77-7.84 (m, 1H, H-Ar), 7.88-7.91 (m, 1H, H-Ar), 8.17 (d, 
3J = 8.2 Hz, 1H, H-Ar), 8.28-8.36 (m, 3H, H-Ar), 8.34 (bs, 1H, CONH), 9.45 (d, 4J = 
1.6 Hz, 1H, H-Ar), 12.31 (bs, 1H, CONH) – 13C-NMR (75 MHz, CDCl3/MeOD): δ = 
27.8 (-), 32.9 (-), 50.7 (-), 52.8 (+), 55.0 (-), 55.9 (+), 56.0 (+), 59.4  (-), 109.4 (+), 111.3 
(+), 117.9 (+), 118.7 (Cquat), 118.8 (+), 120.8 (+), 122.5 (+), 123.3 (Cquat), 124.8 (Cquat), 
125.4 (Cquat), 127.7 (+), 128.5 (+), 129.3 (+), 129.4 (Cquat), 130.2 (+), 130.4 (+), 131.9 
(+), 136.1 (Cquat), 137.8 (+), 140.1 (Cquat), 140.8 (Cquat), 146.6 (Cquat), 147.5 (Cquat), 
147.8 (Cquat), 149.5 (Cquat), 163.9 (Cquat), 164.8 (Cquat), 167.4 (Cquat) – IR (KBr) [cm-1]: ν 
= 3303, 2940, 2831, 1697, 1655, 1570, 1519 – UV/Vis (CHCl3) λmax [nm] (lg ε): 309 
(4.273), 289 (4.316), 245 (4.776) – HRMS calcd. for C38H37N4O6 [M.+]: 645.2713, 
found: 645.2709. 
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Methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2-(quinoxaline-2-carbonylamino)benzoate (7).  
 
The compound was synthesized following general procedure B and purified by flash 
chromatography on silica gel (5% MeOH/CHCl3, Rf = 0.31) to obtain a pale yellow 
solid (40 mg, 14%); mp = 163 °C (decomposition) – 1H-NMR (300 MHz, CDCl3): δ = 
2.76-2.96 (m, 8H, 4 CH2), 3.67 (s, 2H, CH2), 3.85 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 
4.08 (s, 3H, COOCH3), 6.65 (s, 1H, H-Ar), 6.61 (s, 1H, Ar-H), 7.26-7.28 (m, 2H, H-Ar, 
AA’BB’), 7.64-7.67 (m, 2H, H-Ar, AA’BB’), 7.71 (dd, 3J = 8.2 Hz, 4J = 1.6 Hz, 1H, H-
Ar), 7.83-7.93 (m, 2H, H-Ar), 8.18-8.21 (m, 1H, H-Ar), 8.20 (d, 3J = 8.2 Hz, 1H, H-Ar), 
8.26-8.29 (m, 1H, H-Ar), 8.27 (bs, 1H, CONH), 9.40 (d, 4J = 1.6 Hz, 1H, H-Ar), 9.71 
(s, 1H, H-Ar), 13.17 (bs, 1H, CONH) – 13C-NMR (75 MHz, CDCl3): δ = 28.7 (-), 33.5 
(-), 51.1 (-), 52.9 (+), 55.7 (-), 55.9 (+), 55.9 (+), 60.1 (-), 109.5 (+), 111.3 (+), 117.9 
(+), 118.6 (Cquat), 120.7 (+), 122.9 (+), 126.1 (Cquat), 126.4 (Cquat), 129.3 (+), 129.4 (+), 
130.2 (+), 131.0 (+), 131.9 (+), 132.1 (+), 135.8 (Cquat), 137.0 (Cquat), 140.3 (Cquat), 
140.4 (Cquat), 140.5 (Cquat), 143.5 (Cquat), 143.8 (+), 144.0 (Cquat), 147.2 (Cquat), 147.5 
(Cquat), 162.7 (Cquat), 164.6 (Cquat), 167.5 (Cquat) – IR (KBr) [cm-1]: ν = 3310, 2834, 
1688, 1652 – UV/Vis (CHCl3) λmax [nm] (lg ε): 288 (4.503) – HRMS calcd. for 
C37H36N5O6 [M.+]: 646.2666, found: 646.2648. 
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Methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2-(quinoline-6-carbonylamino)benzoate (8).  
 
The compound was synthesized following general procedure B and purified by flash 
chromatography on silica gel (5% MeOH/CHCl3, Rf = 0.27) to obtain a pale yellow 
solid (40 mg, 14%); mp > 200 °C (decomposition) – 1H-NMR (300 MHz, CDCl3): δ = 
2.75-2.95 (m, 8H, 4 CH2), 3.67 (s, 2H, NCH2), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 
4.02 (s, 3H, COOCH3), 6.54 (s, 1H, H-Ar), 6.60 (s, 1H, H-Ar), 7.24-7.27 (m, 2H, H-Ar, 
AA’BB’), 7.48-7.52 (m, 1H, H-Ar), 7.63-7.66 (m, 2H, H-Ar, AA’BB’), 7.72 (dd, 3J = 
8.2 Hz, 4J = 1.6 Hz, 1H, H-Ar), 8.18 (d, 3J = 8.2 Hz, 1H, H-Ar), 8.22-8.33 (m, 3H, H-
Ar), 8.35 (bs, 1H, CONH), 8.52 (d, 4J = 1.6 Hz, 1H, H-Ar), 9.01-9.03 (m, 1H, H-Ar), 
9.39-9.40 (m, 1H, H-Ar), 12.32 (bs, 1H, CONH) – 13C-NMR (75 MHz, CDCl3): δ = 
28.6 (-), 33.5 (-), 51.0 (-), 53.0 (+), 55.7 (-), 55.9 (+), 55.9 (+), 60.1 (-), 109.5 (+), 111.3 
(+), 117.4 (Cquat), 117.8 (+), 120.7 (+), 122.1 (+), 122.7 (+), 126.1 (Cquat), 126.4 (Cquat), 
127.0 (+), 127.7 (Cquat), 128.6 (+), 129.3 (+), 130.4 (+), 131.6 (+), 132.1 (Cquat), 135.9 
(Cquat), 136.9 (Cquat), 137.4 (+), 140.7 (Cquat), 141.6 (Cquat), 147.2 (Cquat), 147.5 (Cquat), 
149.6 (Cquat), 152.5 (+), 164.6 (Cquat), 165.2 (Cquat), 168.5 (Cquat) – IR (KBr) [cm-1]: ν = 
3296, 2951, 1679, 1578, 1521 – UV/Vis (CHCl3) λmax [nm] (lg ε): 316 (4.365), 246 
(4.731) – HRMS calcd. for C38H37N4O6 [MH+]: 645.2713, found: 645.2729. 
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Methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2-(5-methylpyrazine-2-carbonylamino)benzoate (9).  
 
The compound was synthesized following general procedure C and purified by flash 
chromatography on silica gel (5% MeOH/CHCl3, Rf = 0.31) to obtain a pale yellow 
solid (0.15 g, 41%); mp = 182 °C (decomposition) – 1H-NMR (300 MHz, CDCl3): δ = 
2.69 (s, 3H, CH3), 2.88–3.09 (m, 8H, 4 CH2), 3.84 (s, 2H, NCH2), 3.84 (s, 3H, OCH3), 
3.85 (s, 3H, OCH3), 4.02 (s, 3H, COOCH3), 6.54 (s, 1H, H-Ar), 6.61 (s, 1H, H-Ar), 
7.22-7.25 (m, 2H, H-Ar, AA'BB'), 7.63-7.66 (m, 2H, H-Ar, AA'BB'), 7.74 (dd, 3J = 8.5 
Hz, 4J = 1.7 Hz, 1H, H-Ar), 8.19 (d, 3J = 8.5 Hz, 1H, H-Ar), 8.31 (bs, 1H, CONH), 8.59 
(d, 5J = 0.3 Hz, 1H, H-Ar), 9.33 (d, 5J = 0.3 Hz, 1H, H-Ar), 9.40 (d, 4J = 1.7 Hz, 1H, H-
Ar), 12.92 (bs, 1H, CONH) – 13C-NMR (75 MHz, CDCl3): δ = 22.0 (+), 28.7 (-), 33.5 (-
), 51.1 (-), 52.9 (+), 55.7 (-), 55.9 (+), 55.9 (+), 60.2 (-), 109.5 (+), 111.4 (+), 117.9 (+), 
118.5 (Cquat), 120.7 (+), 123.0 (+), 126.1 (Cquat), 126.5 (Cquat), 129.3 (+), 131.9 (+), 
135.7 (Cquat), 137.1 (Cquat), 140.4 (Cquat), 140.7 (Cquat), 142.1 (Cquat), 142.9 (+), 143.9 
(+), 144.0 (Cquat), 147.2 (Cquat), 147.5 (Cquat), 157.7 (Cquat), 164.5 (Cquat), 167.7(Cquat) – 
IR (KBr) [cm-1]: ν = 3288, 2940, 2828, 1691, 1650, 1572 – UV/Vis (CHCl3) λmax [nm] 
(lg ε): 288 (4.129), 244 (4.345) – HRMS calcd. for C34H35N5O6 [M.+]: 609.2587, found: 
609.2590. 
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Methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2-(pyrazine-2-carbonylamino)benzoate (10).  
 
The compound was synthesized following general procedure C and purified by flash 
chromatography on silica gel (5% MeOH/CHCl3, Rf = 0.31) to obtain a pale yellow 
solid (0.12 g, 25%); mp > 200 °C (decomposition) – 1H-NMR (300 MHz, CDCl3; 
HSQC, HMBC, COSY, ROESY): δ = 2.76-2.96 (m, 8H, 4 CH2, H(21/22), H(23/24)), 
3.68 (s, 2H, H(31)), 3.85 (s, 3H, CH3, H(33)), 3.85 (s, 3H, CH3, H(32)), 4.04 (s, 3H, 
CH3, H(35)), 6.55 (s, 1H, H(29)-Ar), 6.61 (s, 1H, H(26)-Ar), 7.27-7.30 (m, 2H, 
AA’BB’, H(19/19’)-Ar), 7.61-7.64 (m, 2H, AA’BB’, H(18/18’)-Ar), 7.77 (dd, 3J = 8.3 
Hz, 4J = 1.7 Hz, 1H, H(12)-Ar), 8.07 (bs, 1H, N(16)-H), 8.23 (d, 3J = 8.3 Hz, 1H, 
H(11)-Ar), 8.76 (dd, 3J = 2.5 Hz, 4J = 1.5 Hz, 1H, H(3)-Ar), 8.84 (dd, 3J = 2.5 Hz, 5J = 
0.3 Hz, 1H, H(2)-Ar), 9.43 (d, 4J = 1.7 Hz, 1H, H(14)-Ar), 9.51 (dd, 4J = 1.5 Hz, 5J = 
0.3 Hz, 1H, H(5)-Ar), 13.04 (bs, 1H, N(8)-H) – 13C-NMR (75 MHz, CDCl3): δ = 28.7 (-
, C(24)), 33.5 (-, C(21)), 51.1 (-, C(23)), 53.0 (+, C(35)), 55.7 (-, C(31)), 55.9 (+, 
C(33)), 55.9 (+, C(32)), 60.2 (-, C(22)), 109.4 (+, C(29)), 111.3 (+, C(26)), 118.0 (+, 
C(14)), 118.4 (Cquat, C(10)), 120.7 (+, C(18/18’)), 123.0 (+, C(12)), 126.1 (Cquat, C(25)), 
126.4 (Cquat, C(30)), 129.4 (+, C(19/19’)), 131.9 (+, C(11)), 135.8 (Cquat, C(20)), 137.1 
(Cquat, C(17)), 140.5 (Cquat, C(13)), 140.6 (Cquat, C(9)), 143.1 (+, C(3)), 144.7 (Cquat, 
C(6)), 144.9 (+, C(5)), 147.2 (Cquat, C(28)), 147.5 (Cquat, C(27)), 147.7 (+, C(2)), 162.4 
(Cquat, C(7)), 164.6 (Cquat, C(15)), 167.7 (Cquat, C(34)) – IR (KBr) [cm-1]: ν = 3310, 
3225, 2928, 2832, 1691, 1651, 1571, 1516 –  UV/Vis (CHCl3) λmax [nm] (lg ε): 289 
(4.501), 244 (4.722) – HRMS calcd. for C33H33N5O6 [M.+]: 595.2431, found: 595.2414.  
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Methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2-(pyridine-3-carbonylamino)benzoate (11).  
 
The compound was synthesized following general procedure B and purified by flash 
chromatography on silica gel (5% MeOH/CHCl3, Rf = 0.24) to obtain a pale yellow 
solid (0.28 g, 78%); mp = 159 °C (decomposition) – 1H-NMR (300 MHz, CDCl3): δ = 
2.75–2.95 (m, 8H, 4 CH2), 3.66 (s, 2H, CH2), 3.84 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 
4.00 (s, 3H, COOCH3), 6.54 (s, 1H, H-Ar), 6.60 (s, 1H, H-Ar), 7.23-7.26 (m, 2H, 
AA'BB'), 7.46-7.50 (m, 1H, H-Ar), 7.61-7.64 (m, 2H, AA'BB'), 7.74 (dd, 3J = 8.5 Hz, 4J 
= 1.6 Hz, 1H, H-Ar), 8.19 (d, 3J = 8.2 Hz, 1H, H-Ar), 8.28-8.32 (m, 1H, H-Ar), 8.38 (s, 
1H, CONH), 8.80-8.82 (m, 1H, H-Ar), 9.28-9.29 (m, 1H, H-Ar), 9.31 (d, 4J = 1.6 Hz, 
1H, H-Ar), 12.24 (s, 1H, CONH) – 13C-NMR (75 MHz, CDCl3): δ = 28.6 (-), 33.4 (-), 
51.0 (-), 53.0 (+), 55.7 (-), 55.8 (+), 55.9 (+), 60.1(-), 109.4 (+), 111.3 (+), 117.3 (Cquat), 
117.9 (+), 120.8 (+), 122.8 (+), 123.7 (+), 126.1 (Cquat), 126.4 (Cquat), 129.3 (+), 131.6 
(+), 134.9 (+), 135.9 (Cquat), 136.9 (Cquat), 140.8 (Cquat), 141.3 (Cquat), 147.2 (Cquat), 
147.5 (Cquat), 148.9 (+), 150.5 (Cquat), 152.9 (+), 164.0 (Cquat), 164.7 (Cquat), 168.5 (Cquat) 
– IR (KBr) [cm-1]: ν = 3291, 2935, 1688, 1656, 1580, 1515 – UV/Vis (CHCl3) λmax 
[nm] (lg ε): 310 (4.133), 279 (4.266), 242 (4.494) – HRMS calcd. for C34H34N4O6 [M.+]: 
594.2478, found: 594.2473. 
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N-(5-((4-(2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2-methoxyphenyl)quinoline-3-carboxamide (12).  
 
The compound was prepared following general procedure B and purified by flash 
chromatography on silica gel (5% MeOH/CHCl3 Rf = 0.18) to obtain a pale yellow solid 
(0.34 g, 79%); mp = 131 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.76-2.95 (m, 8H, 4 
CH2), 3.68 (s, 2H, NCH2), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 4.03 (s, 3H, OCH3), 
6.55 (s, 1H, H-Ar), 6.60 (s, 1H, H-Ar), 7.06 (d, 3J = 8.8 Hz, 1H, H-Ar), 7.23-7.26 (m, 
2H, H-Ar, AA’BB’), 7.61-7.64 (m, 2H, H-Ar, AA’BB’), 7.65-7.70 (m, 1H, H-Ar), 7.84-
7.89 (m, 2H, H-Ar), 7.98-8.00 (m, 1H, H-Ar), 8.19-8.21 (m, 2H, H-Ar/CONH), 8.71-
8.73 (m, 2H, H-Ar/CONH), 9.01-9.02 (m, 1H, H-Ar), 9.39-9.40 (m, 1H, H-Ar) – 13C-
NMR (75 MHz, CDCl3): δ = 28.6 (-), 33.4 (-), 51.0 (-), 55.6 (-), 55.9 (+), 55.9 (+), 56.3 
(+), 60.1 (-), 109.46 (+), 110.3 (+), 111.3 (+), 117.5 (+), 120.6 (+), 125.6 (+), 126.1 
(Cquat), 126.3 (Cquat), 126.9 (Cquat), 127.0 (Cquat), 127.3 (Cquat), 127.8 (Cquat), 127.9 (+), 
128.9 (+), 129.3 (+), 129.5 (+), 131.8 (+), 135.9 (+), 136.3 (Cquat), 136.4 (Cquat), 147.2 
(Cquat), 147.6 (Cquat), 147.9 (+), 149.5 (Cquat), 150.8 (Cquat), 163.8 (Cquat), 165.0 (Cquat) – 
IR (KBr) [cm-1]: ν = 3282, 2939, 2836, 1670, 1591, 1515 – UV/Vis (CHCl3) λmax [nm] 
(lg ε): 275 (4.347), 242 (4.634) – HRMS calcd. for C37H37N4O5 [M.+]: 617.2764, found: 
617.2751. 
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N-(5-((4-(2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2,3-dimethoxyphenyl)quinoline-3-carboxamide (13).  
 
The compound was prepared following general procedure B and purified by flash 
chromatography on silica gel (EtOAc/MeOH 8:2 Rf = 0.27) to obtain a pale yellow solid 
(237 mg, 61%); mp = 181 °C (decomposition) – 1H-NMR (300 MHz, [D6]-DMSO): δ = 
2.63-2.84 (m, 8H, 4 CH2), 3.55 (s, 2H, NCH2), 3.70 (s, 6H, OCH3), 3.87 (s, 3H, OCH3), 
3.96 (s, 3H, OCH3), 6.64 (s, 1H, H-Ar), 6.66 (s, 1H, H-Ar), 7.23-7.26 (m, 2H, H-Ar, 
AA’BB’), 7.53 (d, 4J = 1.9 Hz, 1H, H-Ar), 7.66-7.69 (m, 2H, H-Ar, AA’BB’), 7.71-7.77 
(m, 1H, H-Ar), 7.89-7.94 (m, 1H, H-Ar), 8.03 (d, 4J = 1.9 Hz, 1H, H-Ar), 8.12-8.20 (m, 
2H, H-Ar), 8.99 (d, 4J = 1.9 Hz, 1H, H-Ar), 9.38 (d, 4J = 2.2 Hz, 1H, H-Ar), 10.17 (bs, 
1H, CONH), 10.22 (bs, 1H, H-Ar) – 13C-NMR (75 MHz, [D6]-DMSO): δ = 28.2 (-), 
32.4 (-), 50.5 (-), 55.0 (-), 55.3 (+), 55.3 (+), 56.1 (+), 59.5 (-), 60.3 (+), 109.3 (+), 109.8 
(+), 111.6 (+), 117.2 (+), 120.5 (+), 125.8 (Cquat), 126.4 (Cquat), 126.5 (Cquat), 127.0 
(Cquat), 127.4 (+), 128.7 (+), 128.7 (+), 129.2 (+), 129.9 (Cquat), 131.0 (Cquat), 131.4 (+), 
135.8 (Cquat), 136.1 (+), 136.9 (Cquat), 144.4 (Cquat), 146.8 (Cquat), 147.0 (Cquat), 148.5 
(Cquat), 149.0 (+), 152.1 (Cquat), 164.4 (Cquat), 164.5 (Cquat) – IR (KBr) [cm-1]: ν = 3416, 
2927, 1668, 1595, 1520 – UV/Vis (CHCl3) λmax [nm] (lg ε): 284 (4.527), 242 (4.778) – 
HRMS calcd. for C38H39N4O6 [M.+]: 647.2870, found: 647.2859. 
 
2. ABCG2 Inhibition  
 44 
N
H
N
OMe
OMeO
NH O
N
MeO
 
 
N-(3-((4-(2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-5-methoxyphenyl)quinoline-3-carboxamide (14). 
 
The compound was prepared following general procedure B and crystallized from 
methanol to obtain as a pale yellow solid (154 mg, 91%); mp = 188-196 °C – 1H-NMR 
(300 MHz, [D6]-DMSO): δ = 2.64-2.84 (m, 8H, 4 CH2), 3.56 (s, 2H, NCH2), 3.70 (s, 
3H, OCH3), 3.70 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 6.64 (s, 1H, H-Ar), 6.66 (s, 1H, H-
Ar), 7.24-7.26 (m, 2H, H-Ar, AA’BB’), 7.29-7.30 (m, 1H, H-Ar), 7.67-7.70 (m, 2H, H-
Ar, AA’BB’), 7.72-7.77 (m, 2H, H-Ar), 7.89-7.95 (m, 2H, H-Ar), 8.12-8.18 (m, 2H, H-
Ar), 9.00 (d, 4J = 1.9 Hz, 1H, H-Ar), 9.39 (d, 4J = 2.2 Hz, 1H, H-Ar), 10.23 (bs, 1H, 
CONH), 10.79 (bs, 1H, CONH) – 13C-NMR (75 MHz, [D6]-DMSO): δ = 27.2 (-), 31.4 
(-), 50.1 (-), 54.0 (-), 55.3 (+), 55.4 (+), 55.4 (+), 58.5 (-), 108.3 (+), 108.8 (+), 109.7 
(+), 111.5 (+), 112.3 (+), 120.5 (+), 125.1 (Cquat), 126.3 (Cquat), 127.2 (Cquat), 127.5 
(Cquat), 127.5 (+), 128.7 (+), 129.2 (+), 129.2 (+), 131.4 (+), 136.1 (+), 136.6 (Cquat), 
137.1 (Cquat), 140.1 (Cquat), 147.0 (Cquat), 147.3 (Cquat), 148.5 (Cquat), 149.0 (+), 149.0 
(Cquat), 159.2 (Cquat), 164.2 (Cquat), 165.1 (Cquat) – IR (KBr) [cm-1]: ν = 3264, 2938, 
1651, 1594, 1518 – UV/Vis (CHCl3) λmax [nm] (lg ε): 281 (4.360), 241 (4.683) – HRMS 
calcd. for C37H37N4O5 [M.+]: 617.2764, found: 617.2772.  
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N-(5-((4-(2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2-methylphenyl)quinoline-3-carboxamide (15).  
 
The compound was prepared following general procedure B and purified by flash 
chromatography on silica gel (5% MeOH/CHCl3 Rf = 0.18) to obtain a pale yellow solid 
(230 mg, 51%); mp = 143°C – 1H-NMR (300 MHz, CDCl3): δ = 2.31 (s, 3H, CH3), 
2.70–2.89 (m, 8H, 2*2 CH2), 3.64 (s, 2H, N-CH2), 3.83 (s, 3H, CH3), 3.84 (s, 3H, CH3), 
6.53 (s, 1H, H-Ar), 6.59 (s, 1H, H-Ar), 7.15-7.18 (m, 2H, AA'BB'), 7.22 (d, 3J = 8.2 Hz, 
1H, H-Ar), 7.55-7.58 (m, 2H, AA'BB'), 7.58-7.63 (m, 2H, H-Ar), 7.78-7.84 (m, 1H, H-
Ar), 7.88-7.91 (m, 1H, H-Ar), 8.12-8.15 (m, 2H, H-Ar), 8.46 (bs, 1H, CONH), 8.59 (bs, 
1H, CONH), 8.76 (d, 4J = 1.9 Hz, 1H, H-Ar), 9.39 (d, 4J = 2.2 Hz, 1H, H-Ar) – 13C-
NMR (75 MHz, CDCl3): δ = 18.0 (+), 28.2 (-), 32.3 (-), 50.5 (-), 55.0 (-), 55.3 (+), 55.3 
(+), 59.5 (-), 109.8 (+), 111.6 (+), 120.3 (+), 125.3 (+), 125.8 (Cquat), 125.8 (+), 126.4 
(Cquat), 126.5 (Cquat), 127.0 (Cquat), 127.5 (+), 128.7 (+), 128.7 (+), 129.2 (+), 130.4 (+), 
131.4 (+), 132.8 (Cquat), 135.7 (Cquat), 136.1 (+), 136.9 (Cquat), 137.7 (Cquat), 139.9 
(Cquat), 146.7 (Cquat), 147.0 (Cquat), 148.5 (Cquat), 149.0 (+), 164.1 (Cquat), 164.5 (Cquat) – 
UV/Vis (CHCl3) λmax [nm] (lg ε): 282 (4.442), 240 (4.857) – IR (KBr) [cm-1]: ν = 3275, 
2933, 2835, 1652, 1601, 1516 – HRMS calcd. for C37H36N4O4 [M.+]: 600.2737, found: 
600.2727. 
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Methyl 4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-
aminocarbonyl)-2-nitrobenzoate (18a).  
 
The compound was synthesized following general procedure B and recrystallized from 
methanol to obtain a pale yellow solid (1.44 g, 71%); mp = 101 °C – 1H-NMR (600 
MHz, CDCl3; HSQC, HMBC, COSY): δ = 2.73-2.90 (m, 8H, 4 CH2, H(13/14), 
H(17/18)), 3.64 (s, 2H, CH2, H(15)), 3.81 (s, 3H, OCH3, H(24)), 3.82 (s, 3H, OCH3, 
H(23)), 3.93 (s, 3H, OCH3, H(26)), 6.53 (s, 1H, H(22)-Ar), 6.60 (s, 1H, H(19)-Ar), 
7.21-7.22 (m, 2H, AA'BB', H(11/11’)), 7.55-7.56 (m, 2H, AA'BB', H(10/10’)), 7.80 (d, 
3J = 8.0 Hz, 1H, H(6)-Ar), 8.17 (dd, 3J = 8.0 Hz, 4J = 1.7 Hz, 1H, H(5)-Ar), 8.17 (s, 1H, 
CONH), 8.39 (d, 4J = 1.7 Hz, 1H, H(3)-Ar) – 13C-NMR (150 MHz, CDCl3): δ = 28.7 (-, 
C(18)), 33.4 (-, C(13)), 51.0 (-, C(17)), 53.6 (+, C(26)), 55.7 (-, C(15)), 55.8 (+, C(24)), 
55.9 (+, C(23)), 60.0 (-, C(14)), 109.5 (+, C(22)), 111.4 (+, C(19)), 121.0 (+, 
C(10/10’)), 122.7 (+, C(3)), 126.2 (Cquat, C(18a)), 126.6 (Cquat, C(22a)), 129.3 (+, 
C(11/11’)), 129.7 (Cquat, C(1)), 130.2 (+, C(6)), 131.7 (+, C(5)), 135.3 (Cquat, C(9)), 
137.7 (Cquat, C(12)), 138.5 (Cquat, C(4)), 147.2 (Cquat, C(21)), 147.5 (Cquat, C(20)), 147.9 
(Cquat, C(2)), 162.7 (Cquat, C(7)), 165.3 (Cquat, C(25)) – IR (KBr) [cm-1]: ν = 2924, 1736, 
1676, 1534, 1516 – UV/Vis (CHCl3) λmax [nm] (lg ε): 283 (4.245), 239 (4.160) – MS 
(ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 520 (100) [MH+] – Elemental 
analysis calcd (%) for C28H29N3O7 (519.56): C 64.73, H 5.63, N 8.09; found C 64.03, H 
5.70 N 7.99. 
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N-(4-(2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-4-
methoxy-3-nitrobenzamide (18b).  
 
The compound was prepared following general procedure C and purified by flash 
chromatography on silica gel (CHCl3/MeOH 9:1, Rf = 0.36) to yield the product as a 
pale yellow solid (0.80 g, 81%); mp = 179 °C (decomposition) – 1H-NMR (300 MHz, 
[D6]-DMSO): δ = 2.64-2.83 (m, 8H, 4 CH2), 3.54 (s, 2H, NCH2), 3.69 (s, 3H, OCH3), 
3.70 (s, 3H, OCH3), 4.02 (s, 3H, OCH3), 6.63 (s, 1H, H-Ar), 6.66 (s, 1H, H-Ar), 7.23-
7.26 (m, 2H, AA'BB'), 7.52 (d, 3J = 8.8 Hz, 1H, H-Ar), 7.64-7.67 (m, 2H, AA'BB'), 
8.28 (dd, 3J = 8.8 Hz, 4J = 2.2 Hz, 1H, H-Ar), 8.52 (d, 4J = 2.2 Hz, 1H, H-Ar), 10.30 (s, 
1H, CONH) – 13C-NMR (75 MHz, [D6]-DMSO): δ = 24.4 (-), 28.9 (-), 48.8 (-), 51.2 (-), 
55.4 (+), 55.5 (+), 55.8 (-), 57.1 (+), 109.5 (+), 111.4 (+), 114.2 (+), 119.8 (Cquat), 120.7 
(+), 123.2 (Cquat), 124.5 (+), 126.4 (Cquat), 128.8 (+), 132.3 (Cquat), 133.9 (+), 137.6 
(Cquat), 138.6 (Cquat), 147.6 (Cquat), 148.2 (Cquat), 154.2 (Cquat), 162.8 (Cquat) – IR (KBr) 
[cm-1]: ν = 3240, 2936, 2835, 1659, 1618, 1514 – UV/Vis (CHCl3) λmax [nm] (lg ε): 278 
(4.150), 259 (4.157), 242 (4.255) – MS (ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z 
(%) = 492 (100) [MH+] – Elemental analysis calcd (%) for C27H29N3O6 (491.55): C 
65.98, H 5.95, N 8.55; found C 65.57, H 6.06 N 8.59. 
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N-(4-(2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-3,4-
dimethoxy-5-nitro-benzamide (18c).  
 
The compound was prepared following general procedure C and crystallized from 
EtOAc/MeOH 9:1 to obtain a pale yellow solid (610 mg, 91%); mp = 99-103 °C – 1H-
NMR (300 MHz, CDCl3): δ = 2.73-2.93 (m, 8H, 4 CH2), 3.64 (s, 2H, NCH2), 3.83 (s, 
3H, OCH3), 3.84 (s, 3H, OCH3), 3.98 (s, 3H, OCH3), 4.03 (s, 3H, OCH3), 6.53 (s, 1H, 
H-Ar), 6.60 (s, 1H, H-Ar), 7.23-7.25 (m, 2H, H-Ar, AA’BB’), 7.55-7.58 (m, 2H, H-Ar, 
AA’BB’), 7.75 (d, 4J = 1.9 Hz, 1H, H-Ar), 7.80 (d, 4J = 2.2 Hz, 1H, H-Ar), 8.00 (bs, 
1H, CONH) – 13C-NMR (75 MHz, CDCl3): δ = 28.6 (-), 33.4 (-), 51.0 (-), 55.7 (-), 55.9 
(+), 55.9 (+), 56.7 (+), 60.1 (-), 62.2 (+), 109.4 (+), 111.3 (+), 113.8 (+), 115.5 (+), 
120.7 (+), 126.1 (Cquat), 126.4 (Cquat), 129.4 (+), 130.4 (Cquat), 135.5 (Cquat), 137.3 
(Cquat), 144.1 (Cquat), 145.7 (Cquat), 147.2 (Cquat), 147.5 (Cquat), 154.6 (Cquat), 163.2 (Cquat) 
– IR (KBr) [cm-1]: ν =  2940, 1663, 1609, 1518 – MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 522 (100) [MH+]. 
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N-(4-(2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-3-
methoxy-5-nitro-benzamide (18d).  
 
The compound was prepared following general procedure C and purified by flash 
chromatography on silica gel (EtOAc/MeOH 9:1, Rf = 0.29) to obtain a pale yellow 
solid (0.80 g, 81%); mp = 119-121 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.75-2.95 (m, 
8H, 4 CH2), 3.66 (s, 2H, NCH2), 3.84 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.95 (s, 3H, 
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OCH3), 6.54 (s, 1H, H-Ar), 6.60 (s, 1H, H-Ar), 7.25-7.28 (m, 2H, H-Ar, AA’BB’), 7.55-
7.58 (m, 2H, H-Ar, AA’BB’), 7.79-7.80 (m, 1H, H-Ar), 7.88-7.89 (m, 1H, H-Ar), 8.03 
(bs, 1H, CONH), 8.23-8.25 (m, 1H, H-Ar) – 13C-NMR (75 MHz, CDCl3): δ = 28.6 (-), 
33.4 (-), 51.0 (-), 55.6 (-), 55.9 (+), 55.9 (+), 56.3 (+), 60.0 (-), 109.4 (+), 111.3 (+), 
111.8 (+), 113.5 (+), 113.9 (Cquat), 119.7 (+), 120.7 (+), 126.1 (Cquat), 126.3 (Cquat), 
129.4 (+), 135.5 (Cquat), 137.3 (Cquat), 137.5 (Cquat), 147.2 (Cquat), 147.6 (Cquat), 149.1 
(Cquat), 160.6 (Cquat) – IR (KBr) [cm-1]: ν = 2936, 1735, 1608, 1521 – UV/Vis (CHCl3) 
λmax [nm] (lg ε): 282 (4.117), 242 (4.419) – MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 492 (100) [MH+]. 
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N-(4-(2-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)phenyl)-4-methyl-
3-nitrobenz-amide (18e).  
 
The compound was prepared following general procedure C and purified by flash 
chromatography on silica gel (EtOAc/MeOH 8:2, Rf = 0.49) to yield the product as a 
pale yellow solid (94%); mp = 124°C – 1H-NMR (300 MHz, CDCl3): δ = 2.62 (s, 3H, 
CH3), 2.74-2.94 (m, 8H, 2*2 CH2), 3.67 (s, 2H, N-CH2), 3.81 (s, 3H, OCH3), 3.82 (s, 
3H, OCH3), 6.51 (s, 1H, Ar-H), 6.58 (s, 1H, Ar-H), 7.20 (d, 3J = 8.5 Hz, 2H, AA'BB'), 
7.40 (d, 3J = 8.2 Hz, 1H, H-Ar), 7.61 (d, 3J = 8.5 Hz, 2H, AA'BB'), 8.08 (dd, 3J = 8.0 
Hz, 4J = 1.9Hz, 1H, H-Ar), 8.50 (d, 4J = 1.9 Hz, 1H, H-Ar), 8.91 (bs, 1H, CONH) – 13C-
NMR (75 MHz, CDCl3): δ = 20.6 (+), 28.4 (-), 33.3 (-) 51.0 (-), 55.5 (-), 55.9 (+), 55.9 
(+), 59.9 (-), 109.4 (+), 111.3 (+), 120.9 (+), 123.5 (+), 125.9 (Cquat), 129.2 (+), 131.9 
(+), 133.2 (+), 134.2 (Cquat), 136.0 (Cquat), 136.6 (Cquat), 137.0 (Cquat), 147.3 (Cquat), 
147.6 (Cquat), 148.9 (Cquat), 165.7 (Cquat) – MS (ESI, DCM/MeOH + 10 mmol/L 
NH4Ac): m/z (%) = 476 (100) [MH+], 951 (8) [2MH+] – UV/Vis (CHCl3) λmax [nm] (lg 
ε): 279 (4.132), 241 (4.211) – IR (KBr) [cm-1]: ν = 3315, 2933, 2837, 1647, 1599, 1520 
– Elemental analysis calcd (%) for C27H29N3O5 (475.55): C 68.20, H 6.15, N 8.84; 
found C 68.02, H 6.18 N 8.78. 
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Methyl 2-amino-4-((4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)- 
phenyl)aminocarbonyl)benzoate (19a).  
 
The compound was synthesized following general procedure D and obtained as a pale 
yellow solid in quantitative yield; mp = 104-106 °C – 1H-NMR (300 MHz, [D6]-
DMSO): δ = 2.63-2.82 (m, 8H, 4 CH2), 3.53 (s, 2H, NCH2), 3.69 (s, 3H, OCH3), 3.70 (s, 
3H, OCH3), 3.82 (s, 3H, COOCH3), 6.63 (s, 1H, H-Ar), 6.65 (s, 1H, H-Ar), 6.85 (bs, 
2H, NH2), 7.01 (dd, 4J = 1.7 Hz, 3J = 8.5 Hz, 1H, H-Ar), 7.22 (d, 3J = 8.5 Hz, 2H, 
AA'BB'), 7.29 (d, 4J = 1.7 Hz, 1H, H-Ar), 7.65 (d, 3J = 8.5 Hz, 2H, AA'BB'), 7.80 (d, 3J 
= 8.3 Hz, 1H, H-Ar), 10.23 (s, 1H, CONH) – 13C-NMR (100 MHz, [D6]-DMSO): δ = 
25.5, 29.8, 49.3, 51.6, 52.2, 55.5, 55.6, 56.8, 109.7, 110.6, 111.6, 113.3, 116.1, 120.5, 
124.0, 128.7, 128.8, 130.8, 133.3, 137.5, 140.1, 147.5, 148.0, 151.0, 165.3, 167.4 – IR 
(KBr) [cm-1]: ν = 3334, 2934, 1737, 1663 – UV/Vis (CHCl3) λmax [nm] (lg ε): 283 
(5.201), 239 (5.763) – MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 490 
(100) [MH+].  
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3-Amino-N-(4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)-phenyl)-
4-methoxy-benzamide (19b).  
 
The compound was prepared following general procedure D and was isolated in 
quantitative yield; mp = 178°C – 1H-NMR (300 MHz, CDCl3): δ = 2.75-2.94 (m, 8H, 4 
CH2), 3.67 (s, 2H, NCH2), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 
6.54 (s, 1H, H-Ar), 6.60 (s, 1H, H-Ar), 6.82 (d, 3J = 8.5 Hz, 1H, H-Ar), 7.20-7.24 (m, 
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4H, H-Ar), 7.54 (d, 3J = 8.5 Hz, 2H, H-Ar, AA’BB’), 7.71 (bs, 1H, CONH) – 13C-NMR 
(75 MHz, [D6]-DMSO): δ = 28.2 (-), 32.2 (-), 50.5 (-), 55.0 (-), 55.3 (+), 59.6 (-), 109.3 
(+), 109.8 (+), 111.6 (+), 113.0 (+), 116.0 (+), 120.1 (+), 125.8 (Cquat), 126.5 (Cquat), 
127.5 (Cquat), 128.6 (+), 135.1 (Cquat), 137.3 (Cquat), 146.7 (Cquat), 147.0 (Cquat), 148.8 
(Cquat), 165.6 (Cquat) – IR (KBr) [cm-1]: ν = 3311, 2936, 2839, 1648, 1612, 1514 – 
UV/Vis (CHCl3) λmax [nm] (lg ε): 279 (4.160), 265 (4.166), 241 (4.284) – MS (ESI, 
DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 462 (100) [MH+], 923 (5) [2MH+]. 
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3-Amino-N-(4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)-phenyl)-
4,5-dimethoxybenzamide (19c).  
 
The compound was prepared following general procedure D and isolated in quantitative 
yield; mp = 176-179 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.74-2.93 (m, 8H, 4 CH2), 
3.66 (s, 2H, NCH2), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.91 
(s, 3H, OCH3), 3.99 (bs, 2H, NH2), 6.54 (s, 1H, H-Ar), 6.60 (s, 1H, H-Ar), 6.83 (d, 4J = 
1.9 Hz, 1H, H-Ar), 6.88 (d, 4J = 2.2 Hz, 1H, H-Ar), 7.22-7.25 (m, 2H, H-Ar, AA’BB’), 
7.52-7.55 (m, 2H, H-Ar, AA’BB’), 7.68 (bs, 1H, CONH) – 13C-NMR (75 MHz, 
CDCl3): δ = 28.7 (-), 33.5 (-), 51.1 (-), 55.7 (-), 55.9 (+), 55.9 (+), 56.0 (+), 60.0 (+), 
60.2 (-), 101.8 (+), 107.0 (+), 109.5 (+), 111.4 (+), 120.3 (+), 126.1 (Cquat), 126.5 (Cquat), 
129.3 (+), 131.1 (Cquat), 136.2 (Cquat), 136.6 (Cquat), 138.5 (Cquat), 140.6 (Cquat), 147.2 
(Cquat), 147.5 (Cquat), 153.0 (Cquat), 165.7 (Cquat) – IR (KBr) [cm-1]: ν = 2983, 1730, 
1686, 1576, 1520 – UV/Vis (CHCl3) λmax [nm] (lg ε): 324 (3.788), 255 (4.345) – MS 
(ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 492 (100) [MH+], 983 (15) 
[2M+H+].  
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3-Amino-N-(4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)-phenyl)-
5-methoxybenzamide (19d).  
 
The compound was prepared following general procedure D and isolated in quantitative 
yield; mp = 153-155 °C – 1H-NMR (300 MHz, CDCl3): δ = 2.72-2.92 (m, 8H, 4 CH2), 
3.65 (s, 2H, NCH2), 3.78 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 6.34-
6.35 (m, 1H, H-Ar), 6.54 (s, 1H, H-Ar), 6.60 (s, 1H, H-Ar), 6.72-6.75 (m, 2H, H-Ar), 
7.20-7.23 (m, 2H, H-Ar, AA’BB’), 7.52-7.55 (m, 2H, H-Ar, AA’BB’), 7.84 (bs, 1H, 
CONH) – 13C-NMR (75 MHz, CDCl3): δ = 28.6 (-), 33.4 (-), 51.1 (-), 55.4 (+), 55.7 (-), 
55.9 (+), 55.9 (+), 60.1 (-), 102.6 (+), 103.9 (+), 106.4 (+), 109.5 (+), 111.4 (+), 120.4 
(+), 126.2 (Cquat), 126.5 (Cquat), 129.3 (+), 136.1 (Cquat), 136.6 (Cquat), 137.4 (Cquat), 
147.3 (Cquat), 147.6 (Cquat), 148.2 (Cquat), 161.0 (Cquat), 165.9 (Cquat) – IR (KBr) [cm-1]: ν 
= 3451, 2934, 2836, 1665, 1591, 1520 – UV/Vis (CHCl3) λmax [nm] (lg ε): 282 (4.142) 
– MS (CI-MS, NH3): m/z (%) = 208 (100) [C12H18O2N+], 462 (73) [MH+]. 
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3-Amino-N-(4-(2-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl)-phenyl)-
4-methylbenz-amide (19e).  
 
The compound was prepared following general procedure D and isolated in quantitative 
yield; mp = 144°C (decomposition) – 1H-NMR (300 MHz, CDCl3): δ = 2.20 (s, 3H, 
CH3), 2.76-2.95 (m, 8H, 2*2 CH2), 3.69 (s, 2H, N-CH2), 3.84 (s, 3H, OCH3), 3.84 (s, 
3H, OCH3), 6.53 (s, 1H, Ar-H), 6.60 (s, 1H, Ar-H), 7.21-7.26 (m, 2H, AA'BB'), 7.10-
7.13 (m, 2H, H-Ar), 7.21-7.22 (m, 1H, H-Ar), 7.54-7.57 (m, 2H, AA'BB'), 7.84 (bs, 1H, 
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CONH) – 13C-NMR (75 MHz, CDCl3): δ = 17.5 (+), 28.4 (-), 33.2 (-) 51.0 (-), 55.5 (-), 
55.9 (+), 55.9 (+), 59.9 (-), 109.4 (+), 111.3 (+), 113.7 (+), 116.3 (+), 120.3 (+), 125.9 
(Cquat), 126.3 (Cquat), 129.3 (+), 130.6 (+), 133.8 (Cquat), 136.0 (Cquat), 136.3 (Cquat), 
145.1 (Cquat), 147.3 (Cquat), 147.6 (Cquat), 165.9 (Cquat) – UV/Vis (CHCl3) λmax [nm] (lg 
ε): 277 (4.206), 255 (4.256), 242 (4.289) – IR (KBr) [cm-1]: ν = 3324, 2936, 2835, 
1648, 1573, 1519 – MS (ESI, DCM/MeOH + 10 mmol/L NH4Ac): m/z (%) = 446 (100) 
[MH+], 891 (11) [2MH+]. 
 
HPLC analysis of key target compounds. Analytical HPLC was performed on an 
Agilent 1100 LC system equipped with a Phenomenex Luna C18 (2) column (particle 
size 3 µm, pore size 100 A, 150 mm x 2.00 mm) unless otherwise stated (see HPLC of 
compounds 8 and 12). The column temperature was 25 °C. Gradient elution was done 
with water (0.0059% w/w TFA) (solvent A) and acetonitrile (solvent B) at a constant 
flow rate of 0.3 mL/min. A gradient profile with the following proportions of solvent B 
was applied: 0 min 5% B, 30 min 95% B. Compounds were detected with a diode array 
detector (DAD, 220 nm) and an evaporative light scattering detector (ELSD (PL-ELS 
2100 Ice), gas flow 1.6 L/min, evaporator 30 °C, nebulizer 30 °C). Compounds were 
dissolved either in DMSO or a mixture of chloroform/acetonitrile. 
 
Table. Purities (%) of key target compounds 5-15 
 
Compound UV (220 nm) ELSD 
5 94 99 
6 100 100 
7 100 100 
8a 80a - 
9 98 100 
10 96 100 
11 93 100 
12a 90a - 
13 94 99 
14 94 100 
15 100 100 
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aHPLC of compounds 8 and 12. Column: Luna RP-18 (2), (3µm) (150 mm x 4.6 mm), 
Detector: UV (detection wavelength: 210 nm). Gradient elution was done with water 
(0.05% TFA) (solvent A) and acetonitrile (solvent B) at a constant flow rate of 0.8 
mL/min (30 °C). A gradient profile with the following proportions of solvent B was 
applied: 0 min, 15% B; 19 min, 60% B; 20 min, 95% B; 24.5 min, 95% B; 25 min, 15% 
B; 38 min, 15% B. Prior to injection DMSO stock solutions of compound 8 and 
compound 12 were diluted with a mixture of 85% ammoniumacetate buffer (0.2 M) and 
15% acetonitrile to a final DMSO concentration of 2%. 
 
Drugs and chemicals used for assays. Mitoxantrone stocks were obtained by diluting 
Novantron® (Wyeth Pharma, Muenster, Germany) in 70% ethanol to a concentration of 
2 mM. Test compounds were dissolved in DMSO (Merck, Darmstadt, Germany) at a 
concentration of 10 mM. Fumitremorgin C (gift of Dr. Susan Bates, NIH) was also 
dissolved in DMSO and diluted to a concentration of 1 mM. A 10 mM stock solution of 
Ko143 in DMSO was kindly provided by Dr. A. H. Schinkel (Netherlands Cancer 
Institute). All stocks were stored at -20 °C. Topotecan stocks were prepared by diluting 
Hycamtin® (GlaxoSmithKline, München, Germany) in 70% ethanol to a concentration 
of 0.1 mM and stored at 4 °C. Tariquidar (free base) was synthesized according to the 
literature with slight modifications.[20] Elacridar (GF 120918·HCl) was kindly provided 
by GlaxoSmithKline (Research Triangle Park, North Carolina, United States). Calcein-
AM, purchased from Biotrend (Köln, Germany), was dissolved in DMSO (Merck, 
Darmstadt, Germany) to achieve a final concentration of 1 mM. The aliquoted stock 
solutions were stored at -20 ° C. The 1 mM stock solution of vinblastine (vinblastine 
sulphate, Sigma, Munich, Germany) was prepared in 70% ethanol. 
 
Cell lines and culture condition. MCF-7/Topo cells, an ABCG2 overexpressing 
subclone of MCF-7 breast cancer adenocarcinoma cells (ATTC HTB-22) were obtained 
by passaging the MCF-7 cells with increasing concentrations of topotecan in the culture 
medium to a maximum concentration of 0.55 µM. Having reached the final 
concentration of topotecan, the cells were passaged after trypsinization using 0.05% 
trypsin/0.02% EDTA (PAA Laboratories, Pasching, Austria) every 3-5 days. The 
treated cells showed sufficient quantities of the ABCG2 transporter after 3 passages in 
Eagle’s minimum essential medium (Sigma, Deisenhofen, Germany) containing L-
glutamine, 2.2 g/L NaHCO3 (Merck, Darmstadt, Germany), 0.11 g/L sodium pyruvate 
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(Serva, Heidelberg, Germany), 5% fetal calf serum (FCS, Biochrom , Berlin, Germany) 
and topotecan at a concentration of 0.55 µM. 
KBv1 cells, an ABCB1 overexpressing subclone of Kb cells (ATCC CCL-17), were 
maintained in Dulbecco’s modified Eagle’s medium (Sigma, Deisenhofen, Germany) 
supplemented with 10% FCS (Biochrom, Berlin, Germany) and 270 ng/mL vinblastine. 
U-373 MG cells, an ABCB1 and ABCG2 non-expressing human glioblastoma cell line, 
were cultured in Eagle’s minimum essential medium (Sigma, Deisenhofen, Germany) 
containing L-glutamine, 2.2 g/L NaHCO3 (Merck, Darmstadt, Germany), 0.11 g/L 
sodium pyruvate (Serva, Heidelberg, Germany) and 5% fetal calf serum (Biochrom, 
Berlin, Germany). All cells were cultured in a water-saturated atmosphere (95% air/5% 
CO2) at 37 °C in 75 cm2 and 175 cm2 culture flasks (NUNC, Wiesbaden, Germany and 
Greiner, Frickenhausen, Germany) respectively. Mycoplasma contamination was 
routinely monitored by polymerase chain reaction (Venor GeM, Minerva Biolabs 
GmbH, Berlin, Germany), and only mycoplasma free cultures were used for testing. 
ABCC2 overexpressing MDCKII-MRP2 cells transfected with human ABCC2 were a 
kind gift from Prof. Dr. P. Borst (Netherland Cancer Institute, Amsterdam, NL). The 
cells were grown in Dulbecco´s Modified Eagle medium supplemented with 5% FCS 
(Biochrom, Berlin, Germany).  
 
Modulation of ABCG2 (BCRP, ABCP, MXR): determination in the flow 
cytometric mitoxantrone efflux assay. The assay was essentially performed as 
described.[34] Briefly, 3 to 5 days after passaging, the ABCG2 overexpressing MCF-
7/Topo cells were trypsinized and resuspended in culture medium at 25 °C. After 
adjusting the cells to a number of 1×106 per mL with culture medium, mitoxantrone was 
added to the cell suspension to achieve a concentration of 20 µM. Different 
concentrations of the test compound, solvent and fumitremorgin C (final concentration 
10 µM) were added, respectively. The cell suspensions were vortexed and incubated for 
30 min at 37 °C / 5% CO2 to allow maximal mitoxantrone uptake into the cells. After 
one washing step with 0.8 mL of ice-cold PBS the cells of the fumitremorgin C sample 
were resuspended in 0.5 mL of PBS and placed on ice in the dark until the measurement 
to avoid mitoxantrone efflux (determination of the 100% mitoxantrone uptake). All 
other samples were resuspended in 1 mL of drug-free culture medium and incubated for 
1 h at 37 °C / 5% CO2 in which an equilibrium of mitoxantrone could be reached 
between the cytoplasm and the surrounding medium. Subsequently, after the medium 
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was removed by centrifugation, the cell pellets were rinsed once with 0.8 mL of ice-cold 
PBS and finally resuspended in 0.5 mL of PBS for the flow cytometry. A FACS 
caliburTM (Becton Dickinson, Heidelberg, Germany) was used to analyze the 
fluorescence intensity of the cells. Mitoxantrone accumulation in the cells was 
monitored by using an excitation wavelength of 635 nm whereas emission was detected 
at a wavelength of 661 nm. A minimum of 20000 events was collected per sample, and 
the events were gated according to forward scatter and sideward scatter to exclude 
clumps and debris. Analysis of the raw data was performed with the WinMDI 2.8 
software. The geometric means were calculated from the fluorescence intensity 
histogram and related to the controls. Afterwards, the mean values of 3 independent 
measurements were plotted against the concentration of the test compounds. Addition of 
increasing concentrations of the modulator led to sigmoidal concentration response 
curves. IC50 values were calculated using SIGMA PLOT 9.0, four parameter logistic 
curve fitting. Errors were calculated as standard error of the mean. 
 
Modulation of ABCB1 (p-gp): determination in the flow cytometric calcein-AM 
assay. The assay was performed as described before.[34] 
 
Modulation of ABCC2 (MRP2): determination in the CMFDA assay. Cells were 
kept in culture in 24-well plates. They were washed twice with Krebs-Ringer buffer 
(KRB) at 37 oC prior to experiments, and then incubated with 1 µM CMFDA in absence 
or in presence of the test compounds at increasing concentrations. Typically, the 
modulators were dissolved in DMSO. Control experiments confirmed that the cell 
monolayers tolerated up to 1% DMSO in the incubation medium without functional 
impairment. All monolayers were incubated for 90 min at 37 °C and under constant 
circular shaking at 50 rpm. Subsequently, the culture plates were placed on ice, medium 
in the apical compartment was removed and the cells were washed twice with ice-cold 
KRB. The cells were lysed by incubation with 200 µL of 1% Triton X-100 in KRB for 
30 min under constant shaking. Finally, the culture plates were subjected to 
fluorescence quantification in a plate reader (Tecan Safire XFLUOR4, Tecan Safire, 
Crailsheim, Germany) with filter settings of λex of 485 nm and λem of 516 nm. The 
extent of transport inhibition in presence of ABCC2 modulators was calculated from 
fluorescence intensities using the software GraphPad Prism (GraphPad Software, Inc., 
San Diego, CA, USA). 
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Chemosensitivity assays. The assays were performed as described previously.[34] In 
brief: tumor cell suspensions (100 µL/well) were seeded into 96-well flat bottomed 
microtitration plates (Greiner, Frickenhausen, Germany) at a density of ca. 15 
cells/microscopic field (magnification 320-fold). After 2-3 days the culture medium was 
removed by suction and replaced by fresh medium (200 µL/well) containing varying 
drug concentrations or vehicle. Drugs were added as 1000-fold concentrated feed 
solutions. On every plate 16 wells served as controls and 16 wells were used per drug 
concentration. After various times of incubation the cells were fixed with 
glutardialdehyde (Merck, Darmstadt, Germany) and stored in a refrigerator. At the end 
of the experiment all plates were processed simultaneously (staining with 0.02% 
aqueous crystal violet (SERVA, Heidelberg, Germany) solution (100 µL/well)). Excess 
dye was removed by rinsing the trays with water for 20 min. The stain bound by the 
cells was redissolved in 70% ethanol (180 µL/well) while shaking the microplates for 
about 3 hours. Absorbance (a parameter proportional to cell mass) was measured at 578 
nm using a BIOTEK 309 Autoreader (TECNOMARA, Fernwald, Germany).  
 
Drug effects were expressed as corrected T/C-values for each group according to  
 
T/Ccorr = 
0
0
C- C
C - T
 · 100 [%] 
 
where T is the mean absorbance of the treated cells, C the mean absorbance of the 
controls and C0 the mean absorbance of the cells at the time (t = 0) when drug was 
added. When the absorbance of treated cells T is less than that of the culture at t = 0 
(C0), the extent of cell killing was calculated as 
 
cytocidal effect [%] = 
0
0
C
TC −
 · 100 
 
For assays performed on quiescent U-373 MG cells, a high sowings density was chosen 
in order to observe as much as possible the effects of the compounds against resting 
cells. To detect maximum cytocidal effect rotenone, an ubiquinon reductase inhibitor, 
blocking ATP synthesis, served as positive control. 
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3. Synthesis and Cannabinoid Receptor Activity of Ketoalkenes 
from Echinacea pallida and Non-natural Analogues i 
 
 
 
Despite its popularity and widespread use, the efficacy of Echinacea products remains 
unclear and controversial. Among the various compounds isolated from Echinacea, 
ketoalkenes and ketoalkenynes exclusively found in the pale purple coneflower (E. 
pallida) are major components of the extracts which in contrast to E. purpurea 
alkamides have not been studied for immunostimulatory effects. The E. pallida 
ketoalkenes with skipped conjugation were synthesizedii along with some conjugated 
non-natural analoguesiii and their effects on the human cannabinoid receptors CB1 and 
CB2 were investigated. iv  While no significant activity of the natural products was 
observed at either receptor the new analogues showed micromolar potency at both 
cannabinoid receptors.   
 
 
                                                 
i
 M. Egger, P. Pellett, K. Nickl, S. Geiger, S. Graetz, R. Seifert, J. Heilmann, B. König, Chem. Eur. J. 
2008, 14, 10978-10984. 
ii
 The sequence from compound 12 to compound 15 was carried out in collaboration with Stephanie 
Graetz. 
iii
 The conjugated compounds 36-42 were synthesized by Patrina Pellett. 
iv
 The steady-state GTPase assays were carried out by Kathrin Nickl and Sarah Geiger at the Institute of 
Pharmacy, University of Regensburg. 
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3.1. Introduction 
 
Echinacea extracts are one of the top selling herbal remedies in the USA and Europe to 
treat upper respiratory tract infections.[1] Some studies show that Echinacea is an 
effective immunostimulant,[2,3] while others do not,[4] and much controversy on the 
efficacy of these extracts exists.[5] The extracts consist of a complex mixture of caffeic 
acid derivatives, glycoproteins, polysaccharides and alkamides,[6] from 3 species of 
Echinacea: E. purpura, E. pallida and E. angustifolia.[7] The major components of E. 
purpura and E. angustifolia extracts are alkamides, while E. pallida extracts consist of 
mainly ketoalkenes and ketoalkenynes.[8] 
 
Echinacea products on the market may contain only one of the above mentioned species 
or mixtures of all 3 species, and are not required to guarantee content, quality, 
variability, or contamination of the supplement.[9] Studies have shown that Echinacea 
extracts are wide-spectrum immunomodulators, but the exact phytochemical responsible 
for the active nature of the extracts has not been identified.[10] Determining the activity 
of Echinacea extracts as an effective herbal remedy is of high interest and intense 
research on the subject is being conducted, but further studies to elucidate the mode of 
action are required.[1-3, 7, 10] 
 
Alkamides have been tested for biological activity and have been shown to bind with 
high affinity to the human cannabinoid 2 receptor (CB2R), and may be considered a 
molecular mode of action explaining the immunomodulatory and anti-inflammatory 
effects.[7,11,12] In order to investigate the biological activity of ketoalkenes and 
ketoalkenynes found in many Echinacea extracts, we report a versatile synthetic route 
to the ketones found in E. pallida (Figure 1), and present the results from functional 
GTPase assays of these newly synthesized compounds at the CB1R and the CB2R. To 
determine any structure activity relationship responsible for receptor activation, we 
describe the synthesis and testing results of structurally similar ketone containing 
analogues.  
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Figure 1. Echinacea pallida.  
 
3.2. Results and Discussion 
 
Synthesis. In contrast to other Echinacea species, only E. pallida contains ketoalkenes 
and ketoalkenynes (Figure 2).  
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Figure 2. Ketoalkenes and ketoalkenynes isolated from E. pallida. 
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The syntheses of monoalkene 1 and bisacetylenes 2 and 3 have recently been reported 
by Dickschat et al[13] and Kraus et al.[14,15] Despite the large interest in obtaining 
synthetic samples of the remaining unsaturated compounds for biological evaluation the 
other ketoalkenes have not been prepared so far. We therefore planned to synthesize the 
polyenes 5-8 and test their activity at the human cannabinoid receptors in a functional 
GTPase assay. Our synthetic strategy was to obtain the 1,4-diene motifs via Pd-
catalyzed cross coupling reactions of appropriate allyl acetates with vinyl zinc halides 
that were derived from viyl zinc chloride 10. This route not only enabled us to prepare 
all compounds via one common precursor but also allowed for access to non-natural 
conjugated analogues via Sonogashira and Suzuki cross coupling reactions of the vinyl 
iodide intermediate 10 (Scheme 1). 
 
O
R
ZnCl
OO
O
R I
OO
OO O
H
R = alkyl, alkenyl
R = aryl, alkynyl
9
10
11
 
 
Scheme 1. Retrosynthetic analysis of the natural products found in E. pallida and their 
conjugated analogues. 
 
Aldehyde 11 was previously synthesized from methylacetoacetate in 8 steps with an 
overall yield of 38%.[16] Alternatively, we started from commercially available 
cycloheptanone which was converted into methylcycloheptanol in quantitative yield. 
Retro-Barbier fragmentation[17] and protection of the resulting keto group resulted in 
bromide 15, which was then oxidized to aldehyde 11 (Scheme 2).[18] The synthesis of 
aldehyde 11 could thus be shortened by 4 steps and the overall yield increased to 59%. 
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Conversion to the vinyl iodide 10 was finally achieved by the method of Stork and Zhao 
in good yield and high stereoselectivity.[19] 
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Scheme 2. Improved synthesis of aldehyde 11 and its conversion into the vinyl iodide 
intermediate 10. Reagents and conditions: a) MeLi (1.1 eq), Et2O, -78°C, 100%; b) Br2, 
K2CO3, CHCl3, 0°C, 93%; c) ethylene glycol, pTsOH, toluene, reflux, 92%; d) 
trimethylammonium-N-oxide, DMSO, RT, 69%; e) ICH2PPh3I, NaHMDS, rt; 11, -
78°C, 81%.  
 
The synthesis of the 1,4-dienes required the selective preparation of E- and Z-allyl 
acetates. (Z)-Hex-2-enyl acetate 17 was directly obtained from the commercially 
available corresponding alcohol, whereas (Z)-oct-2-enyl acetate 21 was prepared by 
hydroboration of the THP protected propargyl alcohol 19, followed by deprotection and 
acetylation. Reduction of the propargyl acetate was also attempted but turned out to be 
less selective and gave higher amounts of the undesired trans isomer. Direct conversion 
of the THP protected alcohol 20 into the acetate 21[20] was inferior to the sequence of 
deprotection followed by acetylation due to lower yields and a more difficult separation 
(Scheme 3).  
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Scheme 3. Synthesis of allyl acetates 17 and 21. Reagents and conditions: a) Ac2O, 
DMAP, NEt3, CH2Cl2, rt, 99%; b) DHP, pTsOH, CH2Cl2, rt, 96%; c) BH3*Me2S, 
cyclohexene, Et2O, 0°C to rt; 19, 0°C to rt; HOAc, 0°C to rt, 89%; d) 1.) pTsOH, 
MeOH, rt, 87%; 2.) Ac2O, DMAP, NEt3, CH2Cl2, rt, 99%. 
 
Diene coupling partners 26 and 31 were prepared from 1,3-enynes 24 and 29, which 
were synthesized by Sonogashira cross coupling of cis- or trans-1-bromo-1-propene and 
(THP-protected) propargyl alcohol. The E-allyl acetate 26 was then prepared via trans-
hydroalumination while the Z-isomer 31 was again synthesized as described above 
(Scheme 4).  
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Scheme 4. Synthesis of the diene coupling partners. Reagents and conditions: a) 
PdCl2(PPh3)2 (2 mol-%), CuI (4 mol-%), piperidine, rt, 91%; b) LiAlH4, THF, -10°C to 
rt, 97%; c) Ac2O, DMAP, NEt3, CH2Cl2, rt, 99%; d) PdCl2(PPh3)2 (2 mol-%), CuI (4 
mol-%), piperidine, rt, 92%; e) BH3*Me2S, cyclohexene, Et2O, 0°C to rt; 29, 0°C to rt; 
HOAc, 0°C to rt, 91%; f) pTsOH, MeOH, rt, 84%; g) Ac2O, DMAP, NEt3, CH2Cl2, rt, 
99%. 
 
Pd-catalyzed cross coupling between the vinyl zinc chloride 9 and the corresponding 
allyl acetates gave the desired 1,4-dienes which were finally deprotected to yield the 
ketoalkenes 5-8 (Scheme 5). 
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Scheme 5. Synthesis of the 1,4-dienes 5-8 via Pd-catalyzed cross couplings. Reagents 
and conditions: a) tBuLi, THF, -78°C, then ZnCl2, -78°C to rt; b) PdCl2(PPh3)2 (3 mol-
%), ROAc, THF, rt, 20-27%; c) 1M HCl, THF, rt, quant. 
 
The ketoalkenes of E. pallida share two common structural motifs: a skipped 
conjugation in the unsaturated part and the combination of a methyl ketone and a 
polyene moiety connected by a flexible alkyl chain. In order to explore whether the skip 
in conjugation plays an important role in a potential mechanism of action we prepared a 
series of conjugated analogues via Suzuki and Sonogashira cross coupling reactions of 
the vinyl iodide intermediate 10 (Scheme 6) and compared their activity at the CBRs to 
the natural products. We also investigated the influence of an amide versus a 
methylketone head group, which is the main difference between E. purpurea alkamides 
and E. pallida ketoalkenes. For that reason we replaced the amide group of the 
endogenous ligand anandamide by a simple methylketone, which was prepared by 
derivatization of arachidonic acid (Scheme 7). 
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Scheme 6. Preparation of non-natural conjugated analogues. Reagents and conditions: a) 
RCCH (1.2eq), PdCl2(PPh3)2 (5 mol-%), CuI (5 mol-%), NEt3, rt, 67-71%; b) Bu4NF, 
THF, rt, 76%; c) 1M HCl, THF, rt, 80-96% d) PhB(OH)2 (1.1eq), Pd(OAc)2 (5 mol-%), 
NaOH (2.5eq), THF, reflux, 61%.  
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Scheme 7. Structure of anandamide and synthesis of its keto analogue 44. 
 
Pharmacology. Cannabinoid receptors couple to Gi/Go-proteins and the nucleotide 
exchange can be monitored as an increase in steady-state GTPase activity.[21] All 
synthesized compounds were tested for agonistic activity at the CBRs in a steady-state 
GTPase assay (see Table 1). Compounds were considered to be CBR agonists when 
GTPase activation was more than 20% compared to basal GTPase activity [3% (v/v) 
DMSO]. The maximal stimulatory effect of the most abundant endogenous CBR agonist 
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2-arachidonoyl glycerol (2-AG) was set at 100% to determine Emax values of active 
compounds. The second endogenous CBR agonist, anandamide (ANA), was a full 
agonist at the CB1R and a partial agonist at the CB2R. Compounds 36 and 39 are 
analogues of the natural ketoalkenynes from E. pallida with a keto group at C2, a cis-
double bond at C8 and a triple bond at C10. Introduction of a phenyl ring in compound 
39 led to partial agonism at both CBRs with a potency in the micromolar range. 
Protection of the keto group at C2 (36) resulted in a complete loss of efficacy at the 
CB1R and partial agonism at the CB2R. The potency of compound 36 at the CB2R was 
in the micromolar range. Compound 44, an analogue of the endogenous agonist 
anandamide, was a full agonist at both CBRs. Replacement of the isobutylamide head 
group by a methyl ketone even led to a higher efficacy at the CB2R compared to 
anandamide. However, the logEC50 values of compound 44 were only in the micromolar 
range compared to anandamide or 2-AG. This finding suggests that substitution of the 
carboxyl group at C1 with a larger or an amine-containing group, e.g. ethanolamine 
(anandamide) or glycerol (2-AG) is necessary for a high potency at CBRs.  
 
 
Table 1. Stimulation of GTPase activity, Emax values and logEC50 values of 2-AG, 
anandamide (ANA) and synthesized compounds. GTPase activity was determined in 
Sf9 insect cell membranes expressing CBRs, Gαi2, Gβ1γ2 and RGS4. Results are 
expressed as percentages of mean values ± S.D. compared to basal GTPase activation 
assessed by 3% (v/v) DMSO. Emax values represent the stimulation relative to the 
endogenous agonist 2-AG (defined as 100% stimulation). Data represents 3 independent 
experiments performed with different membrane preparations. 
 
Cpd. CB1R  CB2R  
 
GTPase 
activation 
[%] 
Emax 
[%] 
logEC50 
GTPase 
activation 
[%] 
Emax 
[%] 
logEC50 
2-AG 69 ± 6 100 -6.60 ± 0.12 74 ± 25 100 -6.53 ± 0.51 
ANA 80 ± 8 116 ± 19 -6.80 ± 0.10 49 ± 6 66 ± 15 -6.36 ± 0.44 
36 <20 n.a. n.a. 33 ± 3 45 ± 6 -5.23 ± 0.62 
39 41 ± 20 59 ± 35 -5.28 ± 0.27 44 ± 11 59 ± 18 -5.84 ± 0.19 
44 68 ± 6 99 ± 9 -5.71 ± 0.44 85 ± 7 114 ± 9 -5.46 ± 0.29 
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3.3. Conclusion 
 
We have developed a versatile synthetic route for the preparation of E. pallida 
ketoalkenes and new non-natural conjugated analogues. A particular advantage of our 
synthetic strategy is the possibility of preparing different conjugated and non conjugated 
polyene motifs found in many natural products starting from only one common 
precursor and following the same reaction procedures. The simplicity of the reactions 
involved and the inexpensive commercially available starting materials are also 
advantageous. 
 
Both classes of compounds were tested for their ability to activate the human 
cannabinoid receptors 1 and 2 (CB1R and CB2R). In contrast to the alkamides of E. 
purpurea, which have been shown to be CB2R agonists,[7] no agonistic activity at either 
receptor was found in the functional GTPase assay for the ketoalkenes found in E. 
pallida. If the observed immunomodulatory activity of Echinacea products is mediated 
via the CBR system, E. pallida ketoalkenes will not contribute to this effect. However, a 
different mode of action for these compounds or synergic effects cannot be excluded 
and may be responsible for the observed physiological activity of Echinacea extracts.[2] 
Interestingly, the non-natural phenylacetylene containing analogue 39 as well as its 
keto-protected precursor 36 showed micromolar activity at both receptors. The same 
was true for the keto analogue 44 of anandamide, indicating that an amide or ester 
moiety is not necessarily important for activation but for high affinity at the CBRs. 
 
3.4. Experimental Section 
 
General: Commercial reagents and starting materials were purchased from Aldrich, 
Fluka or Acros and used without further purification. THF was distilled from 
sodium/benzophenone. Flash chromatography was performed on Acros silica gel 60 A 
(35-70 µm). TLC was performed on alumina plates coated with silica gel (Merck silica 
gel 60 F254, thickness 0.2 mm) and products were detected after staining with 15% 
phosphomolybdic acid in ethanol. NMR spectra were recorded with Bruker Avance 300 
(1H: 300.1 MHz, 13C: 75.5 MHz, T = 300 K), Bruker Avance 400 (1H: 400.1 MHz, 13C: 
100.6 MHz, T = 300 K) and Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 
300 K) instruments. Chemical shifts are reported in δ ppm relative to external standards 
and coupling constants J are given in Hz. Abbreviations for the characterization of the 
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signals are: s = singlet, d = doublet, t = triplet, m = multiplet, bs = broad singlet, dt = 
double triplet. The relative number of protons is determined by integration. Error of 
reported values: chemical shift 0.01 ppm (1H-NMR), 0.1 ppm (13C-NMR), coupling 
constant 0.1 Hz. The used solvent for each spectrum is reported. Mass spectra were 
recorded with Finnigan MAT SSQ 710 A (CI) and Finnigan MAT 95 (HRMS), IR 
spectra with a Bio-Rad FT-IR Excalibur FTS 3000 MX spectrometer and UV/Vis 
spectra with a Cary BIO 50 UV/Vis/NIR spectrometer (Varian). The following 
compounds were prepared as described above and have been reported before: 1-
methylcycloheptanol 13,[22] 8-bromooctan-2-one (14),[17] 2-(6-bromohexyl)-2-methyl-
1,3-dioxolane (15),[23] (iodomethyl)triphenyl-phosphonium iodide,[24] 6-(2-methyl-1,3-
dioxolan-2-yl)hexanal (11),[16] (Z)-hex-2-enyl acetate (17),[25] 2-(oct-2-ynyloxy)-
tetrahydro-2H-pyran (19),[26] (Z)-oct-2-en-1-ol,[27] (Z)-hex-4-en-2-yn-1-ol (24),[28] 
(2E,4Z)-hexa-2,4-dien-1-ol (25),[28] (E)-2-(hex-4-en-2-ynyloxy)-tetrahydro-2H-pyran 
(29),[29] (2Z,4E)-hexa-2,4-dien-1-ol.[30]   
 
General procedure A for the semi-reduction of alkynes to the corresponding Z-
alkenes: Borane-dimethylsulfide complex (1.1 eq) was added to dry Et2O (~1 M) and 
cooled to 0 °C. Cyclohexene (2.2 eq) was slowly added by syringe and the mixture was 
stirred at 0 °C for 15 min before it was warmed to rt and stirred for 1 h. The white 
suspension was again cooled to 0 °C and the alkyne (1 eq) was slowly added via 
syringe. The mixture was stirred for 1 hr at 0 °C and 1.5 h at rt until the white 
precipitate completely dissolved and the reaction mixture was again cooled to 0 °C and 
acetic acid (~ 9 eq) was slowly added. The ice bath was removed and the solution was 
stirred at rt for 2 h. Et2O was added and the organic phase was washed with water (4x), 
dried over MgSO4, concentrated and purified by flash chromatography on silica gel 
(petroleum ether/EtOAc).  
 
General procedure B for the acetylation of allyl alcohols: To a 0.3 M solution of the 
alcohol in dry DCM, triethylamine (1.3 eq), freshly distilled acetic anhydride (1.1 eq) 
and catalytic amounts of DMAP was added. The mixture was stirred at rt until complete 
consumption of the alcohol (~ 4 h), diluted with DCM and washed with water. The 
aqueous phase was extracted with DCM and the organic phases were dried over MgSO4. 
The solvent was removed and the product purified by flash chromatography on silica 
gel (pentane/Et2O). 
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General procedure C for the Sonogashira cross coupling with 1-bromo-1-propene 
and various acetylenes: To a 0.3 M solution of bromopropene (1.1 eq) in freshly 
distilled piperidine, PdCl2(PPh3)2 (2 mol-%), the terminal acetylene (1 eq) and CuI (4 
mol-%) was added. The mixture was stirred at rt until complete consumption of the 
acetylene, quenched with saturated solution of NH4Cl and extracted with Et2O. The 
combined organic phases were washed with brine, dried over MgSO4, concentrated and 
purified by flash chromatography on silica gel (pentane/Et2O).  
 
General procedure D for the Pd-catalyzed cross coupling of vinyl zinc chlorides 
and allyl acetates. Under an argon atmosphere a 0.2 M solution of vinyl iodide 11 in 
freshly distilled dry THF (Na/benzophenone) was cooled to -78 °C. tBuLi (1.6 M in 
pentane, 2.2 eq) was added via syringe and the mixture was stirred for 1 hr at -78 °C. 
Dry ZnCl2 (1.1 eq) was added and the mixture was slowly warmed to rt. PdCl2(PPh3)2 
(5 mol%) and the allyl acetate were then added and the mixture was stirred at rt 
overnight, concentrated under a stream of nitrogen, quenched with saturated NH4Cl and 
extracted with DCM. The combined organic phases were washed with brine, dried over 
MgSO4, concentrated and purified by flash chromatography on silica gel (petroleum 
ether/EtOAc).  
 
General procedure E for the deprotection of 1,3-dioxolane-protected ketones: The 
dioxolane was dissolved in THF (5 mL) and 1M HCl (1 mL) was added. The mixture 
was stirred at rt overnight, diluted with Et2O, washed with aqueous saturated solution of 
NaHCO3 and dried over MgSO4. The solvents were removed under reduced pressure 
and the products were purified by flash chromatography on silica gel (petroleum 
ether/EtOAc).  
 
OO
I
 
(Z)-2-(7-Iodohept-6-enyl)-2-methyl-1,3-dioxolane (10). To a suspension of (iodo-
methyl)triphenylphosphonium iodide (5.1 g, 9.7 mmol) in dry THF (75 mL), 1 M 
sodium bis-(trimethylsilyl)amide in THF (11 mmol) was added. The orange suspension 
was cooled to -78 °C and DMPU (5.9 mL) was added. After 15 min aldehyde 11 (1.2 g, 
6.4 mmol) was added via syringe and the mixture was slowly warmed to rt. The solvent 
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was removed under reduced pressure and the resulting brown oil was dissolved in 
DCM, washed with water and concentrated. Byproducts were removed by precipitation 
with petroleum ether, the mother liquor was concentrated and the product was purified 
by flash chromatography on silica gel to yield vinyl iodide 10 as a colourless oil (1.6 g, 
81%). Rf = 0.31 (petroleum ether/EtOAc 9:1); 1H NMR (300 MHz, CDCl3): δ = 1.31 (s, 
3H; CH3), 1.33-1.46 (m, 6H; CH2), 1.61-1.66 (m, 2H; CH2), 2.10-2.17 (m, 2H; CH2), 
3.88-3.98 (m, 4H; OCH2), 6.12-6.19 (m, 2H; CH); 13C NMR (75 MHz, CDCl3): δ = 
23.8 (+), 23.9 (-), 27.9 (-), 29.3 (-), 34.6 (-), 39.1 (-), 64.6 (-), 82.3 (+), 110.1 (Cquat), 
141.3 (+); IR (neat): ν = 2981, 2937, 1375, 1069 cm-1; MS (CI, NH3): m/z (%) = 311 
(100) [MH+], 328 (12) [MNH4+]. 
 
OTHP
 
(Z)-2-(Oct-2-enyloxy)-tetrahydro-2H-pyran (20). The compound was prepared 
following general procedure A and isolated as colourless oil. Yield: 83%. Rf = 0.29 
(petroleum ether/EtOAc 19:1); 1H-NMR (300 MHz, CDCl3): δ = 0.88 (t, 3J = 6.7 Hz, 
3H; CH3), 1.21-1.41 (m, 6H; CH2), 1.50-1.88 (m, 6H; CH2), 2.04-2.10 (m, 2H; CH2), 
3.47-3.55 (m, 1H), 3.85-3.92 (m, 1H), 4.04-4.10 (m, 1H), 4.23-4.29 (m, 1H), 4.64 (t, 3J 
= 2.2 Hz, 1H), 5.50-5.63 (m, 2H); 13C-NMR (75 MHz, CDCl3): δ = 14.1, 19.6, 22.5, 
25.5, 27.5, 29.3, 30.7, 31.4, 62.2, 62.8, 97.9, 125.7, 133.9; IR (neat): ν = 2925, 2856, 
1455, 1025 cm-1; CI-MS (NH3): m/z (%) = 102 (100) [DHP+NH4+], 230 (18) [MNH4+]. 
 
OAc
 
(Z)-Oct-2-enyl acetate (21). The compound was prepared following general procedure 
B and isolated as colourless oil. Yield: 99%. Rf = 0.31 (petroleum ether/EtOAc 19:1); 
1H NMR (300 MHz, CDCl3): δ = 0.88 (t, 3J = 7.0Hz, 3H; CH3), 1.23-1.42 (m, 6H; 
CH2), 2.03-2.12 (m, 5H; CH2/CH3), 4.61 (d, 3J = 6.6 Hz, 2H; OCH2), 5.48-5.69 (m, 2H; 
CH); 13C NMR (75 MHz, CDCl3): δ = 14.0 (+), 21.0 (+), 22.5 (-), 27.5 (-), 29.1 (-), 31.4 
(-), 60.4 (-), 123.2 (+), 135.6 (+), 171.0 (Cquat); IR (neat): ν = 3024, 2928, 1739, 1372, 
1225 cm-1; CI-MS (NH3): m/z (%)=188 (100) [MNH4+]. 
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OAc
 
 
(2E,4Z)-Hexa-2,4-dienyl acetate (26). The compound was prepared following general 
procedure B and isolated as colourless oil. Yield: 99%. Rf = 0.33 (petroleum ether/ 
EtOAc 9:1); 1H NMR (300 MHz, CDCl3): δ = 1.77 (dd, 3J = 7.1 Hz, 4J = 1.6 Hz, 3H; 
CH3), 2.07 (s, 3H; CH3), 4.62 (d, 3J = 6.6 Hz, 2H; CH2), 5.57 (dq, 3J = 7.3 Hz, 3J = 11.0 
Hz, 1H), 5.73 (dt, 3J = 7.0 Hz, 3J = 15.4 Hz, 1H), 6.01 (dt, 4J = 1.4 Hz, 3J = 11.0 Hz, 
1H), 6.55-6.65 (m, 1H); 13C-NMR (75 MHz, CDCl3): δ = 13.4 (+), 21.0 (+), 65.0 (-), 
125.9 (+), 128.2 (+), 128.2 (+), 129.6 (+), 170.8 (Cquat); IR (neat): ν = 3023, 1738, 1373, 
1222 cm-1; CI-MS (NH3): m/z (%) = 158 (10) [MNH4+], 98 (100) [MNH4+-HOAc].  
 
OTHP
 
2-((2Z,4E)-Hexa-2,4-dienyloxy)-tetrahydro-2H-pyran (30). The compound was 
prepared following general procedure A and isolated as colourless oil. Yield: 91%. Rf = 
0.36 (CH2Cl2); 1H NMR (300 MHz, CDCl3): δ = 1.50-1.88 (m, 6H; CH2), 1.78 (d, 3J = 
6.3 Hz, 3H; CH3), 3.49-3.56 (m, 1H), 3.86-3.93 (m, 1H), 4.16-4.38 (m, 2H), 4.64-4.66 
(m, 1H), 5.44 (dt, 3J = 7.1 Hz, 3J = 11.0 Hz, 1H), 5.75 (dq, 3J = 6.7 Hz, 3J = 14.8 Hz, 
1H), 6.11 (t, 3J = 11.0 Hz, 1H), 6.29-6.40 (m, 1H); 13C NMR (75 MHz, CDCl3): δ = 
18.3 (+), 19.5 (-), 25.5 (-), 30.7 (-), 62.3 (-), 62.8 (-), 97.8 (+), 124.4 (+), 126.6 (+), 
131.6 (+), 131.8 (+); IR (neat): ν = 3024, 2940, 1117, 1021 cm-1; CI-MS (NH3): m/z (%) 
= 102 (100) [DHP+NH4+], 200 (22) [MNH4+]. 
 
OAc
 
(2Z,4E)-Hexa-2,4-dienyl acetate (31). The compound was prepared following general 
procedure B and isolated as colourless oil. Yield: 99%. Rf = 0.39 (CH2Cl2); 1H NMR 
(300 MHz, CDCl3): δ = 1.80 (d, 3J = 6.0 Hz, 3H; CH3), 2.07 (s, 3H; CH3), 4.72 (d, 3J = 
7.4 Hz, 2H; CH2), 5.40 (dt, 3J = 7.5 Hz, 3J = 11.0 Hz, 1H), 5.81 (dq, 3J = 7.0 Hz, 3J = 
14.8 Hz, 1H), 6.15 (t, 3J = 11.1 Hz, 1H), 6.30-6.39 (m, 1H); 13C NMR (75 MHz, 
CDCl3): δ = 18.4 (+), 21.0 (+), 60.5 (-), 121.5 (+), 126.0 (+), 132.9 (+), 133.2 (+), 171.0 
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(Cquat); IR (neat): ν = 3031, 1735, 1372, 1223 cm-1; CI-MS (NH3): m/z (%) = 158 (71) 
[MNH4+], 98 (100) [MNH4+-HOAc]. 
 
OO
 
2-Methyl-2-((6Z,9E,11Z)-trideca-6,9,11-trienyl)-1,3-dioxolane (33). The compound 
was prepared following general procedure D and isolated as colourless oil. Yield: 27%. 
Rf = 0.36 (CH2Cl2); 1H NMR (300 MHz, CDCl3): δ = 1.30 (s, 3H; CH3), 1.31-1.43 (m, 
6H; CH2), 1.58-1.65 (m, 2H; CH2), 1.73 (dd, 3J = 6.9 Hz, 4J = 1.6 Hz, 3H; CH3), 2.01-
2.07 (m, 2H, CH2), 2.84 (t, 3J = 6.4 Hz, 2H; CH2), 3.88-3.98 (m, 4H; OCH2), 5.34-5.49 
(m, 3H), 5.63 (dt, 3J = 7.0 Hz, 3J = 15.1 Hz, 1H), 5.93-6.03 (m, 1H), 6.30-6.39 (m, 1H); 
13C NMR (75 MHz, CDCl3): δ = 13.3 (+), 23.7 (+), 24.0 (-), 27.1 (-), 29.5 (-), 29.6 (-), 
30.6 (-), 39.2 (-), 64.6 (-), 110.2 (Cquat), 124.4 (+), 125.6 (+), 126.9 (+), 129.4 (+), 131.0 
(+), 132.3 (+); IR (neat): ν = 2981, 2935, 1375, 1064 cm-1; CI-MS (NH3): m/z (%) = 265 
(100) [MH+], 282 (26) [MNH4+].  
 
O
1 2
3
4
5
6
7
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14
 
(8Z,11E,13Z)-Pentadeca-8,11,13-trien-2-one (6). The compound was prepared 
following general procedure E and isolated as colourless oil in quantitative yield. Rf = 
0.33 (CH2Cl2); 1H NMR (600 MHz, C6D6, COSY): δ = 1.09-1.14 (m, 2H, CH2; H(4)), 
1.23 (q, 3J = 7.5 Hz, 2H, CH2; H(5)), 1.43 (q, 3J = 7.6 Hz, 2H, CH2; H(3)), 1.62 (dd, 3J = 
7.2 Hz, 4J = 1.8 Hz, 3H, CH3; H(14)), 1.64 (s, 3H, CH3; H(1)), 1.90 (t, 3J = 7.3 Hz, 2H, 
CH2; H(2)), 1.95-1.99 (m, 2H, CH2; H(6)), 2.81 (t, 3J = 6.7 Hz, 2H, CH2; H(9)), 5.34 
(dq, 3J = 7.1 Hz, 3J = 10.7 Hz, 1H, H(13)), 5.42-5.52 (m, 2H, H(7)/H(8)), 5.62 (dt, 3J = 
6.9 Hz, 3J = 15.1 Hz, 1H, H(10)), 6.06-6.10 (m, 1H, H(12)), 6.44-6.48 (m, 1H, H(11)); 
13C NMR (75 MHz, CDCl3): δ = 13.3 (+), 23.7 (-), 27.0 (-), 28.8 (-), 29.4 (-), 29.9 (+), 
30.6 (-), 43.7 (-), 124.4 (+), 125.6 (+), 127.1 (+), 129.3 (+), 130.7 (+), 132.2 (+), 209.3 
(Cquat); IR (neat): ν = 3014, 2932, 2856, 1716, 1358 cm-1; CI-MS (NH3): m/z (%) = 238 
(100) [MNH4+]. 
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OO
 
2-Methyl-2-((6Z,9Z,11E)-trideca-6,9,11-trienyl)-1,3-dioxolane (32). The compound 
was prepared following general procedure D and isolated as colourless oil. Yield: 21%. 
Rf = 0.27 (petroleum ether/EtOAc 24:1); 1H NMR (300 MHz, CDCl3): δ = 1.27 (s, 3H; 
CH3), 1.29-1.40 (m, 6H; CH2), 1.57-1.62 (m, 2H; CH2), 1.69 (d, 3J = 6.6 Hz, 3H; CH3), 
2.00 (quint, 3J = 6.0 Hz, 2H; CH2), 2.73-2.88 (m, 2H; CH2), 3.84-3.94 (m, 4H; OCH2), 
5.28-6.03 (m, 6H); 13C NMR (75 MHz, CDCl3): δ = 18.0 (+), 23.7 (+), 24.0 (-), 27.1 (-), 
29.5 (-), 29.6 (-), 30.3 (-), 39.2 (-), 64.6 (-), 110.2 (Cquat), 127.1 (+), 127.2 (+), 129.9 (+), 
130.5 (+), 130.8 (+), 131.5 (+); CI-MS (NH3): m/z (%) = 187 (100) [(C11H22O2)H+], 204 
(61) [(C11H22O2)NH4+]. 
 
O
 
(8Z,11Z,13E)-Pentadeca-8,11,13-trien-2-one (5). The compound was prepared 
following general procedure E and isolated as colourless oil in quantitative yield. Rf = 
0.47 (petroleum ether/EtOAc 4:1); 1H NMR (300 MHz, CDCl3): δ = 1.25-1.41 (m, 4H; 
CH2), 1.52-1.62 (m, 2H; CH2), 1.73 (d, 3J = 6.9 Hz, 3H; CH3), 2.04 (quint, 3J = 6.3 Hz, 
2H; CH2), 2.13 (s, 3H; CH3), 2.41 (t, 3J = 7.7 Hz, 2H; CH2), 2.77-2.92 (m, 2H; CH2), 
5.33-6.07 (m, 6H); 13C NMR (75 MHz, CDCl3): δ = 18.1 (+), 23.7 (-), 26.9 (-), 28.8 (-), 
29.4 (-), 29.9 (+), 30.3 (-), 43.7 (-), 127.2 (+), 127.3 (+), 129.8 (+), 130.5 (+), 130.6 (+), 
131.5 (+), 209.3 (Cquat); IR (neat): ν = 3013, 2927, 2855, 1716, 1359 cm-1; CI-MS 
(NH3): m/z (%) = 238 (100) [MNH4+], 221 (4) [MH+].  
 
OO
 
2-Methyl-2-((6Z,9Z)-pentadeca-6,9-dienyl)-1,3-dioxolane (35). The compound was 
prepared following general procedure D and isolated as colourless oil. Yield: 20%. Rf =  
0.42 (petroleum ether/EtOAc 9:1); 1H NMR (300 MHz, CDCl3): δ = 0.90 (t, 3J = 7.0 
Hz, 3H; CH3), 1.28-1.46 (m, 15H; CH2/CH3), 1.60-1.67 (m, 2H; CH2), 1.96-2.08 (m, 
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4H; CH2), 2.74 (t, 3J = 5.5 Hz, 2H; CH2), 3.90-4.00 (m, 4H; OCH2), 5.34-5.50 (m, 4H; 
CH); 13C NMR (75 MHz, CDCl3): δ =14.1 (+), 22.6 (-), 23.7 (+), 24.0 (-), 27.1 (-), 29.2 
(-), 29.5 (-), 29.6 (-), 30.5 (-), 31.4 (-), 32.6 (-), 39.2 (-), 64.6 (-), 110.2 (Cquat), 127.9 
(+), 128.3 (+), 130.3 (+), 130.9 (+); IR (neat): ν = 2925, 2855, 1376, 1067 cm-1; CI-MS 
(NH3): m/z (%) = 295 (100) [MH+], 312 (16) [MNH4+]. 
 
O
 
(8Z,11Z)-Heptadeca-8,11-dien-2-one (8). The compound was prepared following 
general procedure E and isolated as colourless oil in quantitative yield. Rf = 0.20 
(petroleum ether/EtOAc 19:1); 1H NMR (300 MHz, CDCl3): δ = 0.90 (t, 3J = 6.7 Hz, 
3H; CH3), 1.26-1.44 (m, 10H, CH2), 1.55-1.65 (m, 2H, CH2), 1.96-2.09 (m, 4H, CH2), 
2.15 (s, 3H, CH3), 2.44 (t, 3J = 7.5 Hz, 2H; CH2), 2.74 (t, 3J = 5.6 Hz, 2H; CH2), 5.33-
5.50 (m, 4H; CH); 13C NMR (75 MHz, CDCl3): δ = 14.1 (+), 22.6 (-), 23.7 (-), 26.9 (-), 
28.8 (-), 29.2 (-), 29.4 (-), 29.9 (+), 30.5 (-),31.4 (-), 32.5 (-), 43.8 (-), 128.0 (+), 128.2 
(+), 130.1 (+), 130.9 (+), 209.2 (Cquat); IR (neat): ν = 3008, 2925, 2855, 1717 cm-1; 
HRMS (PI-EI) calcd. for C17H30O [M.+]: 250.2297, found: 250.2295. 
 
OO
 
2-Methyl-2-((6Z,9Z)-trideca-6,9-dienyl)-1,3-dioxolane (34). The compound was 
prepared following general procedure D and isolated as colourless oil. Rf = 0.31 
(pentane/Et2O 9:1); 1H NMR (300 MHz, CDCl3): δ = 0.88 (t, 3J = 8.0 Hz, 3H; CH3), 
1.25-1.42 (m, 11H), 1.60-1.65 (m, 2H; CH2), 1.98-2.09 (m, 4H; CH2), 2.72 (t, 3J = 5.2 
Hz, 2H; CH2), 3.88-3.98 (m, 4H; OCH2), 5.32-5.42 (m, 4H); 13C NMR (75 MHz, 
CDCl3): δ = 13.7 (+), 22.7 (-), 23.7 (+), 24.0 (-), 27.1 (-), 29.5 (-), 29.6 (-), 30.5 (-), 34.7 
(-), 39.2 (-), 64.6 (-), 110.2 (Cquat), 127.9 (+), 128.5 (+), 130.3 (+), 130.6 (+); IR (neat): 
ν = 2933, 2873, 1069, 627 cm-1; CI-MS (NH3): m/z (%) = 267 (100) [MH+], 284 (13) 
[MNH4+]. 
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O
 
(8Z,11Z)-Pentadeca-8,11-dien-2-one (7). The compound was deprotected following 
general procedure E and obtained in quantitative yield. Rf = 0.29 (pentane/Et2O 9:1);  1H 
NMR (300 MHz, CDCl3): δ = 0.84 (t, 3J = 8.0 Hz, 3H; CH3), 1.22-1.40 (m, 6H; CH2), 
1.49-1.59 (m, 2H; CH2), 1.89-2.03 (m, 4H; CH2), 2.09 (s, 3H; CH3), 2.38 (t, 3J = 8.0 
Hz, 2H; CH2), 2.68 (t, 3J = 5.5 Hz, 2H; CH2), 5.29-5.39 (m, 4H); 13C NMR (75 MHz, 
CDCl3): δ = 13.7 (+), 22.7 (-), 23.7 (-), 26.9 (-), 28.8 (-), 29.4 (-), 29.9 (+), 30.5 (-), 34.7 
(-), 43.8 (-), 128.0 (+), 128.4 (+), 130.1 (+), 130.6 (+), 209.3 (Cquat); IR (neat): ν = 2936, 
2867, 1711, 631 cm-1; CI-MS (NH3): m/z (%) = 240 (100) [MNH4+]. 
 
OO
SiMe3
 
Trimethyl((Z)-9-(2-methyl-1,3-dioxolan-2-yl)non-3-en-1-ynyl)silane (37). To a dry 
flask 10 (0.23 g, 0.74 mmol), PdCl2(PPh3)2 (10 mg, 0.032 mmol), CuI (5 mg, 0.026 
mmol), and NEt3 (3 mL) was added under an inert atmosphere. To the cloudy yellow 
solution TMS-acetylene (0.10 g, 1.03 mmol) was added. The reaction was stirred at rt 
for 4 hr, quenched with water (15 mL), extracted with ether (4 x 15 mL), washed with 
brine and purified by flash chromatography to afford 0.15 g (71%) of product. Rf = 0.40 
(petroleum ether/EtOAc 9:1); 1H NMR (300 MHz, CDCl3): δ = 0.20 (s, 9H; SiMe3), 
1.32 (s, 3H; CH3),  1.35-1.47 (m, 6H; CH2), 1.61-1.68 (m, 2H; CH2), 2.27-2.37 (m, 2H; 
CH2), 3.91-3.97 (m, 4H; OCH2), 5.48 (dt, 4J = 1.4 Hz, 3J = 10.8 Hz, 1H), 5.90-5.99 (m, 
1H); 13C NMR (75 MHz, CDCl3): δ = 0, 23.7, 23.9, 28.7, 29.4, 30.2, 39.1, 64.6, 102.1, 
102.8, 109.1, 110.1, 145.5; IR (neat): v = 2941, 2878, 2146 cm-1; HRMS (PI-EI) calcd. 
for C16H28O2Si [M.+]: 280.1859, found: 280.1855. 
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OO
 
2-Methyl-2-((Z)-non-6-en-8-ynyl)-1,3-dioxolane (38). Compound 37 (0.14 g, 0.49 
mmol) was dissolved in THF (25 mL) and Bu4NF (0.16 g, 0.60 mmol) was added. The 
reaction mixture was allowed to stir at rt for 30 min, quenched with water (20 mL), 
extracted with petroleum ether (3×40 mL), washed with water and brine and purified by 
flash chromatography (EtOAc/hexane 1:9, Rf = 0.3) to afford 0.08 g (0.28 mmol, 76%) 
of product. 1H NMR (300 MHz, CDCl3): δ = 1.30 (s, 3H), 1.31-1.44 (m, 6H), 1.59-1.63 
(m, 2H), 2.23-2.34 (m, 2H), 3.05 (d, J = 1.9 Hz, 1H), 3.88-3.95 (m, 4H), 5.40-5.46 (dt, J
 
= 1.2 Hz, J
 
= 10.8 Hz, 1H), 5.93-6.03 (m, 1H); 13C NMR (CDCl3): δ = 23.7, 23.9, 28.7, 
29.3, 30.1, 39.1, 64.6, 80.5, 81.2, 108.1, 110.1, 146.1; IR (neat): v [cm-1] = 3291, 2982, 
2939, 2163, 2097; MS (CI, NH3): m/z (%) = 209.2 [MH+] (100), 226.2 [MNH4+] (14). 
 
OO
Ph
 
2-Methyl-2-((Z)-9-phenylnon-6-en-8-ynyl)-1,3-dioxolane (36). To a dry flask 10 
(0.10 g, 0.32 mmol), PdCl2(PPh3)2 (5 mg, 0.016 mmol), CuI (7 mg, 0.037 mmol), and 
NEt3 (2.5 mL) was added under an nitrogen atmosphere. To the cloudy yellow solution 
phenyl acetylene (0.04 g, 0.42 mmol) was added. The reaction was stirred at rt for 4 h, 
quenched with water (15 mL), extracted with ether, washed with brine and purified by 
column chromatography (EtOAc/hexane 1:9, Rf = 0.3) to afford 0.06 g, (0.22 mmol, 
67%) of product. 1H NMR (300 MHz, CDCl3): δ = 1.30 (s, 3H), 1.34-1.51 (m, 6H), 
1.60-1.67 (m, 2H), 2.35-2.44 (m, 2H), 3.88-3.95 (m, 4H), 5.64-5.70 (dt, J
 
= 1.2 Hz, J
 
= 
10.7 Hz, 1H), 5.92-6.10 (m, 1H), 7.27-7.35 (m, 3H), 7.40-7.46 (m, 2H); 13C NMR 
(CDCl3): δ = 23.7, 23.9, 28.8, 29.4, 30.3, 39.2, 64.6, 86.4, 93.5, 109.1, 110.2, 123.7, 
128.0, 128.3, 131.4, 144.2; IR (neat): v [cm-1] = 2981, 2983, 2861, 1983; HRMS (PI-EI) 
calcd. for C19H24O [M.+]: 284.1776, found: 284.1770. 
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OO
Ph
 
2-Methyl-2-((Z)-7-phenylhept-6-enyl)-1,3-dioxolane (41). To a flask containing 10 
(78 mg, 0.25 mmol) in THF (2 mL), Pd(OAc)2 (4 mg, 0.02 mmol), a solution of NaOH 
(29 mg, 0.72 mmol), THF (1 mL) and phenyl boronic acid (39 mg, 0.32 mmol) was 
added and the reaction mixture was refluxed overnight. The resulting brown solution 
was extracted with pentane, washed with brine and dried over MgSO4. Flash 
chromatography (hexane/EtOAc 9:1, Rf = 0.25) afforded 40 mg of product (0.15 mmol, 
61%). 1H NMR (300 MHz, CDCl3): δ = 1.30 (s, 3H), 1.32-1.51 (m, 4H), 1.54-1.64 (m, 
2H), 2.33 (dq, J
 
= 5.8 Hz, J
  
= 1.6 Hz, 2H), 3.89-3.95 (m, 4H), 5.65 (m, 1H), 6.40 (m, 
1H), 7.18-7.36 (m, 5H); 13C NMR (CDCl3): δ = 23.8, 24.0, 28.6, 29.6, 30.0, 39.2, 64.7, 
110.2, 125.9, 126.5, 128.1, 128.8, 133.1 137.8; IR (neat): v [cm-1] = 2981, 2939, 2178, 
2004; MS (CI, NH3): m/z (%) = 261.2 (100) [MH+], 278.3 (33) [MNH4+]. 
 
O
 
(Z)-Undec-8-en-10-yn-2-one (40). The compound was prepared following general 
procedure E and isolated as colourless oil in 83% yield. 1H NMR (300 MHz, CDCl3): δ 
= 1.28-1.46 (m, 4H; CH2), 1.54-1.65 (m, 2H; CH2), 2.13 (s, 3H; CH3), 2.30-2.36 (m, 
2H; CH2), 2.43 (t, 3J = 7.3 Hz, 2H; CH2), 3.07 (d, 4J = 1.9 Hz, 1H), 5.41-5.48 (m, 1H), 
5.93-6.03 (m, 1H); 13C NMR (75 MHz, CDCl3): δ = 23.6, 28.5, 28.6, 29.9, 30.0, 43.7, 
80.5, 81.3, 108.3, 145.8, 209.2; IR (neat): v = 3290, 3263, 2934, 2858, 2151, 2022, 1712 
cm-1; HRMS (PI-EI) calcd. for C11H15O [MH+]: 163.1123, found: 163.1123. 
 
O
 
(Z)-11-Phenylundec-8-en-10-yn-2-one (39). The compound was prepared following 
general procedure E and isolated as colourless oil in 80% yield. 1H NMR (300 MHz, 
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CDCl3): δ = 1.30-1.67 (m, 6H; CH2), 2.11 (s, 3H; CH3), 2.38-2.46 (m, 4H; CH2), 5.65-
5.71 (m, 1H), 5.91-6.10 (m, 1H), 7.28-7.34 (m, 3H), 7.41-7.45 (m, 2H); 13C NMR (75 
MHz, CDCl3): δ = 23.7, 28.6, 28.7, 29.9, 30.2, 43.7, 86.4, 109.3, 128.1, 128.3, 131.4, 
143.9, 209.2; IR (neat): v = 3019, 2929, 2855, 2197 cm-1; HRMS (PI-EI) calcd. for 
C17H20O [M.+]: 240.1514, found: 240.1517. 
 
O
 
(Z)-9-Phenylnon-8-en-2-one (42). The compound was prepared following general 
procedure E and isolated as colourless oil in 96% yield. 1H NMR (300 MHz, CDCl3): δ 
= 1.16-1.46 (m, 6H; CH2), 2.07 (s, 3H; CH3), 2.22-2.34 (m, 2H; CH2), 2.36 (t, 3J = 7.4 
Hz, 2H; CH2), 5.59 (m, 1H), 6.36 (m, 1H), 7.13-7.32 (m, 5H); 13C NMR (75 MHz, 
CDCl3): δ = 23.7, 28.4, 28.8, 29.7, 29.9, 43.7, 126.5, 128.1, 128.7, 128.9, 132.8, 137.7, 
209.2; IR (neat): v = 3006, 2929, 2855, 2206, 2006 cm-1; HRMS (PI-EI) calcd. for 
C15H20O [M.+]: 216.1514, found: 216.1513. 
 
O
 
(6Z,9Z,12Z,15Z)-Henicosa-6,9,12,15-tetraen-2-one (44). Arachidonic acid 43 (0.25 g, 
0.8 mmol) was dissolved in dry THF (2 mL). MeLi (1.6 M in Et2O, 2.1 mL, 3.3 mmol) 
was added at 0°C resulting in a dark red solution. After 2 hr, freshly distilled TMS-
chloride (0.6 mL, 4.8 mmol) was added and the mixture was allowed to warm to rt. The 
resulting colourless solution was treated with 2M HCl (2 mL), diluted with Et2O, 
washed with water and brine, dried (MgSO4) and concentrated. Purification by flash 
chromatography on silica gel gave 44 as colourless oil (150 mg, 62%). Rf = 0.40 
(hexane/Et2O 4:1); 1H NMR (300 MHz, CDCl3): δ = 0.88 (t, 3J = 6.7 Hz, 3H; CH3), 
1.25-1.39 (m, 6H; CH2), 1.64 (quint, 3J = 7.8 Hz, 2H; CH2), 2.02-2.11 (m, 4H; CH2), 
2.13 (s, 3H; CH3), 2.43 (t, 3J = 7.9 Hz, 2H; CH2), 2.78-2.85 (m, 6H; CH2), 5.28-5.44 (m, 
8H); 13C NMR (75 MHz, CDCl3): δ = 14.1, 22.6, 23.6, 25.7, 26.5, 27.2, 29.3, 29.9, 31.5, 
43.0, 127.5, 127.9, 128.2, 128.2, 128.6, 128.8, 129.2, 130.5, 208.9; IR (neat): ν = 3011, 
2925, 2857, 1715, 631 cm-1; CI-MS (NH3): m/z (%) = 320 (100) [MNH4+]. 
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Pharmacological Materials. GTP, ATP, adenylyl imidodiphosphate, creatine kinase, 
creatine phosphate, bovine serum albumin and salts (highest purity available) were 
purchased either from Roche (Mannheim, Germany) or Sigma (St. Louis, MO, USA). 
Dimethyl sulfoxide was from Merck (Darmstadt, Germany). Tris base was purchased 
from USB (Cleveland, OH, USA). The cannabinoid receptor ligands 2-arachidonoyl 
glycerol and anandamide were purchased from Tocris Cookson (Ballwin, MO, USA). 
[γ-32P]GTP was synthesized through enzymatic phosphorylation of GDP and 
[32P]orthophosphoric acid (8,000 Ci/mmol, PerkinElmer Life Sciences, Boston, MA, 
USA) as described previously[31]. Mono(cyclohexyl)-ammoniumphosphoenolpyruvate, 
pyruvate kinase and myokinase were from Sigma (St. Louis, MO, USA). Stock 
solutions of 2-arachidonoyl glycerol, anandamide and synthesized compounds (10 mM 
each) were prepared in dimethyl sulfoxide. Dilutions of ligands were prepared in such a 
way that the dimethyl sulfoxide concentration was 30% (v/v) and that the final dimethyl 
sulfoxide concentration in the GTPase assay tubes was 3% (v/v).  
 
Pharmacological Methods. The steady-state GTPase assay is an established approach 
to study G-protein coupling of GPCRs at a very proximal point of the signal 
transduction cascade. The GTPase assay was performed as described previously.[32] 
Recombinant baculoviruses encoding FLAG- and hexahistidine-tagged hCB1R and 
hCB2R, Gαi2, Gβ1γ2 and RGS4 (Regulator of G-protein Signaling 4) were generated in 
Sf9 insect cells using the BaculoGOLD transfection kit (BD PharMingen, San Diego, 
CA, USA).[21, 32, 33] For transfection, cells were seeded (cell density 3.0 x 106 cells/mL) 
and infected with a 1:100 dilution of high-titer baculovirus stocks. Cells were cultured 
for 48 h, Sf9 membranes were prepared as described previously[33] and used in the 
steady-state GTPase assay. Assay tubes contained Sf9 membranes (15 µg of 
protein/tube), 1.0 mM MgCl2, 0.1 mM EDTA, 0.1 mM ATP, 100 nM GTP, 0.1 mM 
adenylyl imidodiphosphate, 5 mM creatine phosphate, 40 µg of creatine kinase, 0.2% 
(w/v) bovine serum albumin in 50 mM Tris/HCl, pH 7.4, and synthesized or reference 
compounds at various concentrations. Reaction mixtures (80 µL) were incubated for 2 
min at 25 °C before the addition of 20 µL of [γ-32P]GTP (0.1 µCi/tube). All stock and 
work dilutions of [γ-32P]GTP were prepared in 20 mM Tris/HCl, pH 7.4. Reactions 
were conducted for 20 min at 25 °C. Reactions were terminated by the addition of 900 
µL of slurry consisting of 5% (w/v) activated charcoal and 50 mM NaH2PO4, pH 2.0. 
Charcoal absorbs nucleotides but not 32Pi. Charcoal-quenched reaction mixtures were 
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centrifuged for 7 min at room temperature at 15000 x g. 600 µL supernatant fluid of 
reaction mixtures was removed, and 32Pi was determined by Čerenkov radiation in 3 mL 
water. Enzyme activities were corrected for spontaneous degradation of [γ-32P]GTP. 
Spontaneous [γ-32P]GTP degradation amounted to <1% of the total amount of 
radioactivity added. The experimental conditions chosen ensured that not more than 
10% of the total amount of [γ-32P]GTP added was converted to 32Pi. The GTPase 
activity was calculated and expressed as pmoles of Pi released per mg of membrane 
protein per min. 
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4. Synthesis and Pharmacological Properties of New Tetracyclic 
Forskolin Analogues  
 
 
 
New tetracyclic analogues of forskolin were prepared by derivatization of the natural 
product. Treatment of a primary obtained cyclic thionocarbonate with HSnBu3/AIBN 
lead to 5-exo-trig cyclization with the double bond, whereas Corey-Winter conditions 
resulted in a rearrangement with formation of a cyclic carbonate.i Two of these new 
analogues were investigated for their ability to activate adenylyl cyclases 1, 2 and 5.ii  
 
 
                                                 
i
 Forskolin analogues 5 and 6 were first prepared by Prantik Maity and resynthesized for complete 
characterization. 
ii
 The adenylyl cyclase activity assay was carried out by Melanie Hübner at the Institute of Pharmacy, 
University of Regensburg. 
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4.1. Introduction 
 
The roots of Coleus forskohlii, a member of the mint family that can be found in the 
subtropical areas of India, Pakistan, Sri Lanka and Brazil, have long been used for the 
treatment of asthma, glaucoma and cardiovascular diseases.[1] In 1977 Bhat et al. 
isolated the labdane diterpenoid forskolin as major component[2] which displayed 
antihypertensive and positive inotropic effects.[3] Forskolin was shown to directly 
activate the enzyme adenylyl cyclase (AC), thereby increasing the intracellular level of 
cAMP and leading to various physiological effects such as hypotension, cardiac 
inotropy, bronchodilation and reduction of intraocular pressure.[4] Nine membranous 
AC isoforms with distinct tissue distribution and regulatory properties are known to 
date.[5] Although AC 1-8 represents an interesting pharmaceutical target that is directly 
activated by forskolin, the lack of AC isoform selectivity resulting in numerous side 
effects has prevented a clinical use of forskolin so far. Recently we have shown that AC 
isoforms are not uniformly modulated by forskolin analogues which demonstrates the 
feasibility to develop highly desired isoform-selective AC activators and inhibitors.[6] 
Herein we report the synthesis and pharmacological characterization of new tetracyclic 
forskolin analogues. 
 
4.2. Results and Discussion 
 
Synthesis.  During our investigations on forskolin (1) analogues as isoform-selective 
adenylyl cyclase modulators we wanted to reassess the role of the 1-OH and 9-OH 
groups and therefore reinvestigate the activity profiles of 1-deoxyforskolin 2 and 1,9-
dideoxyforskolin 3 (Figure 1). Both compounds were isolated as minor constituents 
from Coleus forskohlii.[2,7] 1,9-Dideoxyforskolin 3 has been synthesized starting from 
either E,E-farnesol[8] or the natural products larixol[9] and ptychantin A,[10] respectively 
and was itself used as starting material for the preparation of 1-deoxyforskolin 2.[7] 
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Figure 1. Structures of forskolin (1), 1-deoxyforskolin (2) and 1,9-dideoxyforskolin (3). 
 
Because we had a reasonable amount of forskolin in hand we intended to prepare the 
deoxyforskolins 2 and 3 directly from forskolin which had not been described so far. 
From the many OH group functionalizations of forskolin it is known that apart from few 
exceptions 1-OH is generally more reactive than the sterically hindered 6-OH and 
especially 9-OH group.[4b,11] We therefore planned to selectively convert the 1-OH 
group into a suitable thiocarbonyl precursor which should then be used for a radical 
deoxygenation to provide 1-deoxyforskolin 2. However, although this reaction has been 
described for a similar substrate,[10a] all attempts to form thionocarbonate 4 with O-
phenylchlorothionoformate failed and only unreacted starting material was recovered 
(Scheme 1).     
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Scheme 1. Attempted formation of 4 and its intended use in a radical deoxygenation. 
 
When O-phenylchlorothionoformate was exchanged by thiocarbonyldiimidazole, 
quantitative conversion to the corresponding 1,9-disubstituted cyclic product 5 was 
observed. Treatment of 5 with HSnBu3/AIBN resulted not only in the cleavage of the 
C9-O-bond but at the same time led to the formation of a new bicyclic ring system 
(Scheme 2). 
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Scheme 2. Formation of the new forskolin analog 6 via the radical precursor 5. Reagents 
and conditions: a) thiocarbonyldiimidazole, DMAP, CH2Cl2, rt, 97%; b) HSnBu3, 
AIBN, toluene, reflux, 85%. 
 
Compound 5, in which both axial hydroxy groups are connected via a thionocarbonate 
bridge, crystallizes in the chiral space group P 21 21 21 (Figure 2). 
 
 
Figure 2. X-ray crystal structure of thionocarbonate 5. 
 
The proposed mechanism for the formation of 6 is shown in scheme 3. The primary 
radical 7 fragments in a way that the more stable tertiary radical at C9 is formed 
(compound 8) as compared to the potential secondary C1 radical. This new radical 
intermediate then intramolecularly attacks the double bond at C14 in a 5-exo-trig 
cyclization to give after H-abstraction the new tetracyclic forskolin analogue 6. 
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Scheme 3. Proposed mechanism for the formation of 6. 
 
The X-ray diffraction analysis of compound 6 revealed that the newly formed 
stereocenter at C14 is S-configured (figure 3). 
 
 
Figure 3. X-ray crystal structure of compound 6. Hydrogen atoms of the forskolin 
skeleton are removed for more clarity. 
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In addition to this radical pathway 5 was also treated with 1,3-dimethyl-2-phenyl-1,3-
diaza-phospholidine 9, which is generally used for a mild variant of the Corey-Winter 
olefination of thionocarbonates derived from 1,2-diols,[12] to find out whether the 
thionocarbonate group in 5 could be removed. After stirring 5 with 9 at 50 °C, a new 
product had formed and X-ray structure analysis revealed that again a new ring was 
incorporated in the forskolin skeleton (compound 10, Scheme 4, see Figure 4 for the X-
ray crystal structure).  
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Scheme 4. Formation of the new forskolin analogue 10. 
 
 
 
Figure 4. X-ray crystal structure of compound 10. 
 
The Corey-Winter olefination is postulated to proceed over carbene intermediates 
(scheme 5),[13] but the exact mechanism seems to be more complex and is not fully 
clarified.[14]   
OO
S
R R'
R R'
-CO2OO
R R'
 
(MeO)3P
-(MeO)3PS
 
Scheme 5. Proposed mechanism of the Corey-Winter olefination. 
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In the case of trithiocarbonates Corey and Märkl suggested the formation of phosphite 
ylide intermediates.[15] The results from Scherowsky and Weiland on the other hand 
point to the existence of 1,3-dipoles as reactive intermediates and argue against 
carbenes.[16] The existence of carbenes in the case of thionocarbonates is supported by 
the detection of a small amount of orthoester 13 in the reaction from 11 to 12[17] 
(Scheme 6) which is generally cited as direct evidence for the intermediacy of 
carbenes.[14] However, this result may not only be explained by a carbene intermediate 
14 (path A) which is claimed by the authors but also via a 1,3-dipole 15 that first 
deprotonates the free alcohol followed by nucleophilic attack of the alkoxide under 
elimination of thionophosphate (path B, Scheme 6).  
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Scheme 6. Possible reaction pathways that could explain the formation of side product 
13. 
 
Based on these results a proposed mechanism for the formation of 10 is shown in 
Scheme 7. Thiophilic attack at 1,3-dimethyl-2-phenyl-1,3-diazaphospholidine 9 leads to 
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the 1,3-dipole 17 which then either looses diazaphospholidinesulfide to give a carbene 
intermediate 18 or directly attacks the C11 carbonyl group to form 19. Elimination of 
diazaphospholidinesulfide from 19 would then lead to the same zwitterion 20 that is 
formed after nucleophilic attack of the carbene 18 at the carbonyl group. Such inter- and 
intramolecular reactions of dialkoxycarbenes with carbonyl compounds are well-known 
in literature.[18]  
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Scheme 7. Proposed mechanism for the formation of 10. 
 
Finally, in a concerted mechanism the alkoxide attacks the carbenium ion, the C11 – 
C(O)O-bond is broken and the new 7-membered ring is formed. An orthoester 
intermediate that would result from the attack of the alkoxide at the carbenium ion or in 
analogy to the formation of 13 from 16 (Scheme 6) can probably be ruled out due to the 
very high ring strain that would be generated in such a compound.   
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Adenylyl Cyclase Activity Assay. Due to the fact that forskolin is a direct activator of 
membranous AC-isoforms 1-8, it would be very interesting to identify new forskolin 
analogues as pharmaceuticals that show subtype-specificity and a higher potency in 
comparison to forskolin.[6]  The aim of the pharmacological characterization of the new 
compounds was on the one hand to find out whether the tetracyclic analogues are still 
capable of binding to the forskolin binding site of different ACs and on the other hand 
to investigate their AC isoform selectivity. In our previous studies forskolin was found 
to have the highest potency on AC 1 compared to AC 2 and AC 5.[6] AC 1 is 
predominantly expressed in hippocampal areas of the brain and a decreased AC 1 
activity is measured in Alzheimer’s disease.[19] The identification of AC 1-specific 
activators could therefore be useful for the treatment of Alzheimer’s disease. The effects 
of the new forskolin analogues 5 and 10 were investigated on ACs 1, 2 and 5, whereas 
the tin-containing analogue 6 was not used for pharmacological studies due to 
toxicological properties that are associated with organotin compounds.[20] For a better 
comparison of the molecular interactions of the compounds in recombinant membrane 
and tissue preparations we also studied the effect of the forskolin analogues in mouse 
cardiac membranes. Because it was shown in several studies that cardiac membranes are 
enriched in ACs 5 and 6, but have smaller quantities of ACs 1, 3, 4 and 7[5b, 21]   we 
wished to find out whether an isoform-selectivity for AC 5 might be observed. The 
results of the AC activity assays are shown in Figure 5 and Table 1.  
 
Table 1. Calculated potencies and efficacies of the new forskolin analogues 5 and 10. 
AC 
compound 5 
EC50/µM     Efficacy/% 
compound 10 
EC50/µM        Efficacy/% 
forskolin 
EC50/µM     Efficacy/% 
I 20.8 ± 0.7     17.1 ± 4.6 8.03 ± 1.08     45.3 ± 1.9 0.74 ± 0.07          100 
II 228.6 ± 35    -18.7 ± 1.7 46.6 ± 11.1     19.7 ± 4.5 14.3 ± 3.0            100 
V 65.2 ± 16.1    21.5 ± 1.7 7.3 ± 0.9         19.0 ± 2.5 4.65 ± 0.6            100 
cardiac 100.8 ± 30     40.1 ± 4.2 41.7 ± 3.7          62 ± 3.9 4.75 ± 0.8            100 
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Figure 5. AC stimulation of recombinant AC isoforms 1, 2 and 5 as well as cardiac 
membranes by compounds 5 (filled circle) and 10 (filled squares) with 10 mM Mn2+ in 
comparison with forskolin (filled triangles).  
 
Compared to forskolin, compounds 5 and 10 showed lower potency and efficacy for all 
isoforms examined. The cyclic thionocarbonate 5 is a weak partial agonist on AC 1 and 
AC 5 and even inhibits AC 2. Interestingly, 5 shows a stronger efficacy but lower 
potency on the cardiac membrane preparation. This effect could be due to an activation 
of other existing AC isoforms. The cyclic carbonate 10 has a higher potency on ACs 1, 
2 and 5 compared to compound 5, however, the EC50 values on ACs 1 and 5 are very 
similar and do not significantly differ from AC 2. Compound 5 has only a 3-fold higher 
potency on AC 1 than on AC 5. Both compounds do not show substantial selectivity for 
one of the investigated specific AC isoforms. 
 
4.3. Conclusion  
 
The introduction of another ring into the forskolin skeleton did not lead to a loss of 
binding affinity to AC. Although the new compounds are much more spacious they still 
seem to fit into the binding pocket located in close proximity to the catalytic domains 
C1 and C2 and lead to enzyme activation. However, both investigated compounds 
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stimulate cAMP production with a significantly lower efficacy and potency than 
forskolin does. Effective binding of the catalytic subunits seems to be prevented leading 
to less effective enzyme activation.  
 
4.4. Experimental Section 
 
 
General. Commercial reagents and starting materials were purchased from Aldrich, 
Fluka or Acros and used without further purification. Flash chromatography was 
performed on silica gel (Merck silica gel Si 60 40-63 µm); products were detected by 
TLC on alumina plates coated with silica gel (Merck silica gel 60 F254, thickness 0.2 
mm) and visualized after staining with 15% phosphomolybdic acid in ethanol. Melting 
points were determined with a Büchi SMP 20 and are uncorrected. NMR spectra were 
recorded with a Bruker Avance 300 (1H: 300.1 MHz, 13C: 75.5 MHz, T = 300 K) 
instrument. Chemical shifts are reported in δ/ppm relative to external standards and 
coupling constants J are given in Hz. Abbreviations for the characterisation of the 
signals: s = singlet, d = doublet, t = triplet, m = multiplet, dd = double doublet. The 
relative number of protons is determined by integration. Error of reported values: 
chemical shift 0.01 ppm (1H-NMR), 0.1 ppm (13C-NMR), coupling constant 0.1 Hz. The 
used solvent for each spectrum is reported. Mass spectra (ESI) were recorded with a 
Finnigan MAT TSQ 7000 spectrometer and IR spectra with a Bio-Rad FT-IR-FTS 155 
spectrometer.  
 
O
O
OH
OAc
OO
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Compound 5. An oven-dried schlenk tube was charged with forskolin (100 mg, 0.24 
mmol) and dry DCM (2 mL). DMAP (60 mg, 0.49 mmol) and thiocarbonyldiimidazole 
(46 mg, 0.26 mmol) were added under nitrogen and the mixture was allowed to stir 
under nitrogen atmosphere at room temperature for 4 h. After consumption of all 
starting material as judged by TLC the solvent was removed and the crude product was 
purified by flash chromatography on silica gel (petrol ether/acetone 19:6, Rf = 0.27) to 
obtain the product as white crystalline solid (107 mg, 97%). 
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mp > 225°C – 1H NMR (300 MHz) δ = 1.05 (s, 3H, CH3), 1.26 (s, 3H, CH3), 1.29-1.31 
(m, 1H, CH), 1.41 (s, 3H, CH3), 1.48-1.53 (m, 2H, CH/OH), 1.69 (s, 3H, CH3), 1.73 (s, 
3H, CH3), 1.85-2.00 (m, 2H, CH), 2.08-2.16 (m, 1H, CH), 2.18 (s, 3H, C(O)CH3), 2.52 
(d, 2J = 16.0 Hz, 1H, CH), 3.11 (d, 2J = 16.0 Hz, 1H, CH), 4.49-4.52 (m, 1H), 4.85 (t, J 
= 2.7 Hz, 1H), 5.07 (dd, Jcis = 10.7 Hz, 1J = 0.8 Hz, 1H), 5.33 (dd, Jtrans = 17.0 Hz, 1J = 
0.8 Hz, 1H), 5.34 (d, 3J = 4.1 Hz, 1H), 6.01 (dd, Jtrans = 17.0, Jcis = 10.6 Hz, 1H) – 13C-
NMR (75 MHz, CDCl3): δ = 17.8 (+), 21.1 (+), 23.0 (+), 23.2 (+), 29.9 (+), 32.5 (+), 
33.8 (Cquat), 36.2 (-), 36.6 (Cquat), 44.1 (+), 50.6 (-), 68.8 (+), 76.0 (+), 76.9 (Cquat), 80.3 
(Cquat), 84.1 (+), 89.0 (Cquat), 111.9 (-), 144.7 (+), 169.3 (Cquat), 187.0 (Cquat), 200.1 
(Cquat) – IR: ν = 3407, 2931, 1721, 1375, 1251 – MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 453 (100) [MH+], 470 (67) [MNH4+] – Elemental analysis calcd 
(%) for C23H32O7S (452.57): C 61.04, H 7.13, S 7.08; found C 61.12, H 7.00 S 7.29. 
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Compound 6. A solution of thionocarbonate 5 (25 mg, 0.06 mmol), tributyltinhydride 
(0.47 mL, 0.17 mmol), and azoisobutyronitrile (1 mg, 6 µmol) in toluene (1.5 mL) 
under nitrogen atmosphere was heated at 100 °C for 4 h. After consumption of all 
starting material as jugded by TLC the reaction was quenched by adding petrol ether. 
Column chromatography (petrol ether → petrol ether/ether 1:4) afforded the crystalline 
compound 3 (35 mg, 85%).  
mp > 225°C – 1H-NMR (300 MHz, CDCl3): δ = 0.89 (t, 3J = 7.7 Hz, 9H, 3 CH3), 1.04, 
(s, 3H, CH3), 1.13-1.19 (m, 2H), 1.21-1.39 (m, 17H), 1.51-1.63 (m, 13H), 1.67 (s, 3H, 
CH3), 1.70-1.75 (m, 2H), 1.97-2.07 (m, 3H), 2.18 (s, 3H, C(O)CH3), 2.29 (dd, J = 1.4 
Hz, J = 17.8 Hz, 1H), 4.38-4.43 (m, 1H, CH), 5.08-5.12 (m, 1H, CH), 5.44 (d, 3J = 3.8 
Hz, 1H, CH) – 13C-NMR (75 MHz, CDCl3): δ = 13.7 (+), 15.0 (-), 15.4 (+), 17.5 (+), 
19.6 (+), 21.3 (+), 22.9 (-), 25.4 (+), 25.8 (+), 27.0 (-), 27.9 (Cquat), 28.6 (-), 34.2 (+), 
35.9 (-), 42.3 (Cquat), 45.7 (+), 51.5 (-), 53.3 (+), 69.4 (+), 71.5 (Cquat), 78.3 (+), 79.2 (+), 
80.9 (Cquat), 81.4 (Cquat), 170.0 (Cquat), 171.3 (Cquat), 210.2 (Cquat) – IR: ν = 2863, 1741, 
1369, 1238 – MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 745 (31) 
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[MH+] – despite several attempts satisfying combustion analysis or HRMS data could 
not be obtained for this compound. 
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Compound 10. Thionocarbonate 5 (50 mg, 0.1 mmol) and 1,3-dimethyl-2-phenyl-1,3-
diazaphospho-lidine 9 (107 mg, 0.5 mmol) were mixed in a small screw-capped glass 
vial and stirred at 50 °C for 12 h. The crude product was purified by flash 
chromatography on silica gel (petrol ether/acetone 4:1, Rf = 0.24) and isolated as white 
solid (29 mg, 69%). Crystallization for X-ray analysis was achieved from n-hexane. 
mp = 198°C. 1H-NMR (300 MHz, CDCl3): δ = 1.00 (s, 3H, CH3), 1.17-1.23 (m, 1H, 
CH2), 1.22 (s, 3H, CH3), 1.22 (s, 3H, CH3), 1.48 (d, 3J = 2.5 Hz, 1H, CH), 1.63 (s, 3H, 
CH3), 1.63 (s, 3H, CH3), 1.68-1.78 (m, 1H, CH2), 1.82-1.90 (m, 1H, CH2), 2.12-2.24 
(m, 1H, CH2), 2.19 (s, 3H, CH3), 2.40-2.58 (m, 2H, CH2), 4.37-4.39 (m, 1H, CH), 4.68-
4.70 (m, 1H, CH), 4.98-5.05 (m, 3H, CH), 5.88-5.97 (m, 1H, CH) – 13C-NMR (75 MHz, 
CDCl3): δ = 21.3 (+), 23.7 (+), 23.9 (-), 24.7 (+), 27.5 (+), 29.6 (+), 32.4 (+), 34.1 
(Cquat), 36.3 (-), 38.3 (-), 43.5 (Cquat), 46.7 (+), 69.5 (+), 74.3 (Cquat), 77.2 (Cquat), 77.6 
(+), 83.3 (+), 112.9 (-), 127.8 (Cquat), 140.7 (Cquat), 142.6 (+), 152.6 (Cquat), 169.8 (Cquat) 
– IR: ν =  2950, 1762, 1739, 1224, 1036 – MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 438 (100) [MNH4+], 421 (44) [MH+] – Elemental analysis calcd 
(%) for C23H32O7 (420.51): C 65.70, H 7.67; found C 65.48, H 7.80.  
 
Materials. Baculoviruses for the expression of ACs 1, 2 and 5 were kindly provided by 
Drs. G. Gilman and R. K. Sunahara (University of Texas Southwestern Medical Center, 
Dallas, TX). Insect cells of Spodoptera frugiperda (Sf9) were from the American Type 
Cell Culture Collection (Rockville, MD). Guanosine-5´-[γ-thio] triphosphate (GTPγS), 
creatine kinase and adenosine triphosphate (ATP) were purchased from Roche 
Diagnostics (Mannheim, Germany). Isobutylmethylxanthine (IBMX) and cyclic 
adenosine monophosphate (cAMP) were purchased from Sigma Aldrich (Seelze, 
Germany) and forskolin was purchased from LC Laboratories (Woburn, MA). Forskolin 
and the forskolin analogues 5 and 10 were prepared in DMSO stock solutions (20 mM 
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each) and stored at -20 °C. The final DMSO concentration in the assay was 2% (v/v) 
DMSO. [α-32P]-ATP (800 Ci/mmol) was from Perkin Elmer (Wellesley, MA) and 
neutral alumina (N Super I) was from MP Biomedicals (Eschwege, Germany). Highest 
quality MnCl2 was purchased from Merck (Darmstadt, Germany). Protein concentration 
was determined using the DC protein assay kit (Bio-Rad, Hercules, CA). 
 
AC expression and membrane preparation of Sf9 cells. Cell culture of Sf9 cells, 
expression of AC 1, 2 and 5 in Sf9 membranes and membrane preparation were 
performed as described previously.[22] The membrane preparations were stored in 1 mL 
aliquots at -80 °C. After thawing, the membranes were sedimented by a 15 min 
centrifugation at 4 °C, 13000 × g and resuspended in 75 mM TRIS buffer, pH 7.4, to 
obtain a concentration of 30 µg membrane protein/tube.  
 
Preparation of cardiac AC. Female CD1 mice were housed in a controlled 
environment according to the German animal protection law. At the age of ten weeks, 
mice were sacrificed by cervical dislocation and hearts were removed, shock-frozen in 
liquid nitrogen and stored at -80 °C. Hearts were thawed and rinsed in ice-cold 
homogenization buffer containing 5 mM Tris·HCl, pH 7.4, and 5 mM EDTA. The ratio 
of buffer volume to heart tissue was 20-fold. Hearts were fragmented and homogenized 
in a glass-glass homogenizer (Braun, Melsungen, Germany) at 1500 rpm. After removal 
of organ debris (centrifugation at 500×g, 8 min) the supernatant was centrifuged at 
40000 × g for 30 min. The suspended membranes were washed three times to remove 
residual endogenous ligands and nucleotides and then resuspended in assay buffer 
consisting of 50 mM triethanolamine, 10 mM MnCl2 and 1 mM EGTA, pH 7.4. The 
membrane preparation was shock-frozen in liquid nitrogen and stored at -80 °C. The 
frozen cardiac membranes were thawn and centrifuged to reach a concentration of 20 µg 
cardiac membrane protein/tube.  
 
AC- activity assay. AC-activity was determined as described before.[6] For the AC 1, 2 
and 5 membrane preparation, the assay tubes contained 10 µL of forskolin analogue, 20 
µL of membrane preparation (30 µg protein/tube) and 20 µL reaction mixture consisting 
of 2.7 mM phosphoenolpyruvate, 0.125 IU pyruvate kinase and 1 IU myokinase. The 
assay with cardiac ACs had the same composition, but the reaction mixture contained 
0.4 mg/mL creatine kinase, 9 mM phosphocreatine and 100 µM IBMX.  All tubes 
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additionally contained 10 mM Mn2+, 10 µM GTPγS, 40 µM ATP, 100 µM cAMP and 
0.2-1.0 µCi [α-32P]ATP. Tubes were preincubated for 2 min at 30 °C.  The reaction with 
the AC isoform preparation was initiated by the reaction mixture and the cardiac 
membrane preparation was initiated by the addition of 20 µL membrane preparation (20 
µg protein/tube). The AC activity of AC 1, 2 and 5 was measured for a time interval of 
20 minutes at 37 °C. To ensure linear reaction progress for the cardiac AC, those assays 
were incubated for only 10 min at 30 °C. The reactions were terminated by the addition 
of 20 µL 2.2 N HCl to denature the protein and by centrifugation at 12000×g for 2 
minutes. [32P]cAMP was separated from [α-32P]ATP by transfer of the sample to a 1.4 g 
neutral alumina column and elution with 4 mL 0.1 M ammonium acetate, pH 7.0. After 
addition of 10 mL double distilled water, Čerenkov radiation was determined with a 
liquid scintillation counter Tri-Carb 2800 TR (Perkin Elmer, Wellesley, MA). The 
concentration-response curves and potency/efficacy values shown in Table 1 and Figure 
1 were obtained by non-linear regression analysis with the Prism 5.01 software 
(Graphpad, San Diego, CA). 
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5. Summary 
 
The first part of this dissertation (chapters 1 and 2) deals with the inhibition of the ABC 
transporters ABCB1 (p-glycoprotein) and ABCG2 (breast cancer resistance protein). 
Less lipophilic and better water soluble analogues of the known ABCB1 inhibitor 
tariquidar were synthesized from one central building block via Cu(I)-catalyzed N/O-
arylation reactions. These compounds were tested for their inhibitory activity against the 
ABCB1 transporter in a flow cytometric calcein-AM efflux assay and a correlation 
between their calculated log P values and their activities was observed. During this 
work it was discovered that slight structural modifications of the aromatic core resulted 
in potent ABCG2 inhibitors. Based on this finding a series of new ABCG2 inhibitors 
was prepared and found to be highly selective over ABCB1 and ABCC2. Such 
compounds, which are among the most potent and selective ABCG2 inhibitors known 
so far, might be useful for cancer treatment with respect to reversal of drug resistance, 
overcoming the blood brain barrier and targeting of tumor stem cells.  
 
The second part of this work (chapter 3) describes the synthesis of ketoalkenes from the 
pale purple coneflower (Echinacea pallida). These compounds contain diene or triene 
motifs with skipped conjugation and were synthesized from one common vinyl zinc 
chloride precursor via Pd-catalyzed allylation reactions. The synthetic route developed 
at the same time allowed to prepare non-natural conjugated analogues via Suzuki and 
Sonogashira cross coupling reactions. Both the natural products and their analogues 
were tested for their ability to activate the human cannabinoid receptors 1 and 2 to find 
out whether such compounds might be responsible for the observed immunostimulatory 
effects of Echinacea extracts. While no significant activity of the natural products was 
observed at either receptor the new analogues showed micromolar potency at both 
cannabinoid receptors. 
 
The last part (chapter 4) finally deals with the preparation of new tetracyclic forskolin 
analogues. Treatment of a forskolin-derived thionocarbonate with 1,3-dimethyl-2-
phenyl-1,3-diaza-phospholidine resulted in an interesting rearrangement presumably via 
a carbene intermediate to yield a cyclic carbonate. Two new compounds were tested for 
their ability to activate adenylyl cyclase 1, 2 and 5 and found to be able to stimulate 
cAMP production at micromolar concentrations. 
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6. Zusammenfassung 
 
Im ersten Teil dieser Arbeit (Kapitel 1und 2) wird die Hemmung der ABC-Transporter 
ABCB1 (p-Glycoprotein) und ABCG2 (breast cancer resistance protein) beschrieben. 
Ausgehend von einer zentralen Vorstufe wurden durch Cu(I)-katalysierte N- und O-
Arylierungen weniger lipophile und besser wasserlösliche Analoga des ABCB1-
Inhibitors Tariquidar synthetisiert. Die inhibitorische Aktivität dieser neuen 
Verbindungen gegen den ABCB1-Transporter wurde mittels eines 
durchflusszytometrischen Calcein-AM-Efflux-Assays bestimmt, wobei ein 
Zusammenhang zwischen den berechneten log P-Werten und den Aktivitäten der 
Verbindungen beobachtet wurde. Im Rahmen dieses Projekts wurde entdeckt, dass 
geringe strukturelle Modifikationen des aromatischen Grundgerüsts zu einem potenten 
ABCG2-Inhibitor führten. Aufgrund dieses überraschenden Ergebnisses wurde eine 
Reihe von ABCG2-Inhibitoren hergestellt, die sich als hoch selektiv gegenüber ABCB1 
und ABCC2 herausstellten. Solche Verbindungen, die mit die potentesten und 
selektivsten bisher bekannten ABCG2-Inhibitoren sind, könnten im Hinblick auf eine 
Rückgängigmachung der Resistenz gegen Chemotherapeutika, Überwindung der Blut-
Hirn-Schranke und Bekämpfung von Tumorstammzellen bedeutend für die Krebs-
behandlung sein.  
 
Der zweite Teil der Dissertation (Kapitel 3) beschreibt die Synthese von Ketoalkenen 
aus dem Blassen Sonnenhut (Echinacea pallida). Diese Verbindungen enthalten Dien- 
oder Trien-Motive mit unterbrochener Konjugation und wurden ausgehend von einer 
gemeinsamen Vinyl-Zinkchlorid-Vorstufe durch Pd-katalysierte Allylierungen 
hergestellt. Die entwickelte Syntheseroute ermöglichte darüber hinaus die Herstellung 
von konjugierten Analoga durch Suzuki- und Sonogashira-Kreuzkupplungen. Sowohl 
die Naturstoffe als auch ihre Analoga wurden hinsichtlich ihrer Fähigkeit untersucht, die 
humanen Cannabinoid-Rezeptoren 1 und 2 zu aktivieren, um herauszufinden, ob diese 
Verbindungen für den beobachteten immunostimulierenden Effekt von Echinacea-
Extrakten verantwortlich sein könnten. Während für die Naturstoffe keine signifikante 
Aktivität beobachtet wurde, zeigten die Analoga mikromolare Potenz an beiden 
Rezeptoren. 
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Der letzte Teil der Arbeit (Kapitel 4) handelt schließlich von der Herstellung neuer 
tetrazyklischer Analoga des Naturstoffs Forskolin. Die Behandlung eines von Forskolin 
abgeleiteten Thionocarbonats mit 1,3-Dimethyl-2-phenyl-1,3-diaza-phospholidin führte 
zu einer interessanten, vermutlich über eine Carben-Zwischenstufe verlaufenden, 
Umlagerung zu einem zyklischen Carbonat. Zwei der neuen Analoga wurden auf ihre 
Fähigkeit untersucht, die Adenylylcyclase-Isoformen 1, 2 und 5 zu aktivieren. Trotz 
ihres deutlich höheren sterischen Anspruchs scheinen die untersuchten Verbindungen 
noch in die Bindungstasche des Enzyms zu passen und sind in der Lage, die cAMP-
Bildung in mikromolaren Konzentrationen zu stimulieren. 
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7. Abbreviations 
 
 
ABC   ATP-binding cassette 
     
ABCP   ABC transporter expressed  
in placenta 
 
ABCB1 ABC transporter B1,  
p-gylocoprotein 170 
 
ABCG2 ABC transporter G2,  
breast cancer resistance 
protein 
 
ABCC2 ABC transporter C2, 
multidrug resistance related 
protein 2 
 
AC  Adenylyl Cyclase 
 
AIBN  Azoisobutyronitrile 
 
ANA  Anandamide 
 
2-AG  2-Arachidonoyl-glycerol 
 
Aq   aqueous 
 
ATP  Adenosine triphosphate 
 
BBB   Blood-brain-barrier  
 
BCRP   Breast cancer resistance 
protein  
 
Bmim
  
1-butyl-3-
methylimidazolium 
 
Boc   tert-Butyloxycarbonyl  
 
Calcd  Calculated 
 
Calcein-AM Calcein-acetoxymethylester 
 
cAMP   Cyclic adenosine 
monophosphate 
 
CB1R  Human cannabinoid 1 
receptor  
 
CB2R  Human cannabinoid 2 
receptor  
 
CMFDA  Chloromethylfluorescein- 
diacetate 
 
CNS   Central nervous system 
 
COSY  Correlated spectroscopy 
 
DAD   Diode array detector 
 
DCM  Dichloromethane  
 
DIPEA  Diisopropylethylamine  
 
DMAP  4-Dimethylaminopyridine 
  
DMF   Dimethylformamide  
 
DMPU 1,3-Dimethyl-3,4,5,6- 
tetrahydro-2(1H)-
pyrimidinone 
 
DMSO  Dimethylsulfoxide  
 
EC50  Half maximal effective  
concentration 
 
EDC   N-(3-Dimethylamino-
propyl)-N’-ethylcarbo-
diimide 
  
EDTA  Ethylenediamine tetraacetic  
acid  
 
EGTA  Ethylene glycol tetraacetic 
acid 
 
EI-MS  Electron-impact ionization  
mass spectrometry  
 
ELSD   Evaporative light scattering  
detection  
 
ES-MS  Electrospray ionization 
mass spectrometry 
7. Abbreviations 
  
 111 
FACS   Fluorescence activated 
cell 
 
FTC  Fumitremorgin C 
 
FCS  Fetal calf serum 
 
GTP Guanosine-5'-
triphosphate 
 
HBTU  2-(1H-Benzotriazole-1-
yl)-1,1,3,3-tetramethyl-
uronium 
hexafluorophosphate  
 
HMBC Heteronuclear multiple  
bond coherence 
 
HOBt   Hydroxybenzotriazole  
 
HPLC  High pressure liquid  
chromatography 
 
HR-MS  High resolution mass  
spectrometry  
 
HSQC  Heteronuclear single 
quantum coherence 
 
IBMX  Isobutylmethylxanthine 
 
IC50  Half maximal inhibitory  
concentration 
 
IR  Infrared 
 
Log P  Partition coefficient 
between n-octanol and 
water 
 
MCF-7/Topo  Topotecan resistant 
human breast cancer cells  
 
MDR   Multidrug resistance  
 
MDCK  Madin-Darby canine 
kidney cells 
 
Mp  Melting point 
 
MRP   Multidrug-related protein  
 
MXR   Mitoxantrone resistance 
protein  
 
NIR  Near infrared 
 
NMR Nuclear magnetic 
resonance 
 
NOESY  Nuclear overhauser 
enhancement 
spectroscopy  
 
PBS  Phosphate buffered saline 
 
P-gp   p-Glycoprotein  
 
Rf  Retention factor 
 
ROESY Rotating frame NOE 
spectroscopy 
 
RT  Room temperature 
 
SEM   Standard error of the 
mean  
 
TBAF  Tetrabutylammonium 
fluoride 
 
TFA   Trifluoroacetic acid  
 
THF   Tetrahydrofuran  
 
THP  Tetrahydropyranyl 
 
TLC  Thin layer 
chromatography  
 
TMS  Trimethylsilyl 
 
TRIS  Tris(hydroxymethyl)-
aminomethane 
 
U-373 MG  Human glioblastoma cell 
line 
 
UV  Ultraviolett 
 
Vis  Visible
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8. Appendix 
 
Crystal data for the forskolin analogues 
 
O
O
OH
OAc
OO
S
 
Forskolin analogue 5 
 
Empirical formula: C23H32O7S  
Formula weight: 452.56  
Crystal size: 0.220 x 0.180 x 0.120 mm  
Crystal description: prism  
Crystal colour: colourless  
Crystal system: orthorhombic  
Space group: P 21 21 21  
Unit cell dimensions:  a = 11.2098(10) A    α = 90° 
                                   b = 13.4111(10) A     β = 90° 
                                  c = 15.5805(8) A      γ = 90° 
Volume: 2342.3(2) A3  
Z, Calculated density: 4, 1.283 Mg/m3  
Absorption coefficient: 0.178 mm-1  
F(000): 968  
 
O
O
OH
OAc
OS
O
Bu3Sn
 
Forskolin analogue 6 
 
Empirical formula: C35H59O7SSn 
Formula weight: 742.60  
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Crystal size: 0.360 x 0.080 x 0.050 mm  
Crystal description: rod  
Crystal colour: colourless  
Crystal system: orthorhombic  
Space group: P 21 21 21  
Unit cell dimensions:  a = 8.6407(5) A     α = 90° 
                                   b = 16.7723(12) A    β = 90° 
                                  c = 26.7336(17) A     γ = 90° 
Volume: 3874.4(4) A3  
Z, Calculated density: 4, 1.273 Mg/m3  
Absorption coefficient: 0.755 mm-1  
F(000): 1564  
 
O
OH
O
O
O
O
O
 
Forskolin analogue 10 
 
Empirical formula: C23H32O7  
Formula weight: 420.49  
Crystal size: 0.110 x 0.100 x 0.090 mm  
Crystal description: cube  
Crystal colour: colourless  
Crystal system: orthorhombic  
Space group: P 21 21 21  
Unit cell dimensions:  a = 10.06440(10) A    α = 90° 
                                   b = 12.2719(2) A     β = 90° 
                                  c = 17.7626(2) A      γ = 90° 
Volume: 2193.85(5) A3  
Z, Calculated density: 4, 1.273 Mg/m3  
Absorption coefficient: 0.769 mm-1  
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